
<html lang="en"     class="pb-page"  data-request-id="beb305a2-37ae-4759-8ba1-d3ee43fafcf5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-4;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm401805h"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib" /></meta><meta name="dc.Creator" content="Qinhua  Huang" /></meta><meta name="dc.Creator" content="Ted W.  Johnson" /></meta><meta name="dc.Creator" content="Simon  Bailey" /></meta><meta name="dc.Creator" content="Alexei  Brooun" /></meta><meta name="dc.Creator" content="Kevin D.  Bunker" /></meta><meta name="dc.Creator" content="Benjamin J.  Burke" /></meta><meta name="dc.Creator" content="Michael R.  Collins" /></meta><meta name="dc.Creator" content="Andrew S.  Cook" /></meta><meta name="dc.Creator" content="J. Jean  Cui" /></meta><meta name="dc.Creator" content="Kevin N.  Dack" /></meta><meta name="dc.Creator" content="Judith G.  Deal" /></meta><meta name="dc.Creator" content="Ya-Li  Deng" /></meta><meta name="dc.Creator" content="Dac  Dinh" /></meta><meta name="dc.Creator" content="Lars D.  Engstrom" /></meta><meta name="dc.Creator" content="Mingying  He" /></meta><meta name="dc.Creator" content="Jacqui  Hoffman" /></meta><meta name="dc.Creator" content="Robert L.  Hoffman" /></meta><meta name="dc.Creator" content="Patrick S.  Johnson" /></meta><meta name="dc.Creator" content="Robert S.  Kania" /></meta><meta name="dc.Creator" content="Hieu  Lam" /></meta><meta name="dc.Creator" content="Justine L.  Lam" /></meta><meta name="dc.Creator" content="Phuong T.  Le" /></meta><meta name="dc.Creator" content="Qiuhua  Li" /></meta><meta name="dc.Creator" content="Laura  Lingardo" /></meta><meta name="dc.Creator" content="Wei  Liu" /></meta><meta name="dc.Creator" content="Melissa West  Lu" /></meta><meta name="dc.Creator" content="Michele  McTigue" /></meta><meta name="dc.Creator" content="Cynthia L.  Palmer" /></meta><meta name="dc.Creator" content="Paul F.  Richardson" /></meta><meta name="dc.Creator" content="Neal W.  Sach" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Tod  Smeal" /></meta><meta name="dc.Creator" content="Graham L.  Smith" /></meta><meta name="dc.Creator" content="Albert E.  Stewart" /></meta><meta name="dc.Creator" content="Sergei  Timofeevski" /></meta><meta name="dc.Creator" content="Konstantinos  Tsaparikos" /></meta><meta name="dc.Creator" content="Hui  Wang" /></meta><meta name="dc.Creator" content="Huichun  Zhu" /></meta><meta name="dc.Creator" content="Jinjiang  Zhu" /></meta><meta name="dc.Creator" content="Helen Y.  Zou" /></meta><meta name="dc.Creator" content="Martin P.  Edwards" /></meta><meta name="dc.Description" content="Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Un..." /></meta><meta name="Description" content="Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Un..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 6, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401805h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401805h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401805h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401805h" /></link>
        
    
    

<title>Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401805h" /></meta><meta property="og:title" content="Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0021.jpeg" /></meta><meta property="og:description" content="Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401805h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401805h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401805h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401805h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401805h&amp;href=/doi/10.1021/jm401805h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1170-1187</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500178r" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/jm401551n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qinhua++Huang">Qinhua Huang</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ted+W.++Johnson">Ted W. Johnson</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Bailey">Simon Bailey</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexei++Brooun">Alexei Brooun</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+D.++Bunker">Kevin D. Bunker</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+J.++Burke">Benjamin J. Burke</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+R.++Collins">Michael R. Collins</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+S.++Cook">Andrew S. Cook</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Jean++Cui">J. Jean Cui</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+N.++Dack">Kevin N. Dack</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judith+G.++Deal">Judith G. Deal</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Li++Deng">Ya-Li Deng</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dac++Dinh">Dac Dinh</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lars+D.++Engstrom">Lars D. Engstrom</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mingying++He">Mingying He</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacqui++Hoffman">Jacqui Hoffman</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+L.++Hoffman">Robert L. Hoffman</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+S.++Johnson">Patrick S. Johnson</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+S.++Kania">Robert S. Kania</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hieu++Lam">Hieu Lam</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Justine+L.++Lam">Justine L. Lam</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phuong+T.++Le">Phuong T. Le</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiuhua++Li">Qiuhua Li</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Lingardo">Laura Lingardo</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Liu">Wei Liu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+West++Lu">Melissa West Lu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele++McTigue">Michele McTigue</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cynthia+L.++Palmer">Cynthia L. Palmer</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+F.++Richardson">Paul F. Richardson</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neal+W.++Sach">Neal W. Sach</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tod++Smeal">Tod Smeal</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Graham+L.++Smith">Graham L. Smith</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Albert+E.++Stewart">Albert E. Stewart</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sergei++Timofeevski">Sergei Timofeevski</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Konstantinos++Tsaparikos">Konstantinos Tsaparikos</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Wang">Hui Wang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huichun++Zhu">Huichun Zhu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinjiang++Zhu">Jinjiang Zhu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen+Y.++Zou">Helen Y. Zou</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+P.++Edwards">Martin P. Edwards</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="AFF-d2623e278-autogenerated"><span class="aff-text">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone (858)-622-3165; e-mail <a href="/cdn-cgi/l/email-protection#36475f585e4357185e435758517646505f4c53441855595b"><span class="__cf_email__" data-cfemail="addcc4c3c5d8cc83c5d8ccc3caedddcbc4d7c8df83cec2c0">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone (858)-526-4683; e-mail <a href="/cdn-cgi/l/email-protection#d9adbcbdf7aef7b3b6b1b7aab6b799a9bfb0a3bcabf7bab6b4"><span class="__cf_email__" data-cfemail="3b4f5e5f154c15515453554854557b4b5d52415e4915585456">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401805h&amp;href=/doi/10.1021%2Fjm401805h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1170â1187</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 16, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 November 2013</li><li><span class="item_label"><b>Published</b> online</span>6 February 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 February 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401805h" title="DOI URL">https://doi.org/10.1021/jm401805h</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editorsâ Choice" /></img><span>ACS Editorsâ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401805h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8357</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">67</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401805h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qinhua&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Ted&quot;,&quot;last_name&quot;:&quot;W. Johnson&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Bailey&quot;},{&quot;first_name&quot;:&quot;Alexei&quot;,&quot;last_name&quot;:&quot;Brooun&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;D. Bunker&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;J. Burke&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;R. Collins&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;S. Cook&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;N. Dack&quot;},{&quot;first_name&quot;:&quot;Judith&quot;,&quot;last_name&quot;:&quot;G. Deal&quot;},{&quot;first_name&quot;:&quot;Ya-Li&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Dac&quot;,&quot;last_name&quot;:&quot;Dinh&quot;},{&quot;first_name&quot;:&quot;Lars&quot;,&quot;last_name&quot;:&quot;D. Engstrom&quot;},{&quot;first_name&quot;:&quot;Mingying&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Jacqui&quot;,&quot;last_name&quot;:&quot;Hoffman&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;L. Hoffman&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;S. Johnson&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;S. Kania&quot;},{&quot;first_name&quot;:&quot;Hieu&quot;,&quot;last_name&quot;:&quot;Lam&quot;},{&quot;first_name&quot;:&quot;Justine&quot;,&quot;last_name&quot;:&quot;L. Lam&quot;},{&quot;first_name&quot;:&quot;Phuong&quot;,&quot;last_name&quot;:&quot;T. Le&quot;},{&quot;first_name&quot;:&quot;Qiuhua&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Lingardo&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;West Lu&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;McTigue&quot;},{&quot;first_name&quot;:&quot;Cynthia&quot;,&quot;last_name&quot;:&quot;L. Palmer&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;F. Richardson&quot;},{&quot;first_name&quot;:&quot;Neal&quot;,&quot;last_name&quot;:&quot;W. Sach&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Tod&quot;,&quot;last_name&quot;:&quot;Smeal&quot;},{&quot;first_name&quot;:&quot;Graham&quot;,&quot;last_name&quot;:&quot;L. Smith&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;E. Stewart&quot;},{&quot;first_name&quot;:&quot;Sergei&quot;,&quot;last_name&quot;:&quot;Timofeevski&quot;},{&quot;first_name&quot;:&quot;Konstantinos&quot;,&quot;last_name&quot;:&quot;Tsaparikos&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Huichun&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Jinjiang&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Y. Zou&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;1170-1187&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401805h&quot;},&quot;abstract&quot;:&quot;Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401805h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401805h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401805h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401805h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401805h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401805h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401805h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401805h&amp;href=/doi/10.1021/jm401805h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401805h" /></input><a href="/doi/pdf/10.1021/jm401805h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26pmid%3D24432909%26genre%3Darticle%26aulast%3DHuang%26date%3D2014%26atitle%3DDesign%2Bof%2BPotent%2Band%2BSelective%2BInhibitors%2Bto%2BOvercome%2BClinical%2BAnaplastic%2BLymphoma%2BKinase%2BMutations%2BResistant%2Bto%2BCrizotinib%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D4%26spage%3D1170%26epage%3D1187%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jmcmar.2014.57.issue-4/production/jmcmar.2014.57.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Crizotinib (<b>1</b>), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine <b>8e</b>, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) belongs to the insulin receptor (IR) superfamily of receptor tyrosine kinases (RTKs). Normally, ALK plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Inhibition may be a suitable strategy, since ALK knockout mice live a normal life span without obvious abnormalities but are described as having an âanti-depressiveâ phenotype.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Over the last 20 years, ALK has been associated with several cancers. The ALK gene has been shown to be oncogenic by three different mechanisms across a variety of tumors: ALK mutations, amplifications, and translocations (fusions).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The oncogenic nucleophosmin (NPM)âALK fusion gene was first identified in anaplastic large-cell lymphoma (ALCL) in 1994.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Subsequently, multiple ALK fusions have been identified in diffuse large B-cell lymphoma (DLBCL),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> inflammatory myofibroblastic tumors (IMT),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and non-small-cell lung carcinoma (NSCLC).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although many fusion partners exist in a variety of tumor types, echinoderm microtubule-associated protein-like 4 (EML4)âALK represents the largest patient population, accounting for approximately 6% of NSCLC patients. Fusion of ALK with the EML4 protein was thought to constitutively activate the kinase through oligomerization of the coiled-coil domain of EML4.<a onclick="showRef(event, 'cit7b'); return false;" href="javascript:void(0);" class="ref cit7b">(7b)</a> In addition, amplification and oncogenic mutations of ALK in neuroblastoma,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> inflammatory breast cancer,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and ovarian cancer<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> have also been reported. Therefore, ALK has emerged as an attractive drug target for cancer therapy.</div><div class="NLM_p">In 2011, crizotinib (<b>1</b>, brand name Xalkori) became the first ALK inhibitor approved by the U.S. Food and Drug Administration (FDA) as a first-line treatment for ALK-positive lung cancer patients.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Most ALK-fusion-positive NSCLC patients benefit significantly from crizotinib treatment, showing objective response rates (complete and partial) of 60% and progression-free survival of approximately 10 months.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Although the initial therapeutic response is impressive, many patients eventually develop resistance to crizotinib. The tumors that progress on crizotinib have exhibited a range of resistance mechanisms, with ALK gene point mutations and insertions being well-characterized.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> For this reason, there is a need to develop second-generation anti-ALK therapies.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0022.gif" alt="" id="fx1" /></img></div><div class="NLM_p">Recent encouraging phase I/II clinical results for ALK inhibitors <b>2</b> (LDK378, Novartis),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>3</b> (ASP3026, Astellas),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><b>4</b> (CH5424802, Roche/Chugai),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and <b>5</b> (AP26113, Ariad, structure undisclosed and series exemplified as <b>5</b>)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) demonstrate the promise of these classes of therapeutics to treat crizotinib-naive and relapsed ALK-positive NSCLC patients.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected clinical ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Since crizotinib was originally designed as a mesenchymalâepithelial transition factor (c-MET) kinase inhibitor,<a onclick="showRef(event, 'cit11c'); return false;" href="javascript:void(0);" class="ref cit11c">(11c)</a> we sought to optimize its scaffold for ALK potency. Herein, we report design advances on a 3-benzyloxyaminopyridine scaffold toward highly potent inhibitors of ALK wild-type and resistant mutants using lipophilicityâefficiency (LipE)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> analysis and structure-based drug design (SBDD).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14581" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14581" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Characterization of Crizotinib Potency against ALK Mutants</h3><div class="NLM_p">As mentioned, ALK gene point mutations and insertions were well-characterized mechanisms of resistance. The relative positions of ALK kinase domain point mutations and insertions identified from crizotinib-relapsed patient samples are illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. L1196M, G1269A, and G1202R make direct contacts with crizotinib. S1206Y is in close proximity to the crizotinib binding site, while other reported mutations, such as L1152R, C1156Y, F1174L, and 1151Tins are more distal to the inhibitor.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of crizotinib bound to the ALK kinase domain, showing the positions of clinically identified crizotinib-resistant mutations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several engineered cell lines expressing wild-type (wt) and mutant ALK were developed to evaluate crizotinib potency. From clinical data, at the recommended 250 mg b.i.d. (twice a day) dose, the average human free plasma concentration of crizotinib is 45â70 nM, which nearly matches only the wt ALK IC<sub>50</sub> values across cell lines.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(19)</a> In addition to wt ALK IC<sub>50</sub>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> summarizes crizotinib inhibition activity in mechanistic and proliferation inhibition assays using engineered cell lines harboring clinically reported ALK mutations. In NIH-3T3-ALK mutant engineered cell lines, the cell IC<sub>50</sub> vaulue for crizotinib ranges from 165 to 3039 nM, which represents a 2â38-fold shift relative to wt potency. This <i>x</i>-fold shift is mirrored by antiproliferative data in wild-type lines (H3122, H2228, and Karpas299) and various mutant engineered lines (H3122-G1269A and H3122-L1196M). The concentration of crizotinib required to sufficiently inhibit these mutants substantially exceeds clinically relevant concentrations.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cell-Based Efficacy of Crizotinib against Wild Type and Various Mutants of ALK</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="8" align="center">ALK phospho in 3T3-EML4-ALK engineered cells (IC<sub>50</sub>, nM)</th><th class="rowsep1 colsep0" colspan="5" align="center">ALK-fusion-driven cell proliferation (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">wt</th><th class="colsep0 rowsep0" align="center">L1196M</th><th class="colsep0 rowsep0" align="center">G1269A</th><th class="colsep0 rowsep0" align="center">S1206Y</th><th class="colsep0 rowsep0" align="center">C1156Y</th><th class="colsep0 rowsep0" align="center">F1174L</th><th class="colsep0 rowsep0" align="center">L1152R</th><th class="colsep0 rowsep0" align="center">1151Tins</th><th class="colsep0 rowsep0" align="center">H3122</th><th class="colsep0 rowsep0" align="center">H2228</th><th class="colsep0 rowsep0" align="center">Karpas299</th><th class="colsep0 rowsep0" align="center">H3122-L1196M</th><th class="colsep0 rowsep0" align="center">H3122-G1269A</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">843</td><td class="colsep0 rowsep0" align="left">605</td><td class="colsep0 rowsep0" align="left">626</td><td class="colsep0 rowsep0" align="left">478</td><td class="colsep0 rowsep0" align="left">165</td><td class="colsep0 rowsep0" align="left">1026</td><td class="colsep0 rowsep0" align="left">3039</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">838</td><td class="colsep0 rowsep0" align="left">623</td></tr></tbody></table></div></div><div class="NLM_p last">Because of the reported higher frequency of the methionine gatekeeper mutant from analysis of clinical samples<a onclick="showRef(event, 'cit13a'); return false;" href="javascript:void(0);" class="ref cit13a">(13a)</a> and significant resistance in vitro (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), L1196M ALK was chosen as the sentinel mutant for both biochemical and cellular screening assays in our compound progression cascade. Once compounds of interest were identified, subsequent testing was performed on clinically reported mutants (G1269A, S1206Y, C1156Y, F1174L, L1152R, and 1151Tins) to ensure broad coverage of relevant resistant point mutants encountered in vivo.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> CrizotinibâALK Kinase Domain Co-crystal Structure Analysis</h3><div class="NLM_p">Crizotinib is a type I ATP-competitive inhibitor of c-MET and ALK. Previous publications highlight crizotinib bound to the nonphosphorylated state, autoinhibitory conformation of the c-MET kinase.<a onclick="showRef(event, 'cit11c'); return false;" href="javascript:void(0);" class="ref cit11c">(11c)</a> The co-crystal of the wt ALK kinase domain complexed with crizotinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>) shows a binding conformation similar to c-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj">2wgj</a>), yet it lacks the tyrosine ÏâÏ stacking interaction observed with c-MET. This likely contributes to the modest loss in ALK potency relative to c-MET.</div><div class="NLM_p">Co-crystal structures of wt and L1196M ALK were undertaken to identify binding interactions and protein conformations (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The binding mode of crizotinib in both proteins is quite similar. Crizotinib makes similar hydrogen bonds to the hinge residues M1199 and E1197 in the wt (2.9 and 3.0 Ã) and L1196M (2.9 and 3.1 Ã) structures. In both structures, the gatekeeper residue contacts crizotinib at the exocyclic amino group (3.9 Ã in wt, 3.9 Ã in L1196M) and the (<i>R</i>)-methyl group (3.9 Ã in wt, 4.0 Ã in L1196M). The pyrazole ring sits atop G1202 at similar distances (3.7 Ã in wt, 3.6 Ã in L1196M) and the 2,6-dichloro-3-fluorophenyl group is in a very similar position in the wt and L1196M structures. Overall protein conformations look very comparable between the two crystal structures with the exception of the L1196 to M1196 gatekeeper residue difference.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Co-crystal structure of crizotinib with ALK wt (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>) overlaid with L1196M mutant (cyan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yfx">2yfx</a>) and the G1269 residue from L1196M apo structure (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yhv">2yhv</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A closer look at the âheadâ dichlorofluorophenyl group reveals that the fluorine at C3 contributes to potency and binding efficiency by (a) filling a small hydrophobic pocket formed by the G1269 and N1254 residues and (b) polarizing the neighboring C4âH bond to productively interact with the R1253 carbonyl oxygen. A comparison of the apo structure of ALK to the crizotinibâALK bound structure shows that the 2-chloro substituent is in close contact with the backbone carbonyl of G1269. This close contact may be unfavorable, as comparison of apo and crizotinib-bound structures shows that this carbonyl rotates (â¼30Â°) away from the inhibitor to accommodate crizotinib binding (highlighted in green, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). In contrast, the equivalent carbonyl (A1221) in the co-crystal of crizotinib (<b>1</b>)/c-MET (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj">2wgj</a>) is not in this location. There is an inversion of the amide NH and CâO orientation of the c-MET A1221 residue compared to the overlapping ALK G1269 residue, and the 2-chloro was optimized for the inverted c-MET A1221 residue.<a onclick="showRef(event, 'cit11c'); return false;" href="javascript:void(0);" class="ref cit11c">(11c)</a></div><div class="NLM_p">While the overall resolution of the structures is excellent, some disorder is observed. Both bound structures of crizotinib with the wt and L1196M ALK protein show disordered G-loops in the portion adjacent to the 6-Cl substituent of the headgroup. The remaining portions of the G-loop are well-defined (up to G1123 in wt ALK, up to L1122 in L1196M mutant) and are greater than 4.5 Ã from the chlorine.</div><div class="NLM_p last">The pyrazolopiperidine âtailâ group of crizotinib was a region of the molecule that required further optimization for ALK potency and absorption, distribution, metabolism, and excretion (ADME) properties. The pyrazole portion of the tail group filled a lipophilic pocket near the solvent-exposed region, in close proximity to G1202. The piperidinyl group pointed out toward solvent. This group added significant molecular weight and a basic amine, resulting in low in vitro permeability (RRCK = 0.8 Ã 10<sup>â6</sup> cm/s) and high efflux [multidrug resistance (MDR) BA/AB = 45]. The optimization campaign focused on neutral pyrazolopiperidine tail replacements to impart improved permeability. Strategies to optimize both the 2,6-dichloro-3-fluorophenyl head and the pyrazolopiperidine tail in crizotinib (<b>1</b>) will be discussed below.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Optimization of the Head Group</h3><div class="NLM_p">On the basis of the structural analyses above, we believed that a smaller substituent at C2 may complement the protein by allowing a relaxation of the G1269 carbonyl as seen in the apo structure. Furthermore, the C2 hydrogen would be polarized by the adjacent fluorine atom to complement the G1269 carbonyl oxygen. Another benefit of the des-chloro compound would be lower molecular weight and log <i>D</i>, providing physical properties with greater likelihood for improving pharmaceutical properties. Both crizotinib (<b>1</b>) and the 2-des-chloro analogue (<b>1a</b>) were evaluated to quantify the various effects of removing the 2-chloro group (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Indeed, the hydrogen analogue <b>1a</b> exhibited improvements in potency, lipophilic efficiency, and in vitro clearance relative to the chloro analogue <b>1</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency, ADME, and Efficiency of Crizotinib (<b>1</b>) and Its Des-2-chloro Analogue (<b>1a</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0014.gif" alt="" id="tbl2_1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center" char=".">L1196M <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">L1196M cell IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl<sub>int,app</sub><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (mLÂ·min-<sup>â1</sup>Â·kg<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">RRCK <i>P</i><sub>app</sub> (A to B)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> (10<sup>â6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center" char=".">LipE<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a> (<i>K</i><sub>i</sub>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">843</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">387</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Log <i>D</i> measured at pH 7.4.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(20)</a></p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Cl<sub>int,app</sub> refers to the total intrinsic clearance obtained from scaling in vitro half-lives in human liver microsomes.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a></p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">RRCK cells with low transporter activity were isolated from MadinâDarby kidney cells and were used to estimate intrinsic absorptive permeability.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(22)</a></p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">LipE = âlog <i>K</i><sub>i</sub> â log <i>D</i>.</p></div></div></div><div class="NLM_p">Holding the des-chloro modification constant and utilizing a small and potent pyrazole tail moiety, a variety of fluorophenyl analogues with different R<sup>2</sup> groups (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) were synthesized to identify higher LipE replacements of the 6-chloro substituent (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Enzymatic LipE of the larger groups CN (<b>6b</b>), OMe (<b>6c</b>), and triazolo (<b>6d</b>) were one unit higher than the smaller fluorine analogue (<b>6a</b>). Other matched pairs containing different tail groups followed a similar trend (data not shown). In addition to lipophilic efficiency, the triazolo motif better balanced cell potency and ADME properties. For example, nitrile <b>6b</b> had similar in vitro clearance to triazole <b>6d</b> but lost more than 10-fold cell potency. On the other hand, the methoxy-substituted analogue (<b>6c)</b> had good mutant cell potency but contained a metabolically labile methoxy group displaying high in vitro clearance. Therefore, the 2-triazolo-5-fluorophenyl head group was chosen as our standard head group for tail group optimization based on balanced potency, efficiency, clearance, and permeability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potency, ADME, and Efficiency of the Substituted Fluorophenyl Head Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0015.gif" alt="" id="tbl3_1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0016.gif" alt="" id="tbl3_2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Log <i>D</i> was measured at pH 7.4.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(20)</a><sup><i>b</i></sup>Cl<sub>int,app</sub> refers to the total intrinsic clearance obtained from scaling in vitro half-lives in human liver microsomes.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a><sup><i>c</i></sup>RRCK cells with low transporter activity were isolated from MadinâDarby kidney cells and were used to estimate intrinsic absorptive permeability.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(22)</a><sup><i>d</i></sup>LipE = âlog <i>K</i><sub>i</sub> â log <i>D</i>. <sup><i>e</i></sup>clog <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">A co-crystal structure with ALK was obtained for the more potent and lipophilic efficient triazole lead (<b>6d</b>). Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> shows the aligned and overlapped bound structures for triazole <b>6d</b> (cyan, 2.0 Ã) and crizotinib <b>1</b> (gray, 1.9 Ã) in wt ALK kinase domain. The triazole group of <b>6d</b> forms a 60Â° torsion angle with the phenyl ring and is positioned to make contact with the backbone of residues L1122-G1123 of the ALK G-loop. By contrast, the chloro of crizotinib does not extend far enough to make contact with the G-loop. Note that the G1269 carbonyl in the bound structure of <b>6d</b>/wt ALK (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) was relaxed, as seen in the apo structure, by removing the 2-chloro in the head group compared with the crizotinib/wt ALK bound structure.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystal structures of crizotinib/ALK wt (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>) and <b>6d</b>/ALK wt (cyan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb">4ccb</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Optimization of the Tail Group</h3><div class="NLM_p">The 2-triazolo-5-fluorophenyl head group was held constant while neutral replacements for the basic pyrazolopiperidine group in crizotinib (<b>1</b>) were sought. A variety of substituted cyclic tail groups were designed, synthesized, and tested for both biological potency and ADME properties (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). While <b>6d</b> exhibited good potency, it was a substrate for glucuronidation at the unsubstituted pyrazole site. Methyl-protected 4-pyrazolo analogues (<b>7a</b> and <b>7b</b>) maintained similar enzymatic potency and LipE. Although introduction of the cyano group in <b>7b</b> did not lower lipophilicity much, it improved the in vitro clearance relative to the methyl analogue <b>7a</b>. Other molecules containing five-membered-ring R<sup>3</sup> groups, such as <b>7c</b> and <b>7d</b>, decreased LipE approximately 0.5 units compared with the 4-pyrazolo tails (<b>6d</b>, <b>7a</b>, and <b>7b</b>). The six-membered-ring R<sup>3</sup> group in <b>7f</b> reduced LipE by 0.4 units relative to the similar but more electron-rich group in <b>7e</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Potency, ADME, and Efficiency of R<sup>3</sup> Substitution</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0017.gif" alt="" id="tbl4_1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0018.gif" alt="" id="tbl4_2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Log <i>D</i> was measured at pH 7.4.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(20)</a><sup><i>b</i></sup>Cl<sub>int,app</sub> refers to the total intrinsic clearance obtained from scaling in vitro half-lives in human liver microsomes.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a><sup><i>c</i></sup>RRCK cells with low transporter activity were isolated from MadinâDarby kidney cells and were used to estimate intrinsic absorptive permeability.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(22)</a><i><sup>d</sup></i>LipE = âlog <i>K</i><sub>i</sub> â log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">In order to improve both the binding affinity and efficiency, we took a close look at proteinâligand interactions in the region of the binding site near the solvent front. Co-crystal structure analysis indicated that several polar carbonyls, including the carboxyl side chain of D1203, resided near the solvent front and were proximal to the R<sup>3</sup> tail aromatic ring (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Two designs (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) introduced an alcohol in the R<sup>3</sup> group to form a hydrogen-bond interaction with this side chain. Alcohol <b>7h</b> showed higher lipophilic efficiency than <b>7g</b>. The increase in both potency and lipophilic efficiency of <b>7h</b> was derived from a hydrogen-bonding interaction with the D1203 side chain. A similar H-bond is not likely achievable by para-substituted alcohol <b>7g</b> since the ring size and substitution vectors are not suitable. Structural data confirmed a close contact between the tertiary alcohol of <b>7h</b> and the D1203 side-chain acid carbonyl (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Co-crystal structure of <b>7h</b> and ALK wt protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu">4ccu</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, the co-crystal sctructure of <b>7h</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) showed the thiazole aromatic ring of <b>7h</b> was rotated about 30Â° from the plane of the 2-aminopyridine hinge-binding moiety. This conformation presented the R<sup>3</sup> aryl ring at a suitable angle and distance to form a CH donorâÏ interaction with G1202.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(23)</a> Dihedral angles over 45Â° created a bump with the protein. Although it is very challenging to isolate the impact of the electron-richness of the aromatic to the CHâÏ interaction, trends highlight the general decrease in LipE with reduced electronic density of the aromatics. For example, enzymatic LipE decreased about 0.4 units from pyridine to pyrimidine analogues (<b>7e</b> and <b>7f</b> in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><div class="NLM_p">Conformational analysis was carried out on compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. The computed energies of various conformers rotated about the arylâaryl bond (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) show that compounds able to adopt a 30Â° conformation with small energetic penalty tend to provide the tightest binding affinity and efficiency. For example, <b>7i</b> has a 1.3 kcal/mol strain energy to adopt a protein-preferred â¼30Â° torsion angle. This is partly reflected in a 25-fold potency loss and a half-unit LipE decrease for <b>7i</b> compared to similar compounds such as <b>7c</b>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Relative energy profile for the torsion angle between the aminopyridine core and the R<sup>3</sup> aryl ring for <b>6d</b> and <b>7a</b>â<b>7i</b> as calculated by the density functional theory (DFT) B3LYP/6-31g** method in Jaguar.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With potent inhibitor <b>7h</b> (L1196M cell IC<sub>50</sub> = 27 nM, log <i>D</i> = 3.6) in hand, the design focused on the thiadiazole modification to improve overall ADME properties. Compounds with lower log <i>D</i> than <b>7h</b> are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Because many analogues containing thiazole groups were reaching the lower limit of the enzymatic assay, in addition to enzymatic LipE, cell LipE was also reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. The cyclization of geminal dimethyl groups to a four-membered azetidine lowered log <i>D</i> to 2.6 due to the introduction of a basic amine (<b>8a</b>), but it had inferior cell potency and higher microsomal clearance compared with <b>7h</b>. Although <b>8b</b> lowered the lipophilicity slightly compared with <b>7h</b>, the specific structural feature yielded high in vitro clearance. The introduction of a sulfone motif decreased log <i>D</i> from 3.6 (<b>7h</b>) to 3.2 (<b>8c</b>), while maintaining similar cell potency, and resulted in cell LipE improvement from 4.0 (<b>7h</b>) to 4.5 (<b>8c</b>). In addition, <b>8c</b> displayed good microsomal stability and RRCK permeability.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Potency, ADME, and Efficiency of Substituted Thiazoles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0019.gif" alt="" id="tbl5_1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0020.gif" alt="" id="tbl5_2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Log <i>D</i> was measured at pH 7.4.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(20)</a><sup><i>b</i></sup>Cl<sub>int,app</sub> refers to the total intrinsic clearance obtained from scaling in vitro half-lives in human liver microsomes.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a><sup><i>c</i></sup>RRCK cells with low transporter activity were isolated from MadinâDarby kidney cells and were used to estimate intrinsic absorptive permeability.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(22)</a><i><sup>d</sup></i>LipE = âlog <i>K</i><sub>i</sub> â log <i>D</i>. <sup><i>e</i></sup>LipE = âlog IC<sub>50</sub> â log <i>D</i>. <sup><i>g</i></sup>While <b>8b</b> and <b>8c</b> are the more potent enatiomers, the absolute chirality at the R<sup>5</sup> substitution is undefined.</p></div></div><div></div></div><div class="NLM_p">The bound structure of <b>7h</b> with the ALK kinase domain (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) showed one methyl of the 2-propanol to be proximal to the NH of D1203 (4.2 Ã). Furthermore, this NH is unsatisfied with no discernible interactions with water, ligand, or protein. Modeling suggested the addition of a hydroxyl group to this methyl could satisfy the NH as an acceptor while donating to either the carboxyl side chain of D1203 or a water molecule stabilized by the carbonyls of G1201 and D1203. Gratifyingly, the cellular potency of <b>8e</b> improved to 6.6 nM with a cellular lipophilic efficiency of 5.3, providing a highly efficient neutral ligand. Indeed, <b>8e</b> bound (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) with the tertiary OH group forming a hydrogen bond with D1203 and the primary alcohol forming hydrogen bonds with the amino group of D1203 (2.8 Ã) and the dicarbonyl stabilized water (2.9 Ã). The distance to the carboxyl group of D1203 is 2.9 Ã.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Co-crystal structure of <b>8e</b> and ALK L1196M protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0">4cd0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Importantly, introduction of the OH group reduces lipophilicity (<b>8e</b> log <i>D</i> = 2.9) while maintaining similar RRCK P<sub>app</sub> AB compared to <b>7h</b>. Presumably, masking of the additional hydrogen-bond donor through an intramolecular hydrogen bond is a key contributor to maintaining permeability. Consistent with our modeling, the enantiomer (<b>8d</b>) resulting from introduction of a hydroxy functionality at the other carbon has eroded lipophilic efficiency.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Activity against Other ALK Mutations and in Vivo Data for <b>8e</b></h3><div class="NLM_p">On the basis of improved L1196M mutant potency, lipophilic efficiency, and balanced physicochemical properties, <b>8e</b> emerged as a candidate for broader profiling in wild-type and mutant ALK driven cell lines and kinase counterscreen assays. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, <b>8e</b> significantly improved cell potency against ALK wt and ALK clinical mutations compared with crizotinib (<b>1</b>). In the engineered wt 3T3-EML4-ALK phosphorylation assay, the potency of <b>8e</b> has been improved 100-fold (from 80 nM for <b>1</b> to 0.8 nM for <b>8e</b>). Across the clinically identified ALK mutants in the engineered cell lines, <b>8e</b> showed 67â825-fold potency increases compared to crizotinib (<b>1</b>). The potency gains measured by inhibition of ALK phosphorylation were consistent with the significantly improved antiproliferative potency of <b>8e</b> relative to crizotinib (<b>1</b>) in both wild-type cell lines (parental H3122, H2228, and Karpas299) and engineered mutant lines (H3122-L1196M and H3122-G1269A).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Cell-Based Potency of Crizotinib (<b>1</b>) and <b>8e</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="8" align="center">ALK phospho in 3T3-EML4-ALK engineered cells (IC<sub>50</sub>, nM)</th><th class="rowsep1 colsep0" colspan="5" align="center">ALK-fusion-driven cell proliferation (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">wt</th><th class="colsep0 rowsep0" align="center">L1196M</th><th class="colsep0 rowsep0" align="center">G1269A</th><th class="colsep0 rowsep0" align="center">S1206Y</th><th class="colsep0 rowsep0" align="center">C1156Y</th><th class="colsep0 rowsep0" align="center">F1174L</th><th class="colsep0 rowsep0" align="center">L1152R</th><th class="colsep0 rowsep0" align="center">1151Tins</th><th class="colsep0 rowsep0" align="center">H3122</th><th class="colsep0 rowsep0" align="center">H2228</th><th class="colsep0 rowsep0" align="center">Karpas299</th><th class="colsep0 rowsep0" align="center">H3122-L1196M</th><th class="colsep0 rowsep0" align="center">H3122-G1269A</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">843</td><td class="colsep0 rowsep0" align="left">605</td><td class="colsep0 rowsep0" align="left">626</td><td class="colsep0 rowsep0" align="left">478</td><td class="colsep0 rowsep0" align="left">165</td><td class="colsep0 rowsep0" align="left">1026</td><td class="colsep0 rowsep0" align="left">3039</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">838</td><td class="colsep0 rowsep0" align="left">623</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>x</i>-fold change</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">128</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">139</td><td class="colsep0 rowsep0" align="left">797</td><td class="colsep0 rowsep0" align="left">825</td><td class="colsep0 rowsep0" align="left">293</td><td class="colsep0 rowsep0" align="left">127</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">148</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">26</td></tr></tbody></table></div></div><div class="NLM_p">While it was extremely potent against wt and mutant ALK, <b>8e</b> also showed good kinase selectivity. Against a diverse panel of 207 kinases tested at Invitrogen, 33 off-target kinases were reported with >80% inhibition at a 1 Î¼M dose and further evaluated by the enzyme IC<sub>50</sub>. The measured Invitrogen enzyme IC<sub>50</sub> values for the kinases that showed the most sensitivity toward <b>8e</b> are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. In addition, <b>8e</b> is very potent against ROS1 with <i>K</i><sub>i</sub> = 0.02 nM (in-house data).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(24)</a> See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for further details of biochemical kinase selectivity of <b>8e</b>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Invitrogen Enzymatic IC<sub>50</sub> Values of Kinases Showing the Most Sensitivity toward <b>8e</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">ALK L1196M</th><th class="colsep0 rowsep0" align="center">ROS1</th><th class="colsep0 rowsep0" align="center">FER</th><th class="colsep0 rowsep0" align="center">LTK</th><th class="colsep0 rowsep0" align="center">NTRK2 (TrkB)</th><th class="colsep0 rowsep0" align="center">FES</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">PTK2B (FAK2)</th><th class="colsep0 rowsep0" align="center">TNK2 (ACK)</th><th class="colsep0 rowsep0" align="center">PTK2 (FAK)</th><th class="colsep0 rowsep0" align="center">NTRK1 (TrkA)</th><th class="colsep0 rowsep0" align="center">NTRK3 (TrkC)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.2<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.02<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Invitrogen enzyme IC<sub>50</sub> using <i>K</i><sub>m</sub> levels of ATP except where noted differently. <i>K</i><sub>i</sub> = â¼IC<sub>50</sub>/2 from the ChengâPrusoff equation, <i>K</i><sub>i</sub> = IC<sub>50</sub>/(1 + [ATP]/<i>K</i><sub>m</sub>), for competitive inhibition.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last"><i>K</i><sub>i</sub> values calculated from tight-binding (Morrison) equation for competitive inhibitors tested in a Pfizer mobility shift assay.</p></div></div></div><div class="NLM_p">Preclinical pharmacokinetic (PK) data was obtained on <b>8e</b> to assess rat clearance, volume of distribution, half-life, and bioavailability (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). The compound demonstrated 86% bioavailability in the rat. Moderate-to-high in vivo rat plasma clearance with moderate volume of distribution provided about a 1 h half-life in rat.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Rat Pharmacokinetic Profile of <b>8e</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">intravenous</th><th class="colsep0 rowsep0" align="center">per os (oral)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (hÂ·nM)</td><td class="colsep0 rowsep0" align="left">667</td><td class="colsep0 rowsep0" align="left">2869</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mLÂ·min<sup>â1</sup>Â·kg<sup>â1</sup>)</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d,ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">568</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">86</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Formulated in a solution of 10% EtOH, 40% PEG200, and 50% water. AUC, area under curve; CL, clearance; <i>V</i><sub>d,ss</sub>, steady-state volume of distribution</p></div></div></div><div class="NLM_p">To evaluate the antitumor efficacy of <b>8e</b>, a mouse tumor xenograft study was performed. Dosing started from day 15 post-cell implantation with tumor size around 250 mm<sup>3</sup>. As illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>, <b>8e</b> demonstrated dose-responsive tumor growth inhibitory activity in the NCI H3122 cell line engineered to harbor the L1196M mutation. It showed tumor stasis (100% TGI) at both the 30 mg/kg q.d. and 15 mg/kg b.i.d. doses. The highest dose <b>(</b>50 mg/kg b.i.d) showed significant tumor growth regression (56%) on day 27. No significant body weight reduction was observed throughout the course of the study. The corresponding twice-daily dose PK of <b>8e</b> in the last day of the TGI experiment (day 29) are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Doseâresponse curve of <b>8e</b> in H3122<sup>L1196M</sup> xenografts in athymic mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Twice-daily dose PK of <b>8e</b> from last day of TGI experiment (day 29) in H3122-L1196M xenografts in athymic mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>6a</b>â<b>c</b> were synthesized as outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The starting alcohols <b>9</b>, which were either commercially available or prepared according to literature procedures, underwent a Mitsunobu reaction with 5-bromo-3-hydroxy-2-nitropyridine to afford intermediates <b>10</b>. For the cases in which X = OMe or F, the alcohols <b>9</b> were prepared in an enantiopure form by a diisopinocampheyl chloroborane (DIP-Cl)-mediated acetophenone reduction.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(25)</a> The nitro group was reduced by heating with iron powder in a mixture of AcOH and EtOH to afford amines <b>11</b>. Conventional Suzuki coupling of <b>11</b> with the boronate ester of the pyrazole afforded compounds <b>6a</b>â<b>c</b> directly. For the racemic final analogue (X = CN), the enantiomers were resolved by chiral supercritical fluid chromatography (SFC).</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of <b>6a</b>â<b>c</b> from Alcohol <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of Ph<sub>3</sub>P, 1.1 equiv of 5-bromo-3-hydroxy-2-nitropyridine, 1.1 equiv of DIAD, toluene, 0 Â°C, 18 h. (b) 5 equiv of Fe, dioxane/AcOH (4:1), 40 Â°C reflux, 0.5 h. (c) 2 equiv of pyrazole boronate ester, 0.1 equiv of Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 equiv of NaHCO<sub>3</sub>, dioxane/water (2.5/1), 110 Â°C, 1.5 h.</p></p></figure><div class="NLM_p">A reliable and scalable route was developed to access the key boronate ester <b>17</b> in an enantiopure form. Compound <b>17</b>, featuring the optimized triazole headpiece, was utilized to synthesize the remainder of the analogues reported herein (<b>6d</b>, <b>7a</b>â<b>i</b>, and <b>8a</b>â<b>e</b>) through Suzuki coupling reaction or Ullman coupling (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The commercially available ketone <b>12</b> was reacted with triazole in the presence of Cs<sub>2</sub>CO<sub>3</sub> to generate <b>13</b>. Chiral reduction of <b>13</b> by use of (â)-DIP-Cl led to the formation of (<i>S</i>)-<b>14</b> in 96% enantiomeric excess (ee). Activation of the alcohol through formation of methanesulfonate ester <b>15</b>, followed by S<sub>N</sub>2 displacement with 2-amino-5-bromo-3-hydroxypyridine in the presence of Cs<sub>2</sub>CO<sub>3</sub>, generated <b>16</b> in 56% yield over two steps. Gratifyingly, the S<sub>N</sub>2 process proceeded with clean inversion, and no racemization was observed. The subsequent Pd-catalyzed borylation afforded boronate ester <b>17</b>. For the initial analogues, either the boronate ester of the aryl substituent was commercially accessible and this was coupled with <b>16</b> in a fashion analogous to Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, or boronate ester <b>17</b> was generated in situ and used directly in the Suzuki coupling process with the aryl halide. In order to optimize and expedite the chemistry, a workup protocol was developed to enable isolation of <b>17</b> as a colorless solid. With bulk quantities of <b>17</b> in hand, reaction screening provided optimal Suzuki coupling conditions, which were utilized in reactions with the corresponding aryl halides (tail groups) to afford the desired final compounds (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Exceptionally, <b>7i</b> was formed by Ullman coupling of aryl bromide <b>16</b> with 2-methylimidazole.</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>6d</b>, <b>7a</b>â<b>i</b>, and <b>8a</b>-<b>e</b> from Ketone <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.5 equiv of triazole, 1.0 equiv of Cs<sub>2</sub>CO<sub>3</sub>, NMP, 140 Â°C, 3 h, 35%. (b) 1.25 equiv of (â)-DIP-Cl, THF, â35 Â°C for 3 h and then rt for 18 h; 2.7 equiv of diethanolamine, TBME, rt reflux, 2 h, 99%, 96% ee. (c) 1.2 equiv of MsCl, 1.5 equiv of Et<sub>3</sub>N, TBME, â10 Â°C to rt, 17 h. (d) 1.2 equiv of 2-amino-5-bromo-3-hydroxypyridine, 1.2 equiv of Cs<sub>2</sub>CO<sub>3</sub>, acetone, 60 Â°C, 16 h, 56% over two steps. (e) 1.7 equiv of bis(pinacalato)diboron, Pd(dppf)Cl<sub>2</sub> (5 mol %), 3.5 equiv of KOAc, DMSO, 80 Â°C, 3 h, 77%. (f) 1.5 equiv of ArBr, 0.05 equiv of Pd(dppf)Cl<sub>2</sub>, 3.0 equiv of K<sub>2</sub>CO<sub>3</sub>, DME/water (5:1), 120 Â°C microwave, 1 h; or 1.5 equiv of ArBr, 0.05 equiv of Pd(dppf)Cl<sub>2</sub>, 2.5 equiv of CsF, MeOH, 120 Â°C microwave, 1 h; or 1.3 equiv of ArBr, 0.05 equiv of Pd-132, 3 equiv of CsF, MeOH, 50 Â°C, 1 h. (g) 5 equiv of methylimidazole, 1.5 equiv of CuI, 3 equiv of Cs<sub>2</sub>CO<sub>3</sub>, NMP, 150 Â°C, microwave, 5 h, 2%.</p></p></figure><div class="NLM_p">The majority of aryl halides used for the final Suzuki reaction are commercially available or could be readily accessed through standard literature procedures except for those thiazolo halides. A general synthetic route to access the thiazolo halides is outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Treatment of 4-methylthiazole (<b>18</b>) with <i>n</i>-BuLi followed by subsequent trapping of the anion with a range of ketones generated tertiary alcohols <b>19a</b> and <b>19b</b>. For a range of substrates, bromination afforded the desired thiazolo bromide<b>s 20</b>â<b>23</b> for Suzuki coupling. For thiazoles featuring the diol motif, elimination of the alcohol under acidic conditions from <b>20</b> provided 1,1-disubstituted olefin <b>24</b>, which was a suitable substrate for Sharpless asymmetric dihydroxylation.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(26)</a> Use of either AD-mix-Î± or AD-mix-Î² provided both diol enantiomers <b>25</b> and <b>26</b> (80â85% ee, >98% ee after recrystallization), which could be utilized in Suzuki coupling to afford <b>8d</b> and <b>8e,</b> respectively.</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthesis of Thiazole Halides as Precursors for Suzuki Coupling Reactions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.0 equiv of ketone, 1.0 equiv of <i>n</i>-BuLi, THF, â78 Â°C, 0.5 h. (b) 1.0 equiv of NBS, DMF 0 Â°C, overnight. (c) 1.1 equiv of H<sub>2</sub>SO<sub>4</sub>, AcOH, 80â85 Â°C, 20 h. (d) AD-mix-Î± or -Î², THF/<i>t</i>-BuOH/H<sub>2</sub>O (1:1:1), 25 Â°C, 60 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The co-crystal structure of crizotinib (<b>1</b>) in the ALK kinase domain provided a basis for design of more potent second-generation ALK inhibitors. Efforts to improve the potency and efficiency of the 3-benzyloxy aminopyridine series focused on optimizing both the 2,6-dichloro-3-fluorophenyl head and pyrazolopiperidine tail groups in crizotinib (<b>1</b>). A potent and lipophilic-efficient triazolophenyl head group was identified. Successful application of both structure-based and lipophilic-efficiency-focused design on the tail group optimization led to <b>8e</b>, which was potent across a broad panel of engineered ALK mutant cell lines. In addition, <b>8e</b> showed a suitable preclinical PK profile and demonstrated robust tumor growth inhibition in a crizotinib-resistant (H3122-L1196M) in vivo model.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82178" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82178" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting materials and other reagents were purchased from commercial suppliers and were used without further purification unless otherwise indicated. Compound <b>8e</b>, also known as PF-06439015, is now commercially available from Sigma Aldrich. All reactions were performed under a positive pressure of nitrogen or argon or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, unless otherwise indicated. Analytical thin-layer chromatography was performed on glass-backed silica gel 60_F 254 plates [Analtech (0.25 mm)] and eluted with the appropriate solvent ratios (v/v). The reactions were assayed by high-performance liquid chromatography (HPLC) or thin-layer chromatography (TLC) and terminated as judged by the consumption of starting material. The TLC plates were visualized by UV, phosphomolybdic acid stain, or iodine stain. Microwave-assisted reactions were run in a Biotage Initiator. <sup>1</sup>H NMR spectra were recorded on a Bruker instrument operating at 400 MHz unless otherwise indicated. <sup>1</sup>H NMR spectra are obtained as DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> solutions as indicated (reported in parts per million, ppm), with chloroform as the reference standard (7.25 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets. Coupling constants, when given, are reported in hertz. Mass spectra were obtained via liquid chromatographyâmass spectrometry (LC-MS) on an Agilent instrument with atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). High-resolution mass measurements were carried out on an Agilent TOF 6200 series with ESI. All test compounds showed >95% purity as determined by combustion analysis or by HPLC. HPLC conditions were as follows: XBridge C18 column @ 80 Â°C, 4.6 mm Ã 150 mm, 5 Î¼m, 5%/95% MeOH/H<sub>2</sub>O buffered with 0.2% formic acid/0.4% ammonium formate, 3 min run, flow rate 1.2 mL/min, UV detection (Î» = 254, 224 nm). Combustion analyses were performed by Atlantic Microlab, Inc. (Norcross, GA).</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 3-[(<i>R</i>)-1-(2-Chloro-5-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-2-amine (<b>1a</b>)</h3><div class="NLM_p last">For the synthetic approach to <b>1a</b>, see ref <a onclick="showRef(event, 'cit11c'); return false;" href="javascript:void(0);" class="ref cit11c">11c</a>. LC-MS (APCI) <i>m</i>/<i>z</i> 417 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (700 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.95 (s, 1H), 7.75 (s, 1H), 7.59 (s, 1H), 7.54â7.58 (m, 1H), 7.51 (dd, <i>J</i> = 8.80, 4.84 Hz, 1H), 7.17 (td, <i>J</i> = 8.20, 2.97 Hz, 1H), 7.03 (s, 1H), 5.84 (s, 2H), 5.83â5.79 (m, 1H), 4.17â4.09 (m, 1H), 3.02 (d, <i>J</i> = 12.10 Hz, 2H), 2.56 (t, <i>J</i> = 11.77 Hz, 2H), 1.92 (d, <i>J</i> = 10.56 Hz, 2H), 1.76 (br s, 2H), 1.59 (d, <i>J</i> = 6.16 Hz, 3H), one NH proton is missing due to deuterium exchange.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>R</i>)-5-Bromo-3-[1-(2,5-difluorophenyl)ethoxy]-2-nitropyridine (<b>10a</b>)</h3><div class="NLM_p last">To an ice-cooled solution (0 Â°C) of (<i>S</i>)-1-(5-fluoro-2-methoxyphenyl)ethanol<a onclick="showRef(event, 'cit26b'); return false;" href="javascript:void(0);" class="ref cit26b">(25b)</a> (99. 5% ee, 10.0 g, 63.2 mmol) and triphenylphosphine (19.1 g, 72.7 mmol) in toluene (400 mL) was added a solution of 5-bromo-3-hydroxy-2-nitropyridine (14.5 g, 66.4 mmol) in toluene (100 mL), followed by diisopropyl azodicarboxylate (14.8 g, 73 mmol) at such a rate as to maintain the temperature below 10 Â°C. The resulting mixture was stirred at room temperature for 18 h. The crude reaction mixture was concentrated and 100 mL of fresh toluene was added. The yellow solution was stirred at â78 Â°C for 90 min, after which the precipitate was filtered off and washed with precooled toluene (3 Ã 75 mL). The filtrate was concentrated under reduced pressure and fresh toluene was added (150 mL). The solution was washed with 1 M NaOH (75 mL) to remove excess hydroxypyridine and then dried over magnesium sulfate, filtered, and evaporated to give a yellow gum. The crude material was purified by column chromatography on silica gel, eluted with 3/1 heptane/EtOAc, to give the desired product <b>10a</b> (21.03 g, 93% yield) as a yellow oil. LC-MS (APCI) <i>m</i>/<i>z</i> 359 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.12 (d, <i>J</i> = 1.6 Hz, 1H), 7.48 (d, <i>J</i> = 2 Hz, 1H), 7.17 (ddd, <i>J</i> = 8.5, 5.6, 3.1 Hz, 1H), 7.11â7.06 (m, 1H), 7.02â6.98 (m, 1H), 5.75 (q, <i>J</i> = 6.4 Hz, 1H), 1.71 (d, <i>J</i> = 6.2 Hz, 3H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>R</i>)-5-Bromo-3-[1-(2,5-difluorophenyl)ethoxy]pyridin-2-amine (<b>11a</b>)</h3><div class="NLM_p last">To a solution of <b>10a</b> (21.0 g, 46 mmol) in dioxane (200 mL), was added glacial AcOH (26 mL) at room temperature. The solution was warmed to 40 Â°C. At this temperature, 325 mesh iron (12.7 g) was added to the solution in a portionwise manner. After the reaction mixture was stirred at 40 Â°C for 30 min, another 26 mL of glacial AcOH was added. After the reaction mixture was stirred for 10 min, 2 M HCl (200 mL) was added and the solution was filtered through Celite. The remaining iron residue was washed with 2 M HCl (2 Ã 100 mL). The aqueous layer was extracted with <i>tert</i>-butyl methyl ether (TBME; 1 Ã 250 mL) and the TBME layer was back-washed with 2 M HCl (150 mL). The aqueous layer was made basic with ammonia and extracted with TBME (2 Ã 250 mL). The combined TBME layers were decanted off and filtered through Celite. The filtrate was dried with MgSO<sub>4</sub>, filtered, and evaporated to give <b>11a</b> (17.5 g, 91% yield) as a clear oil. This material was used without further purification in the subsequent Suzuki coupling step. LC-MS (APCI) <i>m</i>/<i>z</i> 329 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.69 (d, <i>J</i> = 2 Hz, 1H), 7.11â6.95 (m, 3H), 6.85 (d, <i>J</i> = 2 Hz, 1H), 5.57 (q, <i>J</i> = 6.5 Hz, 1H), 4.90 (br s, 2H), 1.68 (d, <i>J</i> = 6.6 Hz, 3H).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>R</i>)-3-[1-(2,5-Difluorophenyl)ethoxy]-5-(3-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>6a</b>)</h3><div class="NLM_p last">To a suspension of <b>11a</b> (100 mg, 0.3 mmol), 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (158 mg, 0.76 mmol), and palladium tetrakis( triphenylphosphine) (35 mg, 0.03 mmol) in dioxane (12.5 mL) were added NaHCO<sub>3</sub> (64 mg, 0.76 mmol) and water (5 mL). The reaction mixture was thoroughly degassed. After being heated at 110 Â°C for 90 min, the reaction mixture was cooled to room temperature and partitioned between 10% citric acid solution (25 mL) and TBME (25 mL). The aqueous layer was made basic with ammonia and further extracted with TBME (25 mL). The organic layer was then dried with MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash column chromatography over silica gel, eluted with 1/4 heptane/EtOAc followed by 100% EtOAc, to provide the desired product <b>6a</b> (60 mg, 60% yield) as a clear oil. LC-MS (APCI) <i>m</i>/<i>z</i> 331 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.66 (d, <i>J</i> = 2 Hz, 1H), 7.47 (s, 1H), 7.12â7.04 (m, 2H), 6.99â6.93 (m, 1H), 6.78 (d, <i>J</i> = 1.6 Hz, 1H), 5.73 (br s, 2H), 5.62 (q, <i>J</i> = 6.50 Hz, 1H), 5.12 (br s, 1H), 2.22 (s, 3H), 1.71 (d, <i>J</i> = 6.26 Hz, 3H).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 2-[(1<i>S</i>)-1-{[2-Amino-5-(3-methyl-1<i>H</i>-pyrazol-4-yl)-pyridin-3-yl]oxy}ethyl]-4-fluorobenzonitrile (<b>6b</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>6a</b>, racemic <b>11b</b> (280 mg, 0.83 mmol) was reacted with 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (433 mg, 2.08 mmol) to afford <b>6b</b> (45 mg, 15% yield) as a colorless solid after chiral separation. LC-MS (ESI) <i>m</i>/<i>z</i> 338.04 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.79â7.63 (m, 2H), 7.51 (s, 1H), 7.31â7.25 (m, 1H), 7.21â7.03 (m, 1H), 6.73 (d, <i>J</i> = 1. 95 Hz, 1H), 5.79â5.58 (m, 1H), 4.95 (br s, 2H), 2.25 (s, 3H), 1.78 (d, <i>J</i> = 6.25 Hz, 3H), one NH proton is missing due to deuterium exchange. Chiral separation by HPLC afforded <b>6b</b> with >99% ee by use of an AD-H column eluted with 50/50 MeOH/EtOH at 0.5 mL/min. Compound <b>6b</b> was obtained as peak 1 (9.55 min) and the inactive enantiomer as peak 2 (13.56 min).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-[(1<i>R</i>)-1-(5-Fluoro-2-methoxyphenyl)ethoxy]-5-(5-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>6c</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>6a</b>, <b>11c</b> (250 mg, 0.66 mmol) was reacted with 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (239 mg, 1.15 mmol) to afford <b>6c</b> (128 mg, 57% yield) as a pale, dense yellow foam after purification. LC-MS (APCI) <i>m</i>/<i>z</i> 343 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) Î´ 7.53â7.42 (m, 2H), 7.08 (dd, <i>J</i> = 2.73, 8.98 Hz, 1H), 7.04â6.93 (m, 2H), 6.79 (d, <i>J</i> = 1.56 Hz, 1H), 5.78 (q, <i>J</i> = 6.51 Hz, 1H), 4.89 (br s, 2H), 3.89 (s, 3H), 2.10 (s, 3H), 1.64 (d, <i>J</i> = 6.25 Hz, 3H), one NH proton is missing due to deuterium exchange.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 1-(5-Fluoro-2-[1,2,3]-triazol-2-ylphenyl)ethanone (<b>13</b>)</h3><div class="NLM_p last">To a solution of 2,5-difluoroacetophenone <b>12</b> (10.0 g, 64 mmol) in 1-methyl-2-pyrrolidinone (10 mL) were added potassium carbonate (8.84 g, 64 mmol) and 1<i>H</i>-1,2,3-triazole (6.64 g, 96 mmol). The mixture was heated to 140 Â°C for 3 h under an atmosphere of nitrogen. The reaction was allowed to cool and then partitioned between ethyl acetate (300 mL) and aqueous ammonium chloride solution (1 M, 100 mL). The organic phase was washed with water (3 Ã 200 mL) and then dried over magnesium sulfate, filtered, and concentrated. The residue was purified by chromatography on silica gel, eluted with 9/1 heptane/EtOAc, to produce <b>13</b> (4.6 g, 35% yield) as a brown oil. LC-MS (APCI) <i>m</i>/<i>z</i> 206 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) Î´ 7.85â7.80 (m, 3H), 7.28â7.20 (m, 2H), 2.17 (s, 3H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethanol (<b>14</b>)</h3><div class="NLM_p last">To a solution of (â)-DIP-Cl (21.3 g, 66.4 mmol) in THF (60 mL) at â35 Â°C was added a solution of <b>13</b> (10.9 g, 53.1 mmol) in THF (20 mL) in a dropwise manner at such a rate as to maintain the temperature below â27 Â°C. The resulting mixture was stirred at â35 Â°C for 3 h and then allowed to warm slowly to room temperature over a period of 18 h. The mixture was evaporated under reduced pressure to remove the majority of the THF. The resulting residue was dissolved in TBME (150 mL) and rapidly stirred with an overhead stirrer while diethanolamine (15.1 g, 2.7 equiv) was added, and the temperature was allowed to rise to 50 Â°C during the addition. The resulting mixture was stirred for 1 h before filtration. The filter cake was washed with TBME (2 Ã 100 mL) and discarded. The combined filtrate was evaporated under reduced pressure and the resulting crude product was purified by chromatography on silica gel, eluted with 1/1 heptane/toluene, followed by a gradient of heptane/TBME (1/1 to 0/1) to produce <b>14</b> (10.9 g, 99% yield) as a colorless oil. LC-MS (APCI) <i>m</i>/<i>z</i> 208 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) Î´ 7.86 (s, 2H), 7.59 (dd, <i>J</i> = 8.98, 5.08 Hz, 1H), 7.38 (dd, <i>J</i> = 9.57, 2.93 Hz, 1H), 7.09 (ddd, <i>J</i> = 8.79, 7.62, 3.12 Hz, 1H), 4.85 (dd, <i>J</i> = 6.64, 1.17 Hz, 1H), 1.43 (d, <i>J</i> = 6.64 Hz, 3H), one OH proton is missing due to deuterium exhcange. Compound <b>14</b> was obtained in 96% ee (<i>S</i>) as determined by SFC on a Chiralpak AD-H 4.6 Ã 250 mm column, 10% MeOH @ 140 bar, 3 mL/min.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethyl Methanesulfonate (<b>15</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (15.1 g, 72.9 mmol) in TBME (150 mL) was added triethylamine (15.4 mL, 110 mmol). The solution was cooled to â20 Â°C, and methanesulfonyl chloride (6.72 mL, 86.8 mmol) was added as a solution in TBME (30 mL) via an addition funnel. The reaction mixture was kept at â10 Â°C for 1 h and then allowed to warm to room temperature. After the mixture was stirring at room temperature for 16 h, water (80 mL) was added to the reaction mixture. The organic layer was washed with saturated NaHCO<sub>3</sub> (80 mL) and 0.1 M HCl (2 Ã 80 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give <b>15</b> (17.74 g, 85% yield) as a yellow oil, which was used without further purification. LC-MS (APCI) <i>m</i>/<i>z</i> 286 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.89 (s, 2H), 7.69 (dd, <i>J</i> = 9.09, 5.05 Hz, 1H), 7.43 (dd, <i>J</i> = 9.22, 2.91 Hz, 1H), 7.19 (ddd, <i>J</i> = 8.91, 7.39, 2.91 Hz, 1H), 6.16 (qd, <i>J</i> = 6.40, 1.01 Hz, 1H), 2.86 (s, 3H), 1.71 (d, <i>J</i> = 6.57 Hz, 3H). Compound <b>15</b> was obtained in 96â96.5% ee (<i>S</i>) as determined by SFC on a Chiralpak AD-H 4.6 Ã 250 mm column, 10% MeOH @ 140 bar, 3 mL/min.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>R</i>)-5-Bromo-3-{1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-2-amine (<b>16</b>)</h3><div class="NLM_p last">To a suspension of cesium carbonate (24.3 g, 74.6 mmol) and 2-amino-5-bromopyridin-3-ol (14.1 g, 74.6 mmol) in acetone (100 mL) was added a solution of <b>15</b> (17.73 g, 62.1 mmol) in acetone (100 mL) via an addition funnel. After the reaction mixture was heated at 60 Â°C for 16 h and stirred at room temperature for a further 16 h, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was concentrated and purified by column chromatography on silica gel, eluted with 0â20% EtOAc/heptane, to give <b>16</b> (15 g, 67% yield) as a yellow foam. LC-MS (APCI) <i>m</i>/<i>z</i> 378 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.92 (s, 2H), 7.69â7.63 (m, 2H), 7.30â7.24 (m, 1H), 7.18â7.12 (m, 1H), 6.87 (d, <i>J</i> = 1.77 Hz, 1H), 5.73 (d, <i>J</i> = 6.32 Hz, 1H), 4.73 (br s, 2H), 1.58 (s, 3H). Compound <b>16</b> was obtained in 96% ee as determined by SFC on a LUX cellulose 4.6 Î¼m Ã 250 mm column, 5â45% MeOH ramping 10%/min @ 140 bar, 3 mL/min.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-[(<i>R</i>)-1-(5-Fluoro-2-[1,2,3]-triazol-2-ylphenyl)ethoxy]-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridin-2-ylamine (<b>17</b>)</h3><div class="NLM_p last">Dimethyl sulfoxide (DMSO, 15 mL) was bubbled with argon gas for 15 min and then added to a mixture of bis(pinacolato)diboron (B<sub>2</sub>pin<sub>2</sub>; 332 mg, 1.31 mmol), <b>16</b> (291 mg, 0.769 mmol), and potassium acetate (264 mg, 2.69 mmol) under argon atmosphere. 1,1â²-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride [Pd(dppf)Cl<sub>2</sub>, 31 mg, 0.038 mmol] was added to the mixture, which was further bubbled with argon gas for 5 min and then placed in an 80 Â°C oil bath for 3 h. After the mixture was cooled to room temperature, ethyl acetate, aqueous NaH<sub>2</sub>PO<sub>4</sub> (1 M), and brine were added. The mixture was extracted three times with EtOAc, and the combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to a black tar, which was then resuspended in EtOAc. The product was extracted into water (10 mL) containing HCI (0.8 mmol). To the product in water was added aqueous Na<sub>2</sub>HPO<sub>4</sub> (0.25 M, 0.75 mmol, 3 mL). The pH was then further adjusted to ca. 5 by addition of aqueous NaH<sub>2</sub>PO<sub>4</sub> (1 M). The cream-colored product precipitated, and EtOAc and brine were added. The product dissolved, and the aqueous layer was extracted with EtOAc (3 Ã 30 mL). The combined EtOAc extracts were dried over sodium sulfate, filtered, and evaporated to afford <b>17</b> (250 mg, 77% yield) as a cream-colored solid, which was used without further purification. LC-MS (APCI) <i>m</i>/<i>z</i> 426 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.23 (s, 2H), 7.77â7.65 (m, 3H), 7.36 (dt, <i>J</i> = 8.5, 2.8 Hz, 1H), 6.72 (s, 1H), 6.70 (br s, 2H), 5.70 (q, <i>J</i> = 6. 63 Hz, 1H), 1.58 (d, <i>J</i> = 6.15 Hz, 3H), 1.23 (s, 12H).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-{(1<i>R</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}-5-(5-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>6d</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>6a</b>, <b>16</b> (250 mg, 0.66 mmol) was reacted with 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (343 mg, 1.65 mmol) to afford <b>6d</b> (135 mg, 54% yield) as a white foam after purification. LC-MS (ESI) <i>m</i>/<i>z</i> 380.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.22 (s, 2H), 7.67 (dd, <i>J</i> = 8.84, 5.05 Hz, 1H), 7.59 (dd, <i>J</i> = 9.73, 2.91 Hz, 1H), 7.53 (d, <i>J</i> = 1.77 Hz, 1H), 7.44 (br s, 1H), 7.34 (td, <i>J</i> = 8.34, 3.03 Hz, 1H), 6.60 (d, <i>J</i> = 1.52 Hz, 1H), 5.82 (s, 2H), 5.71â5.35 (m, 1H), 2.05 (s, 3H), 1.59 (d, <i>J</i> = 6.06 Hz, 3H), one NH proton is missing due to deuterium exchange.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 5-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-3-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-2-amine (<b>7a</b>)</h3><div class="NLM_p last">A mixture of <b>16</b> (75 mg, 0.2 mmol), 1,3-dimethyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1<i>H</i>-pyrazole (74.8 mg, 0.34 mmol), and cesium fluoride (91.1 mg, 0.91 mmol) was taken up in methanol (2 mL), and the solution was thoroughly degassed. PdCl<sub>2</sub>(dppf) (8.2 mg, 0.01 mmol) was added to the solution, and the reaction was heated in the microwave at 120 Â°C for 1 h. The reaction was allowed to cool, and the filtrate was passed through a 2 Î¼m syringe filter prior to being purified by SFC to afford <b>7a</b> (51 mg, 66% yield) as a colorless solid. LC-MS (APCI) <i>m</i>/<i>z</i> 394 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.23 (s, 2H), 7.66 (dd, <i>J</i> = 8.88, 5.10 Hz, 1H), 7.58 (dd, <i>J</i> = 9.82, 3.02 Hz, 1H), 7.54 (s, 1H), 7.48 (d, <i>J</i> = 1.51 Hz, 1H), 7.33 (td, <i>J</i> = 8.50, 3.02 Hz, 1H), 6.56 (d, <i>J</i> = 1.89 Hz, 1H), 5.86 (s, 2H), 5.53 (q, <i>J</i> = 6.29 Hz, 1H), 3.72 (s, 3H), 1.94 (s, 3H), 1.58 (d, <i>J</i> = 6.42 Hz, 3H).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-1-methyl-1<i>H</i>-pyrazole-3-carbonitrile (<b>7b</b>)</h3><div class="NLM_p last">Compound <b>17</b> (500 mg, 1.18 mmol), 4-bromo-1-methyl-1<i>H</i>-pyrazole-3-carbonitrile (328 mg, 1.76 mmol), and potassium carbonate (488 mg, 3.53 mmol) were all added to a microwave vial, followed by the addition of dimethyl ether (DME; 10 mL) and water (2 mL). The mixture was thoroughly degassed, and Pd(dppf)Cl<sub>2</sub> (48.2 mg, 0.059 mmol) was added. The reaction was heated in the microwave at 120 Â°C for 1 h. The reaction was partitioned between EtOAc and water. The organic layers were separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to give a residue, which was purified by reverse-phase HPLC to provide <b>7b</b> (139 mg, 29% yield) as a white solid. LC-MS (APCI) <i>m</i>/<i>z</i> 405 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.22 (s, 2H), 7.98 (s, 1H), 7.73 (d, <i>J</i> = 2.02 Hz, 1H), 7.69 (dd, <i>J</i> = 9.73, 2.91 Hz, 1H), 7.62 (dd, <i>J</i> = 8.84, 5.05 Hz, 1H), 7.32 (td, <i>J</i> = 8.40, 2.91 Hz, 1H), 6.81 (d, <i>J</i> = 1.52 Hz, 1H), 6.20 (s, 2H), 5.56 (q, <i>J</i> = 6.32 Hz, 1H), 3.94 (s, 3H), 1.57 (d, <i>J</i> = 6.32 Hz, 3H).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3-{(1<i>R</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}-5-(1-methyl-1<i>H</i>-pyrazol-5-yl)pyridin-2-amine (<b>7c</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>6a</b>, <b>16</b> (200 mg, 0.53 mmol) was reacted with 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (220 mg, 1.06 mmol) to afford <b>7c</b> (168 mg, 84% yield) as a white solid after purification. LC-MS (APCI) <i>m</i>/<i>z</i> 379.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.87 (s, 2H), 7.71 (d, <i>J</i> = 1.6 Hz, 1H), 7.62 (dd, <i>J</i> = 8.8, 4.9 Hz, 1H), 7.44 (d, <i>J</i> = 2 Hz, 1H), 7.29 (dd, <i>J</i> = 6.2, 3.1 Hz, 1H), 7.12 (ddd, <i>J</i> = 8.8, 7.4, 2.9 Hz, 1H), 6.80 (d, <i>J</i> = 1.6 Hz, 1H), 6.16 (d, <i>J</i> = 2 Hz, 1H), 5.78 (dd, <i>J</i> = 6.2, 1.2 Hz, 1H), 4.92 (br s, 2H), 3.67 (s, 3H), 1.61 (d, <i>J</i> = 6.2 Hz, 3H).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 3-{(1<i>R</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}-5-(1-methyl-1<i>H</i>-1,2,3-triazol-5-yl)pyridin-2-amine (<b>7d</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>6a</b>, <b>17</b> (263 mg, 0.64 mmol) was reacted with 1-methyl-5-iodotriazole (134 mg, 0.64 mmol) to afford <b>7d</b> (63 mg, 26% yield) as a white foam after purification. LC-MS (ESI) <i>m</i>/<i>z</i> 381 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) Î´ 7.89 (s, 2H), 7.70 (d, <i>J</i> = 1.56 Hz, 1H), 7.62â7.59 (m, 1H), 7.60 (s, 1H), 7.29â7.26 (m, 1H), 7.14â7.11 (m, 1H), 6.80 (d, <i>J</i> = 1. 95 Hz, 1H), 5.71 (q, <i>J</i> = 6.2 Hz, 1H), 5.22 (br s, 2H), 3.86 (s, 3H), 1.62 (d, <i>J</i> = 6.25 Hz, 3H).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 5-{(1<i>R</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}-2â²-methoxy-3,3â²-bipyridin-6-amine (<b>7e</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>7a</b>, <b>16</b> (50 mg, 0.13 mmol) was reacted with 2-methoxy-3-pyridineboronic acid (54.9 mg, 0.26 mmol) to afford <b>7e</b> (29 mg, 54% yield) as a white solid after purification. LC-MS (ESI) <i>m</i>/<i>z</i> 407.1 (M + H)<sup>+</sup>; <sup>1</sup>H (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.18 (s, 2H), 8.05 (dd, <i>J</i> = 4.93, 1.64 Hz, 1H), 7.70â7.59 (m, 3H) 7.53 (dd, <i>J</i> = 7.33, 1.52 Hz, 1H), 7.34 (td, <i>J</i> = 8.34, 3.03 Hz, 1H), 7.00 (dd, <i>J</i> = 7.33, 5.05 Hz, 1H), 6.81 (d, <i>J</i> = 1.26 Hz, 1H), 6.08 (s, 2H), 5.59 (q, <i>J</i> = 5.73 Hz, 1H), 3.70 (s, 3H), 1.59 (d, <i>J</i> = 5.73 Hz, 3H).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-{(1<i>R</i>)-1-[5-Fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}-5-(4-methoxypyrimidin-5-yl)pyridin-2-amine (<b>7f</b>)</h3><div class="NLM_p last">In a similar manner to the preparation of <b>6a</b>, <b>16</b> (150 mg, 0.40 mmol) was reacted with 4-methoxy-5-pyrimdineboronic acid (84 mg, 0.55 mmol) to afford <b>7f</b> (32 mg, 20% yield) as a white solid after purification. LC-MS (APCI) <i>m</i>/<i>z</i> 408.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.71 (s, 1H), 8.35 (s, 1H), 7.89 (s, 2H), 7.80 (d, <i>J</i> = 1.6 Hz, 1H), 7.64 (dd, <i>J</i> = 8.8, 4.9 Hz, 1H), 7.28â7.23 (m, 2H), 7.18â7.13 (m, 1H), 6.44 (br s, 2H), 5.84 (q, <i>J</i> = 6.04 Hz, 1H), 3.92 (s, 3H), 1.65 (d, <i>J</i> = 6.6 Hz, 3H).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2-(6â²-Amino-5â²-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}-2-methyl-3,3â²-bipyridin-6-yl)propan-2-ol (<b>7g</b>)</h3><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.26 mmol), B<sub>2</sub>Pin<sub>2</sub> (114 mg, 0.45 mmol), KOAc (91 mg, 0.92 mmol), and Pd(dppf)Cl<sub>2</sub> (9.5 mg, 0.01 mmol) were combined in a microwave vial, and DMSO (1 mL) was added. The mixture was thoroughly degassed and heated in the microwave at 80 Â°C for 3 h. LC-MS indicated that all <b>16</b> had been consumed, and the intermediate boronate ester <b>17</b> could be observed. 2-(5-Bromo-6-methylpyridin-2-yl)propan-2-ol (91 mg, 0.40 mmol), cesium fluoride (120 mg, 0.79 mmol), Pd(dppf)Cl<sub>2</sub> (9.5 mg, 0.01 mmol), and methanol (2 mL) were all added to the vial, which was heated in the microwave at 120 Â°C for 1 h. The reaction was partitioned between EtOAc and saturated aqueous NaHCO<sub>3</sub>. The organic layers were separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to give a residue, which was purified by reverse-phase HPLC to provide <b>7g</b> (56 mg, 47% yield) as a white solid. LC-MS (APCI) <i>m</i>/<i>z</i> 449.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.15 (s, 2H), 7.67â7.58 (m, 2H), 7.48â7.42 (m, 2H), 7.39 (d, <i>J</i> = 8.31 Hz, 1H), 7.35 (s, 1H), 6.59 (d, <i>J</i> = 1.51 Hz, 1H), 6.06 (s, 2H), 5.56 (d, <i>J</i> = 6.04 Hz, 1H), 5.24â5.15 (m, 1H), 2.15 (s, 3H), 1.58 (d, <i>J</i> = 6.42 Hz, 3H), 1.42 (s, 6H).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 2-[5-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propan-2-ol (<b>7h</b>)</h3><div class="NLM_p last">Compound <b>17</b> (112 mg, 0.26 mmol), 2-(5-bromo-4-methylthiazol-2-yl)propan-2-ol (92 mg, 0.39 mmol), and cesium fluoride (139 mg, 0.91 mmol) were all added to a microwave vial, and methanol (4 mL) was added. The mixture was thoroughly degassed, and Pd(dppf)Cl<sub>2</sub> (10.6 mg, 0.01 mmol) was added. The reaction was heated in the microwave at 120 Â°C for 1 h. The reaction was partitioned between EtOAc and water. The organic layers were separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to give a residue, which was purified by reverse-phase HPLC to provide <b>7h</b> (30 mg, 25% yield) as a tan powder. LC-MS (APCI) <i>m</i>/<i>z</i> 455 (M + H)<sup>+</sup>; <sup>1</sup> H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.19 (s, 2H), 7.67 (dd, <i>J</i> = 8.72, 5.18 Hz, 1H), 7.61 (dd, <i>J</i> = 9.60, 2.78 Hz, 1H), 7.52 (d, <i>J</i> = 1.77 Hz, 1H), 7.39â7.31 (m, 1H), 6.63 (s, 1H), 6.17 (br s, 2H), 5.84 (s, 1H), 5.66â5.56 (m, 1H), 2.06 (s, 3H), 1. 58 (d, <i>J</i> = 6.32 Hz, 3H), 1.47 (s, 6H).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 3-[(<i>R</i>)-1-(5-Fluoro-2-[1,2,3]triazol-2-ylphenyl)ethoxy]-5-(2-methylimidazol-1-yl)pyridin-2-ylamine (<b>7i</b>)</h3><div class="NLM_p last">A mixture of <b>16</b> (50 mg, 0.13 mmmol), 2-methylimidazole (54.2 mg, 0.66 mmmol), Cs<sub>2</sub>CO<sub>3</sub>(129 mg, 0.4 mmol), and CuI (37.7 mg, 0.2 mmmol) in <i>N</i>-methyl-2-pyrrolidone (NMP; 0.44 mL) was degassed, purged with nitrogen, and heated to 150 Â°C in the microwave. After 5 h, the crude reaction mixture was poured into water (100 mL) and extracted with TBME (2 Ã 50 mL). The combined organic extracts were washed with water and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to give 75 mg of a crude material as an amber oil. The product was purified by reverse-phase HPLC and submitted direct to screening as a 30 mM solution, with 859 Î¼L being obtained. The concentration was determined by evaporative light scattering detector (ELSD). LC-MS (APCI) <i>m</i>/<i>z</i> 380 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.14 (s, 2H), 7.67â7.61 (m, 2H), 7.52â7.51 (m, 1H), 7.36â7.33 (m, 1H), 7.09â7.05 (m, 1H), 6.89â6.85 (m, 1H), 6.57 (s, 1H), 6.31 (br s, 2H), 5.52â5.50 (m, 1H), 3.34 (s, 3H), 1.59â1.58 (m, 3H).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-(4-Methylthiazol-2yl)propan-2-ol (<b>19a</b>)</h3><div class="NLM_p last">This reaction was carried out in two batches of 33.9 g, which were subsequently combined for purification. Compound <b>18</b> (33.9 g, 341.7 mmol) was dissolved in dry Et<sub>2</sub>O (700 mL) under nitrogen and cooled to â78 Â°C. A solution of <i>n</i>-BuLi in heptane (2.1 M, 179.0 mL, 375.9 mmol) was added slowly from a pressure-equalizing dropping funnel over 2 h, with the internal temperature being maintained between â60 and â65 Â°C during the addition. After the mixture was stirred for a further 45 min at â60 Â°C, acetone (27.6 mL, 375.9 mmol) was added over 45 min while the reaction was maintained at this temperature. The reaction was then stirred for 30 min at â60 Â°C before being quenched by the careful addition of 25% ammonium acetate solution (200 mL). The mixture was extracted several times with EtOAc (1 L total), and the combined organic extracts were washed with H<sub>2</sub>O (150 mL) and brine (150 mL), dried over MgSO<sub>4</sub>, and concentrated to give a yellow solid. The combined batches of solid were recrystallized from hot heptane, and the solid was collected and dried to give <b>19a</b> (70 g, 65% yield) as an off-white solid. LC-MS (APCI) <i>m</i>/<i>z</i> 158.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.78 (s, 1H), 3.15 (s, 1H), 2.41 (s, 3H), 1.64 (s, 6H).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-(5-Bromo-4-methylthiazol-2-yl)propan-2-ol (<b>20</b>)</h3><div class="NLM_p">To a solution of <b>19a</b> (70 g, 445.19 mmol) in dichloromethane (DCM; 750 mL) at 5 Â°C was added N-bromosuccinimide (NBS; 87.16 g, 489.71 mmol) portionwise over 20 min. After being stirred at room temperature for 2.5 h, the reaction was diluted with DCM (250 mL) and washed with 10% sodium thiosulfate solution (200 mL), H<sub>2</sub>O (100 mL), and brine (150 mL). The organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give crude <b>20</b> (110 g, >100% yield) as a yellow oil, which was used without further purification. LC-MS (APCI) <i>m</i>/<i>z</i> 236.2 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 2.37 (s, 3H), 1.63 (s, 6H), one OH proton is missing due to deuterium exchange.</div><div class="NLM_p last">Compounds <b>21</b>â<b>23</b> were synthesized via the same two-step sequence used to prepare <b>20</b>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-(5-Bromo-4-methylthiazol-2-yl)-1-methylazetidin-3-ol (<b>21</b>)</h3><div class="NLM_p last">LC-MS (APCI) <i>m</i>/<i>z</i> 262.95 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.51 (br s, 1H), 3.69 (d, <i>J</i> = 9.3 Hz, 2H), 3.54 (d, <i>J</i> = 9.3 Hz, 2H), 2.44 (s, 3H), 2.32 (s, 3H).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-(5-Bromo-4-methylthiazol-2-yl)tetrahydrofuran-3-ol (<b>22</b>)</h3><div class="NLM_p last">LC-MS (APCI) <i>m</i>/<i>z</i> 264.05 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.14â4.05 (m, 2H), 3.94â3.85 (m, 2H), 3.28 (s, 1H), 2.52 (dt, <i>J</i> = 13.3, 8.8 Hz, 1H), 2.30 (s, 3H), 2.24â2.21 (m, 1H).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-(5-Bromo-4-methylthiazol-2-yl)-3-hydroxytetrahydrothiophene 1,1-Dioxide (<b>23</b>)</h3><div class="NLM_p last">LC-MS (APCI) <i>m</i>/<i>z</i> 311.90 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 3.70 (s, 1H), 3.65 (d, <i>J</i> = 6.6 Hz, 2H), 3.48â3.42 (m, 1H), 3.37â3.31 (m, 1H), 2.74 (ddd, <i>J</i> = 14, 11.2, 8.7 Hz, 1H), 2.53â2.47 (m, 1H), 2.30 (s, 3H).</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Synthesis of 5-Bromo-2-isopropenyl-4-methylthiazole (<b>24</b>)</h3><div class="NLM_p last">This reaction was carried out in two batches of 55 g, which were subsequently combined for workup and purification. Compound <b>20</b> (55 g, 232.92 mmol) was dissolved in acetic acid (500 mL), and concentrated H<sub>2</sub>SO<sub>4</sub> (13.36 mL, 249.2 mmol) was added. The reaction mixture was then heated at 80â85 Â°C for 20 h. The reaction mixtures was cooled and combined, and the acetic acid was removed by distillation under reduced pressure (bp â¼45 Â°C, â¼70 mmHg). The residue was carefully neutralized by the addition of solid NaHCO<sub>3</sub>, diluted with H<sub>2</sub>O (400 mL), and extracted with EtOAc (3 Ã 750 mL). The combined organic extracts were washed with H<sub>2</sub>O (100 mL) and brine (250 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give a brown oil. The crude oil was purified by flash chromatography over silica gel (heptane to 10% EtOAc in heptane) to give <b>24</b> (36.5 g, 36% yield) as a yellow oil. LC-MS (APCI) <i>m</i>/<i>z</i> 218.2 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 5.73â5.71 (m, 1H), 5.29â5.26 (m, 1H), 2.39 (s, 3H), 2.18â2.16 (m, 3H).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Synthesis of (<i>R</i>)-2-(5-Bromo-4-methylthiazol-2-yl)propane-1,2-diol (<b>26</b>)</h3><div class="NLM_p last">This reaction was carried out in two batches of 21.5 g, which were subsequently combined for workup and purification. To a solution of <b>24</b> (21.5 g, 98.5 mmol) in a mixed solvent of THF (300 mL), <i>t</i>-BuOH (300 mL), and H<sub>2</sub>O (300 mL) was added AD-mix-Î± (97.5 g) in a portionwise manner with the internal temperature being maintained between 20 and 25 Â°C. The reaction mixture was then stirred at room temperature for 60 h. The two batches were combined, H<sub>2</sub>O (500 mL) was added, and the mixture was extracted with EtOAc (3 Ã 1 L). The combined organic extracts were washed with H<sub>2</sub>O (200 mL) and brine (500 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give a brown oil. The crude material was purified by column chromatography over silica (1/1 heptane/EtOAc) to give the enantioenriched diol as a colorless solid (41.6 g, 83% yield, 91.3% ee). Recrystallization from a mixture of EtOAc (48 mL) and heptane (240 mL) gave enantiopure <b>26</b> (26.2 g, 73% yield, 99.5% ee) as a white solid. LC-MS (APCI) <i>m</i>/<i>z</i> 251.9 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.03 (d, <i>J</i> = 11.12 Hz, 1H), 3.68 (d, <i>J</i> = 11.12 Hz, 1H), 3.43 (s, 1H), 2.49 (s, 1H), 2.36 (s, 3H), 1.54 (s, 3H). Compound <b>26</b> was obtained in >99% ee by chiral HPLC on a Chiralpak IA 4.6 Ã 250 mm column, eluted with 80% heptane/20% ethanol with 0.2% diethylamine (DEA) at a flow rate of 0.7 mL/min. Retention time of <b>26</b> under these conditions is 6.63 min. The opposite enantiomer <b>25</b> has a retention time of 7.83 min. Compound <b>25</b> was synthesized in a similar manner to <b>26</b> by reacting <b>24</b> with AD-mix-Î².</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 3-[5-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]-1-methylazetidin-3-ol (<b>8a</b>)</h3><div class="NLM_p last">In a similar manner to <b>7h</b>, <b>17</b> (150 mg, 0.35 mmol) was reacted with 3-(5-bromo-4-methylthiazol-2-yl)-1-methylazetidin-3-ol <b>21</b> (139 mg, 0.53 mmol) to afford <b>8a</b> (17 mg, 10% yield) as a tan solid after reverse-phase HPLC. LC-MS (APCI) <i>m</i>/<i>z</i> 482.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.19 (s, 2H), 7.67 (dd, <i>J</i> = 8.97, 5.18 Hz, 1H), 7.61 (dd, <i>J</i> = 9.73, 2.91 Hz, 1H), 7.53 (d, <i>J</i> = 1.77 Hz, 1H), 7.39â7.30 (m, 1H), 6.67 (br s, 1H), 6.63 (d, <i>J</i> = 2.02 Hz, 1H), 6.21 (br s, 2H), 5.59 (q, <i>J</i> = 6.12 Hz, 1H), 3.62 (d, <i>J</i> = 8.08 Hz, 2H), 3.30 (d, <i>J</i> = 8.08 Hz, 2H), 2.32 (s, 3H), 2.11 (s, 3H), 1.57 (d, <i>J</i> = 6.12 Hz, 3H).</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 3-[5-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]tetrahydrofuran-3-ol (<b>8b</b>)</h3><div class="NLM_p last">In a similar manner to <b>7h</b>, <b>17</b> (115 mg, 0.27 mmol) was reacted with 3-(5-bromo-4-methylthiazol-2-yl)tetrahydrofuran-3-ol <b>22</b> (107 mg, 0.41 mmol) to afford a racemic product (51 mg, 39% yield) as a tan solid after reverse-phase HPLC. Chiral separation was carried out by SFC on an AD-H column (4.6 Ã 250 mm), eluted with 30% MeOH @140 bar with a flow rate of 3 mL/min. Compound <b>8b</b> was obtained as peak 2 (6.67 min) and the inactive enantiomer as peak 1 (4.10 min). LC-MS (APCI) <i>m</i>/<i>z</i> 483.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.20 (s, 2H), 7.68 (dd, <i>J</i> = 9.0, 5.2 Hz, 1H), 7.61 (dd, <i>J</i> = 9.7, 2.9 Hz, 1H), 7.53 (d, <i>J</i> = 1.8 Hz, 1H), 7.36 (td, <i>J</i> = 8.4, 2.9 Hz, 1H), 6.63 (d, <i>J</i> = 1.5 Hz, 1H), 6.33 (s, 1H), 6.20 (br s, 2H), 5.61 (q, <i>J</i> = 5.6 Hz, 1H), 4.05â3.94 (m, 2H), 3.93â3.76 (m, 2H), 2.49â2.35 (m, 1H), 2.20â2.10 (m, 1H), 2.07 (s, 3H), 1.58 (d, <i>J</i> = 6.3 Hz, 3H).</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-[5-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]tetrahydrothiophene-3-ol 1,1-Dioxide (<b>8c</b>)</h3><div class="NLM_p last">Compound <b>17</b> (1.38 g, 3.24 mmol), 3-(5-bromo-4-methylthiazol-2-yl)-3-hydroxytetrahydrothiophene 1,1-dioxide <b>23</b> (1.35 g, 4.33 mmol), and cesium fluoride (1.55 g, 10.1 mmol) were combined, and methanol (4 mL) was added. The solution was thoroughly degassed before bis[di-<i>tert</i>-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II) (Pd-132, 102 mg, 0.14 mmol) was added. After being heated at 50 Â°C for 1 h, the reaction was concentrated, taken up in EtOAc, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by column chromatography over silica gel (0â100% EtOAc in heptane) to afford a racemic product (1.15 g, 65%) as a yellow foam. Chiral separation was carried out by SFC on an AD-H column (4.6 Ã 250 mm) eluting with 50% MeOH @120 bar with a flow rate of 5 mL/min. Compound <b>8c</b> was obtained as peak 1 (0.53 min) and the inactive enantiomer as peak 2 (1.67 min). LC-MS (APCI) <i>m</i>/<i>z</i> 531.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.20 (s, 2H), 7.70â7.59 (m, 2H), 7.55 (d, <i>J</i> = 1.77 Hz, 1H), 7.40â7.31 (m, 1H), 7.03 (s, 1H), 6.64 (d, <i>J</i> = 1.77 Hz, 1H), 6.25 (br s, 2H), 5.64â5.56 (m, 1H), 3.61â3.54 (m, 1H), 3.51â3.33 (m, 3H), 2.59â2.40 (m, 2H), 2.11 (s, 3H), 1.58 (d, <i>J</i> = 6.32 Hz, 3H).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 5-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-2-[(2<i>R</i>)-1,2-dihydroxypropan-2-yl]-1,3-thiazole-4-carbonitrile (<b>8e</b>)</h3><div class="NLM_p last">In a sealed vessel, <b>17</b> (11.6 g, 27.3 mmol) was combined with <b>26</b> (6.88 g, 27.3 mmol), Pd(dppf)Cl<sub>2</sub> (1.05 g, 1.36 mol), cesium fluoride (14.5 g, 95.5 mmol), and methanol (300 mL). After the reaction mixture was heated at 120 Â°C for 1 h, it was concentrated and partitioned between EtOAc and water. The dark insoluble materials were filtered off. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a dark brown oil. The oil was preabsorbed onto silica and purified by column chromatography, eluted with 0â10% MeOH in DCM, to give <b>8e</b> as a brown foam. This foam was stirred in water for 1 h and then filtered under vacuum and washed with more water. After being dried under vacuum at 60 Â°C for 18 h, <b>8e</b> was obtained as a free-flowing tan powder (7.78 g, 61% yield). LC-MS (APCI) <i>m</i>/<i>z</i> 471.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.20 (s, 2H), 7.67 (dd, <i>J</i> = 8.72, 5.18 Hz, 1H), 7.61 (dd, <i>J</i> = 9.60, 2.78 Hz, 1H), 7.52 (d, <i>J</i> = 1.52 Hz, 1H), 7.34 (td, <i>J</i> = 8.4, 2.9 Hz, 1H), 6.62 (d, <i>J</i> = 1.26 Hz, 1H), 6.17 (br s, 2H), 5.70 (s, 1H), 5.61 (q, <i>J</i> = 6.30 Hz, 1H), 4.83 (t, <i>J</i> = 6.06 Hz, 1H), 3.51 (d, <i>J</i> = 6.06 Hz, 2H), 2.07 (s, 3H), 1.58 (d, <i>J</i> = 6.06 Hz, 3H), 1.41 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 174.52, 162.28 (<i>J</i><sub>FâC</sub> = 246 Hz), 150.65, 145.63, 139.78 (<i>J</i><sub>FâC</sub> = 7.0 Hz), 138.67, 138.14, 136.51, 133.80 (<i>J</i><sub>FâC</sub> = 3.0 Hz), 128.37, 127.88 (<i>J</i><sub>FâC</sub> = 9.0 Hz), 117.05, 115.96, 115.93 (<i>J</i><sub>FâC</sub> = 23 Hz), 113.23 (<i>J</i><sub>FâC</sub> = 24 Hz), 75.01, 70.02, 69.39, 25.10, 23.01, 15.66; <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ â110.68 (note that it is negative relative to the reference CFCl<sub>3</sub> at 0 ppm for <sup>19</sup>F).</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 5-(6-Amino-5-{(1<i>R</i>)-1-[5-fluoro-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-2-[(2<i>S</i>)-1,2-dihydroxypropan-2-yl]-1,3-thiazole-4-carbonitrile (<b>8d</b>)</h3><div class="NLM_p last">Compound <b>8d</b> was prepared in a similar manner to <b>8e</b>, with <b>25</b> as opposed to <b>26</b> in the Suzuki coupling reaction. LC-MS (APCI) <i>m</i>/<i>z</i> 471.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.20 (s, 2H), 7.69 (dd, <i>J</i> = 8.8, 5.1 Hz, 1H), 7.63 (dd, <i>J</i> = 9.7, 2.9 Hz, 1H), 7.53 (d, <i>J</i> = 2 Hz, 1H), 7.36 (td, <i>J</i> = 8.4, 2.9 Hz, 1H), 6.63 (d, <i>J</i> = 1.9 Hz, 1H), 6.17 (br s, 2H), 5.71 (s, 1H), 5.62 (q, <i>J</i> = 6.3 Hz, 1H), 4.84 (t, <i>J</i> = 6.2 Hz, 1H), 3.52 (d, <i>J</i> = 6.1 Hz, 2H), 2.09 (s, 3H), 1.58 (d, <i>J</i> = 6.3 Hz, 3H), 1.42 (s, 3H).</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Co-crystal Structures</h3><div class="NLM_p last">The co-crystal structures described for the first time here have been deposited to the Protein Data Bank (wwPDB), and the details of the methods used can be found under accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb">4ccb</a> (wt ALK + <b>6d</b>, 2.0 Ã), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu">4ccu</a> (wt ALK + <b>7h</b>, 2.0 Ã), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0">4cd0</a> (L1196M ALK + <b>8e</b>, 2.2 Ã). Nonphosphorylated human wt and L1196M mutant ALK kinase domain proteins (amino acids 1093â1411) were crystallized by the hanging drop vapor diffusion method at 13 Â°C by mixing equal volumes of a purified protein (11â15 mg/mL)âinhibitor (â¼1.0 mM) complex solution with a crystallization solution containing 0.15 M ammonium sulfate, 9â10.5% (w/v) monomethyl ether poly(ethylene glycol) (MW 5000), and 0.1 M 2-(<i>N</i>-morpholino)ethanesulfonic acid (MES) buffer in a pH range of 5.3â5.6 for wt ALK or 0.2 M lithium sulfate, 18% (w/v) poly(ethylene glycol) (MW 5000), and 0.1 M Tris at pH 8.5 for L1196M ALK.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Biochemical Kinase Assays</h3><div class="NLM_p last">Recombinant human wild-type and L1196M mutant ALK kinase domain proteins (amino acids 1093â1411) were produced in-house in a baculoviral expression system and preactivated via autophosphorylation. Enzymes were assayed for kinase activity by a microfluidic mobility shift assay. The reactions were conducted in 50-Î¼L volumes in 96-well plates and contained 1.3 nM wild-type or 0.5 nM mutant ALK, 3 Î¼M phosphoacceptor peptide (5â²FAM-KKSRGDYMTMQIG-CONH<sub>2</sub>, synthesized by CPC Scientific, Sunnyvale, CA), test compound (11-dose 3-fold serial dilutions, 2% DMSO final) or DMSO only, 1 mM dithiothreitol (DTT), 0.002% Tween-20, and 5 mM MgCl<sub>2</sub> in 25 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>â²-ethanesulfonic acid (Hepes), pH 7.1, and were initiated by addition of ATP at the <i>K</i><sub>M,app</sub> level (53 and 51 Î¼M for wild-type and L1196M ALK, respectively), following a 15-min preincubation. The reactions were incubated for 1 h at room temperature, stopped by the addition of equal volume of ethylenediaminetetraacetic acid (EDTA), pH 8 (0.1 M final concentration), and the extent of reactions (â¼15â20% conversion with no inhibitor) was determined after electrophoretic separation of the fluorescently labeled peptide substrate and phosphorylated product on a LabChip EZ Reader II (Caliper Life Sciences, Hopkinton, MA). The inhibitors were shown to be ATP-competitive from kinetic and crystallographic studies. The <i>K</i><sub>i</sub> values were calculated by fitting the percent conversion to the Morrison equation for tight-binding competitive inhibition by a nonlinear regression method (GraphPad Prism, GraphPad Software, San Diego, CA).</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Kinase Selectivity Enzyme Assays</h3><div class="NLM_p last">The experiments were conducted by Invitrogen Inc. (Carlsbad, CA) in their Madison, WI facility. Most of the kinase panel assays were the fluorescence resonance energy transfer (FRET)-based Å¹-LYTE assays that employ a fluorescence-based, coupled-enzyme format, taking advantage of the differential sensitivity of phosphorylated and nonphosphorylated peptides to proteolytic cleavage. Other assays were the time-resolved (TR) FRET-based Adapta assay format that employs an Alexa Fluor 647 labeled ADP tracer and Eu-labeled anti-ADP antibody. The assays of the above two formats were normally conducted with ATP concentration near <i>K</i><sub>M,app</sub>. Another assay format used was the TR-FRET-based LanthaScreen binding assays utilizing an Alexa Fluor tracer and Eu-labeled anti-tag antibody that binds to the respective affinity tag of the target kinase. Details of these assay procedures are described on the vendorâs Web site.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Cell-Based Phospho-ALK Enzyme-Linked Immunosorbent Assay</h3><div class="NLM_p last">Cells were seeded at 20â000 cells/well in a 96-well plate in growth medium with 0.5% serum and incubated overnight. Compounds were diluted in medium without serum, added to the cells, incubated for 1 h, and then removed by aspirating the medium by vacuum suction. Cell lysates were generated and the phospho-ALK (Tyr1604) levels were determined by use of the PathScan Phospho-ALK (Tyr1604) Chemiluminescent Sandwich ELISA Kit (Cell Signaling, catalog no. 7020) or PathScan Total ALK Chemiluminescent Sandwich ELISA Kit (Cell Signaling, catalog no. 7084) as described in the manufacturerâs protocol. IC<sub>50</sub> values were calculated by concentrationâresponse curve fitting utilizing a four-parameter analytical method.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Tumor Cell Proliferation Assay</h3><div class="NLM_p last">Cells were seeded in 96-well plates in growth medium + 10% fetal bovine serum (FBS) (50 mL) and cultured overnight at 37 Â°C. The following day, serial dilutions of <b>8e</b> or appropriate controls were added to the designated wells, and cells were incubated at 37 Â°C for 72 h. A Cell Titer Glo assay (Promega, Madison, WI) was then performed to determine the relative cell numbers. IC<sub>50</sub> values were calculated by concentrationâresponse curve fitting utilizing a four-parameter analytical method.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> In Vivo Xenograft Models in Athymic Mice</h3><div class="NLM_p last">Female nu/nu mice were obtained from Charles River. All of the procedures were conducted in accordance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and with Pfizer Animal Care and Use Committee guidelines. Tumor cells were implanted subcutaneously into the right flank region of each mouse and allowed to grow to the designated size. The athymic mice bearing established tumors were administered <b>8e</b> by oral gavage in 0.5% methylcellulose suspension or 0.5% methylcellulose solution alone for the control group. Tumor volume was measured by use of electronic digital calipers.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/jm401805h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75184" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75184" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">One table listing additional experimental details of biochemical kinase selectivity for <b>8e</b>, and SMILES molecular formula strings and compound data information in a csv file. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401805h/suppl_file/jm401805h_si_001.pdf">jm401805h_si_001.pdf (146.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401805h/suppl_file/jm401805h_si_002.csv">jm401805h_si_002.csv (1.8 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">ALK kinase domain crystal structures deposited to the Protein Data Bank (wwPDB) are wtâcrizotinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>), L1196M (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yhv">2yhv</a>), L1196Mâcrizotinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yfx">2yfx</a>), G1269A (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anl">4anl</a>), G1269Aâcrizotinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anq">4anq</a>), wtâ<b>6d</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb">4ccb</a>), wtâ<b>7h</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu">4ccu</a>), and L1196Mâ<b>8e</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0">4cd0</a>).</p><div class="testing" data-doi="10.1021/jm401805h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qinhua Huang</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cebfa7a0a6bbafe0a6bbafa0a98ebea8a7b4abbce0ada1a3"><span class="__cf_email__" data-cfemail="27564e494f5246094f524649406757414e5d42550944484a">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ted W. Johnson</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c4b0a1a0eab3eaaeabacaab7abaa84b4a2adbea1b6eaa7aba9"><span class="__cf_email__" data-cfemail="cabeafaee4bde4a0a5a2a4b9a5a48abaaca3b0afb8e4a9a5a7">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Bailey</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexei Brooun</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin D. Bunker</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin J. Burke</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael R. Collins</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew S. Cook</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Jean Cui</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin N. Dack</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judith G. Deal</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Li Deng</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dac Dinh</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lars D. Engstrom</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingying He</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacqui Hoffman</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert L. Hoffman</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick S. Johnson</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert S. Kania</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hieu Lam</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justine L. Lam</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phuong T. Le</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuhua Li</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Lingardo</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Liu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa West Lu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele McTigue</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cynthia L. Palmer</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul F. Richardson</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neal W. Sach</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tod Smeal</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graham L. Smith</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert E. Stewart</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sergei Timofeevski</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Konstantinos Tsaparikos</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Wang</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huichun Zhu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinjiang Zhu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Y. Zou</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin P. Edwards</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2623e4595-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87358" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87358" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Dr. Klaus Dress for helpful data analyses and discussions.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">This manuscript was published ASAP on February 6, 2014, without a Supporting Information csv file. The revised version with the Supporting Information csv file was posted on February 13, 2014.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i65" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i65"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i66" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i66"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">c-MET</td><td class="NLM_def"><p class="first last">mesenchymal epithelial transition factor</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule associated protein-like 4</p></td></tr><tr><td class="NLM_term">G-loop</td><td class="NLM_def"><p class="first last">glycine loop</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% inhibitory concentration</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">log <i>D</i></td><td class="NLM_def"><p class="first last">octanol/buffer (pH 7.4) distribution coefficient</p></td></tr><tr><td class="NLM_term">IMT</td><td class="NLM_def"><p class="first last">myofibroblastic tumor</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">wt</td><td class="NLM_def"><p class="first last">wild type</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. P.</span><span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkinâs lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2175</span><span class="NLM_x">â</span> <span class="NLM_lpage">2188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bilsland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mead, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Znamenskiy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz-Sanjuan, I.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">â</span> <span class="NLM_lpage">700</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=685-700&author=J.+G.+Bilslandauthor=A.+Wheeldonauthor=A.+Meadauthor=P.+Znamenskiyauthor=S.+Almondauthor=K.+A.+Watersauthor=M.+Thakurauthor=V.+Beaumontauthor=T.+P.+Bonnertauthor=R.+Heavensauthor=P.+Whitingauthor=G.+McAllisterauthor=I.+Munoz-Sanjuan&title=Behavioral+and+neurochemical+alterations+in+mice+deficient+in+anaplastic+lymphoma+kinase+suggest+therapeutic+potential+for+psychiatric+indications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DZnamenskiy%26aufirst%3DP.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DThakur%26aufirst%3DM.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DBonnert%26aufirst%3DT.%2BP.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DBehavioral%2520and%2520neurochemical%2520alterations%2520in%2520mice%2520deficient%2520in%2520anaplastic%2520lymphoma%2520kinase%2520suggest%2520therapeutic%2520potential%2520for%2520psychiatric%2520indications%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D685%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chiarle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">â</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0ljDzIJHthU5vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rentrop, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">â</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+lymphoma+kinase%3A+role+in+cancer+pathogenesis+and+small-molecule+inhibitor+development+for+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lirDRe0o-pGSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520cancer%2520pathogenesis%2520and%2520small-molecule%2520inhibitor%2520development%2520for%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Iwahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cupples, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratzkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span> </span><span class="NLM_article-title">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">â</span> <span class="NLM_lpage">449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=439-449&author=T.+Iwaharaauthor=J.+Fujimotoauthor=D.+Wenauthor=R.+Cupplesauthor=N.+Bucayauthor=T.+Arakawaauthor=S.+Moriauthor=B.+Ratzkinauthor=T.+Yamamoto&title=Molecular+characterization+of+ALK%2C+a+receptor+tyrosine+kinase+expressed+specifically+in+the+nervous+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIwahara%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DBucay%26aufirst%3DN.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DRatzkin%26aufirst%3DB.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DMolecular%2520characterization%2520of%2520ALK%252C%2520a%2520receptor%2520tyrosine%2520kinase%2520expressed%2520specifically%2520in%2520the%2520nervous%2520system%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D439%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkinâs lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">â</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">ALK-positive large B-cell lymphoma: report of two cases and review of the literature</span> <span class="citation_source-journal">J. Cancer Sci. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.4172%2F1948-5956.1000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Oqu7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=228-232&author=H.+Yuauthor=X.+Liuauthor=H.+Liauthor=D.+Shiauthor=C.+Wang&title=ALK-positive+large+B-cell+lymphoma%3A+report+of+two+cases+and+review+of+the+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-postive large B-cell lymphoma: report of two cases and review of the literature</span></div><div class="casAuthors">Yu, Hong; Liu, Xiao-Jian; Li, Hui; Shi, Da-Ren; Wang, Chao-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Science & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">228-232</span>CODEN:
                <span class="NLM_cas:coden">JCSTGU</span>;
        ISSN:<span class="NLM_cas:issn">1948-5956</span>.
    
            (<span class="NLM_cas:orgname">OMICS Publishing Group</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase pos. large B-cell lymphoma (ALK+LBCL) is a rare variant of large B-cell lymphoma, but it rarely expresses B-lineage antigens (e.g CD20, CD79a) while showing an abnormal immunophenotype, such as pos. for ALK, EMA, CD38, CD138.  Only 55 cases of ALK+LBCL have been reported so far in the published literature.  We present two addnl. cases of ALK+LBCL, which were sent to our department for consultation from other hospitals.  One was initially diagnosed as metastatic poorly differentiated carcinoma and the other was not able to be diagnosed.  The two cases were finally diagnosed as "ALK+LBCL" at our department of pathol.  The chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) was given, resp.  Case 1 was given radiation therapy after chemotherapy, and case 2 wasn't.  Case 1, followed up for 16 mo, was free of disease.  Case 2 died at 8 mo after the diagnosis.  Due to the abnormal immunophenotype and rareness, the diagnosis of ALK+LBCL is often difficult, even being misdiagnosed as carcinoma or plasma cell neoplasm.  However, the treatment for these diseases is quite different from each another.  Avoiding misdiagnosis of ALK+LBCL is of great clinic importance.  In this report, we describe the clin., morphol., immunohistiochem. and cytogenetic features of the two ALK+LBCL cases, reviewed 55 published cases, and compared the features with those of literature-reported cases.  We came to the conclusions: 1. ALK+LBCL could affect non-adult and adult with a bimodal age distribution, with an av. age of 12.5 years in the non-adult, and 43.5 years in the adult.  2. ALK+LBCL is a potential diagnostic pitfall for pathologists.  Its diagnosis clues are that neoplastic cells are immunoblastic or/and plasmacytoid with prominent central nucleoli, pos. for ALK, EMA and some markers of late (plasma cell-like) B-cell differentiation, like CD138, VS38 and Igs, neg. for B-cell markers like CD20 and CD79a.  3. The investigation of involved genetic abnormality (CLTC-ALK fusion, or NPM-ALK rearrangement) contributes to confirm ALK+LBCL.  ALK+LBCL has highly aggressive biobehavior and poor response to std. therapies.  More patient case collection and prospective studies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv7AvZfJEk5rVg90H21EOLACvtfcHk0lirDRe0o-pGSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Oqu7fP&md5=d95d55af9f260685279f1d9152bc9d3a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4172%2F1948-5956.1000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F1948-5956.1000094%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DALK-positive%2520large%2520B-cell%2520lymphoma%253A%2520report%2520of%2520two%2520cases%2520and%2520review%2520of%2520the%2520literature%26jtitle%3DJ.%2520Cancer%2520Sci.%2520Ther.%26date%3D2011%26volume%3D3%26spage%3D228%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">â</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0ljvjyZ-e25vEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4âALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4%E2%80%93ALK+fusion+gene+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4%25E2%2580%2593ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2349</span><span class="NLM_x">â</span> <span class="NLM_lpage">2355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1111%2Fj.1349-7006.2008.00972.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=19032370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=2349-2355&author=H.+Mano&title=Non-solid+oncogenes+in+solid+tumors%3A+EML4-ALK+fusion+genes+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span></div><div class="casAuthors">Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2349-2355</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that recurrent chromosome translocations play a major role in the mol. pathogenesis of hematol. malignancies but not of solid tumors.  However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.  Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-assocd. protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.  A recurrent chromosome translocation, inv(2)(p21p23), in NSCLC generates fused mRNA encoding the amino-terminal half of EML4 ligated to the intracellular region of the receptor-type protein tyrosine kinase ALK.  EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.  Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute -5% of NSCLC cases, at least in the Asian ethnic group.  In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are pos. for the fusion gene, and discuss whether suppression of ALK enzymic activity could be an effective treatment strategy against this intractable disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbxSS7U51wKbVg90H21EOLACvtfcHk0ljvjyZ-e25vEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D&md5=84386550daedbd29b3a34b11a4774684</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00972.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00972.x%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DNon-solid%2520oncogenes%2520in%2520solid%2520tumors%253A%2520EML4-ALK%2520fusion%2520genes%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D2349%26epage%3D2355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Targeting anaplastic lymphoma kinase in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">â</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+anaplastic+lymphoma+kinase+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0ljvjyZ-e25vEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Caren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinsson, I.</span><span> </span><span class="NLM_article-title">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">416</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Carenauthor=F.+Abelauthor=P.+Kognerauthor=I.+Martinsson&title=High+incidence+of+DNA+mutations+and+gene+amplifications+of+the+ALK+gene+in+advanced+sporadic+neuroblastoma+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaren%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DI.%26atitle%3DHigh%2520incidence%2520of%2520DNA%2520mutations%2520and%2520gene%2520amplifications%2520of%2520the%2520ALK%2520gene%2520in%2520advanced%2520sporadic%2520neuroblastoma%2520tumors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">MossÃ©, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">â</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">â</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0liRH9LZw4hFKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">â</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=Li.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DLi.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanael, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provides a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">â</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+Gregorauthor=T.+R.+Webbauthor=S.+Nathanaelauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=W.+Stephanauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provides+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DNathanael%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DStephan%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provides%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Azarova, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span> </span><span class="NLM_article-title">Emerging importance of ALK in neuroblastoma</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8f&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2Fj.semcancer.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8f&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21945349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8f&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=267-275&author=A.+M.+Azarovaauthor=G.+Gautamauthor=R.+E.+George&title=Emerging+importance+of+ALK+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8fR"><div class="casContent"><span class="casTitleNuber">8f</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging importance of ALK in neuroblastoma</span></div><div class="casAuthors">Azarova, Anna M.; Gautam, Gargi; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated.  As a group, the activating point mutations in full-length ALK, found in approx. 8% of all neuroblastoma tumors, are distributed evenly across different clin. stages.  However, the most frequent somatic mutation, F1174L, is assocd. with amplification of the MYCN oncogene.  This combination of features appears to confer a worse prognosis than MYCN amplification alone, suggesting a cooperative effect on neuroblastoma formation by these two proteins.  Indeed, F1174L has shown more potent transforming activity in vivo than the second most common activating mutation, R1275Q, and is responsible for innate and acquired resistance to crizotinib, a clin. relevant ALK inhibitor that will soon be com. available.  These advances cast ALK as a bona fide oncoprotein in neuroblastoma and emphasize the need to understand ALK-mediated signaling in this tumor.  This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clin. effective targeted treatments based on ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqmFzh9Q3frVg90H21EOLACvtfcHk0lgE6WZA5-dXlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN&md5=e07445aecd9829c465f1f4023124521f</span></div><a href="/servlet/linkout?suffix=cit8f&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DGautam%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DEmerging%2520importance%2520of%2520ALK%2520in%2520neuroblastoma%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D267%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">ALK gene amplified in most inflammatory breast cancers</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1093%2Fjnci%2Fdjr553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=22215853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=87-88&author=R.+S.+Tuma&title=ALK+gene+amplified+in+most+inflammatory+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Gene Amplified in Most Inflammatory Breast Cancers</span></div><div class="casAuthors">Tuma, Rabiya S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from non-inflammatory breast cancer in presentation and response to therapy. Despite those differences, researchers have uncovered few mol. characteristics that distinguish IBC from non-inflammatory breast cancer, and IBC treatment generally relies on std. breast cancer regimens.  Recently, it has been reported that ALK gene amplification is a common feature of IBC tumors and that small-mol. ALK inhibitors are effective in mouse xenograft models.  Current developments on this recent report are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9yX6fegRi7Vg90H21EOLACvtfcHk0lgE6WZA5-dXlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D&md5=46e7633055aadc3aacfc6bac9b4cb591</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr553%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DALK%2520gene%2520amplified%2520in%2520most%2520inflammatory%2520breast%2520cancers%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D87%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beausoleil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">â</span> <span class="NLM_lpage">3323</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=X.+Z.+Tanauthor=C.+Crosbyauthor=H.+Haackauthor=J.-M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.-M.+Zhouauthor=T.-L.+Guauthor=Y.-F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DX.%2BZ.%26aulast%3DCrosby%26aufirst%3DC.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.-M.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DY.-F.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">â</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=B.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-MET%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lgE6WZA5-dXlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DB.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-MET%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">â</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+Altonauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-MET%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, â¼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-Î³, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lhV2pSUxpEYXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-MET%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymalâepithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">â</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Case History: Xalkori<sup>TM</sup> (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=421-432&author=J.+J.+Cuiauthor=M.+McTigueauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Case+History%3A+XalkoriTM+%28crizotinib%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal+epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DCase%2520History%253A%2520XalkoriTM%2520%2528crizotinib%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%2520epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520for%2520cancer%2520treatment%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2013%26volume%3D48%26spage%3D421%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">â</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2FS1470-2045%2811%2970232-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21933749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1004-1012&author=A.+T.+Shawauthor=B.+Y.+Yeapauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=J.+Gainorauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=D.+B.+Costaauthor=S.-H.+I.+Ouauthor=M.+Butaneyauthor=R.+Salgiaauthor=R.+G.+Makiauthor=M.+Varella-Garciaauthor=R.+C.+Doebeleauthor=Y.-J.+Bangauthor=K.+Kuligauthor=P.+Selaruauthor=Y.+Tangauthor=K.+D.+Wilnerauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=A.+J.+Iafrateauthor=D.+R.+Camidge&title=Effect+of+crizotinib+on+overall+survival+in+patients+with+advanced+non-small-cell+lung+cancer+harbouring+ALK+gene+rearrangement%3A+a+retrospective+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</span></div><div class="casAuthors">Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1004-1012</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">ALK gene rearrangement defines a new mol. subtype of non-small-cell lung cancer (NSCLC).  In a recent phase 1 clin. trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumor activity in patients with advanced, ALK-pos. NSCLC.  To assess whether crizotinib affects overall survival in these patients, we did a retrospective study comparing survival outcomes in crizotinib-treated patients in the trial and crizotinib-naive controls screened during the same time period.  We examd. overall survival in patients with advanced, ALK-pos. NSCLC who enrolled in the phase 1 clin. trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010.  For comparators, we identified 36 ALK-pos. patients from trial sites who were not given crizotinib (ALK-pos. controls), 67 patients without ALK rearrangement but pos. for EGFR mutation, and 253 wild-type patients lacking either ALK rearrangement or EGFR mutation.  To assess differences in overall survival, we assessed subsets of clin. comparable ALK-pos. and ALK-neg. patients.  Among 82 ALK-pos. patients who were given crizotinib, median overall survival from initiation of crizotinib has not been reached (95% CI 17 mo to not reached); 1-yr overall survival was 74% (95% CI 63-82), and 2-yr overall survival was 54% (40-66).  Overall survival did not differ based on age, sex, smoking history, or ethnic origin.  Survival in 30 ALK-pos. patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-pos. controls given any second-line therapy (median overall survival not reached [95% CI 14 mo to not reached] vs 6 mo [4-17], 1-yr overall survival 70% [95% CI 50-83] vs 44% [23-64], and 2-yr overall survival 55% [33-72] vs 12% [2-30]; hazard ratio 0.36, 95% CI 0.17-0.75; p = 0.004).  Survival in 56 crizotinib-treated, ALK-pos. patients was similar to that in 63 ALK-neg., EGFR-pos. patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 mo to not reached] vs 24 mo [15-34], 1-yr overall survival 71% [95% CI 58-81] vs 74% [61-83], and 2-yr overall survival 57% [40-71] vs 52% [38-65]; p = 0.786), whereas survival in 36 crizotinib-naive, ALK-pos. controls was similar to that in 253 wild-type controls (median overall survival 20 mo [95% CI 13-26] vs 15 mo [13-17]; p = 0.244).  In patients with advanced, ALK-pos. NSCLC, crizotinib therapy is assocd. with improved survival compared with that of crizotinib-naive controls.  ALK rearrangement is not a favorable prognostic factor in advanced NSCLC.  Funding: Pfizer Inc, V Foundation for Cancer Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMS7fRYJSyrrVg90H21EOLACvtfcHk0lggTmDkYoTn9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL&md5=5482da97726293764c9fe42419d187cb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970232-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970232-7%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DGainor%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKulig%26aufirst%3DK.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DEffect%2520of%2520crizotinib%2520on%2520overall%2520survival%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harbouring%2520ALK%2520gene%2520rearrangement%253A%2520a%2520retrospective%2520analysis%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D1004%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">â</span> <span class="NLM_lpage">1739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lhQlM0zL35TMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">6051</span><span class="NLM_x">â</span> <span class="NLM_lpage">6060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=A+novel+ALK+secondary+mutation+and+EGFR+signaling+cause+resistance+to+ALK+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520ALK%2520secondary%2520mutation%2520and%2520EGFR%2520signaling%2520cause%2520resistance%2520to%2520ALK%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6051%26epage%3D6060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miret, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">â</span> <span class="NLM_lpage">1005</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1111%2Fj.1747-0285.2011.01239.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=22034911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=999-1005&author=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=X.+Zhuauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=L.+Moranauthor=Q.+K.+Mohemmadauthor=R.+Anjumauthor=Y.+Wangauthor=N.+I.+Narasimhanauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=J.+J.+Miretauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Crizotinib-resistant+mutants+of+EML4-ALK+identified+through+an+accelerated+mutagenesis+screen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span></div><div class="casAuthors">Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1005</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers.  Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clin. activity in patients with non-small-cell lung cancer and inflammatory myofibroblastic tumors harboring ALK translocations.  Inhibitors of driver kinases often elicit kinase domain mutations that confer resistance, and such mutations have been successfully predicted using in vitro mutagenesis screens.  Here, this approach was used to discover an extensive set of ALK mutations that can confer resistance to crizotinib.  Mutations at 16 residues were identified, structurally clustered into five regions around the kinase active site, which conferred varying degrees of resistance.  The screen successfully predicted the L1196M, C1156Y, and F1174L mutations, recently identified in crizotinib-resistant patients.  In sep. studies, we demonstrated that crizotinib has relatively modest potency in ALK-pos. non-small-cell lung cancer cell lines.  A more potent ALK inhibitor, TAE684, maintained substantial activity against mutations that conferred resistance to crizotinib.  Our study identifies multiple novel mutations in ALK that may confer clin. resistance to crizotinib, suggests that crizotinib's narrow selectivity window may underlie its susceptibility to such resistance and demonstrates that a more potent ALK inhibitor may be effective at overcoming resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU21SkJFhWI7Vg90H21EOLACvtfcHk0lhQlM0zL35TMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI&md5=7f1f1d4ad48d1801cd3f9c44f7ef4615</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2011.01239.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2011.01239.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMiret%26aufirst%3DJ.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DCrizotinib-resistant%2520mutants%2520of%2520EML4-ALK%2520identified%2520through%2520an%2520accelerated%2520mutagenesis%2520screen%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D78%26spage%3D999%26epage%3D1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutateladze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to crizotinib in patients with ALK gene rearranged nonâsmall cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1472</span><span class="NLM_x">â</span> <span class="NLM_lpage">1482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+resistance+to+crizotinib+in+patients+with+ALK+gene+rearranged+non%E2%80%93small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0lhL9zERjeO54A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520crizotinib%2520in%2520patients%2520with%2520ALK%2520gene%2520rearranged%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancer</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_elocation-id">120ra17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2FB978-0-12-396492-2.00019-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=281-293&author=K.+Kinoshitaauthor=N.+Oikawaauthor=T.+Tsukuda&title=Anaplastic+lymphoma+kinase+inhibitors+for+the+treatment+of+ALK-positive+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13fR"><div class="casContent"><span class="casTitleNuber">13f</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span></div><div class="casAuthors">Kinoshita, Kazutomo; Oikawa, Nobuhiro; Tsukuda, Takuo</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-293</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review on the development of anaplastic lymphoma kinase (ALK) inhibitors which is the most highly competitive drug targets in oncol. research.  A no. of research groups have identified promising drugs, where Pfizer succeeded in launching a potent ALK inhibitor, crizotinib, for treatment of EML4-ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX549XOu0aZrVg90H21EOLACvtfcHk0lhL9zERjeO54A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE&md5=2fb9597a39e7dd478a4ef41be4df7be6</span></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00019-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00019-9%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520ALK-positive%2520cancers%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D281%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+potent%2C+selective%2C+and+efficacious+inhibitor+of+NPM-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Marsilje, T. H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structureâactivity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">â</span> <span class="NLM_lpage">5690</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kuromitsu, S.; Mori, M.; Shimada, I.; Kondoh, Y.; Shindoh, N.; Soga, T.; Furutani, T.; Konagai, S.; Sakagami, H.; Nakata, M.; Ueno, Y.; Saito, R.; Sasamata, M.; Kudou, M.</span> Anti-tumor activity of ASP3026, a novel and selective ALK inhibitor of anaplastic lymphoma kinase (ALK). Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 2821.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kuromitsu%2C+S.%3B+Mori%2C+M.%3B+Shimada%2C+I.%3B+Kondoh%2C+Y.%3B+Shindoh%2C+N.%3B+Soga%2C+T.%3B+Furutani%2C+T.%3B+Konagai%2C+S.%3B+Sakagami%2C+H.%3B+Nakata%2C+M.%3B+Ueno%2C+Y.%3B+Saito%2C+R.%3B+Sasamata%2C+M.%3B+Kudou%2C+M.+Anti-tumor+activity+of+ASP3026%2C+a+novel+and+selective+ALK+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29.+Presented+at+the+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Orlando%2C+FL%2C+2011%3B+Abstract+2821."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKuromitsu%26aufirst%3DS.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">â</span> <span class="NLM_lpage">690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6286</span><span class="NLM_x">â</span> <span class="NLM_lpage">6294</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lgUt6HYZV2ajg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eb, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">River, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">â</span> <span class="NLM_lpage">7540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebauthor=V.+M.+Riverauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=A.+Jeffreyauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEb%26aufirst%3DH.%26aulast%3DRiver%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DJeffrey%26aufirst%3DA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">â</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+ligand+lipophilicity+efficiency+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520efficiency%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Freeman-cook, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span> </span><span class="NLM_article-title">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">â</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.4155%2Ffmc.12.208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=23360135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=113-115&author=K.+D.+Freeman-cookauthor=R.+L.+Hoffmanauthor=T.+W.+Johnson&title=Lipophilic+efficiency%3A+the+most+important+efficiency+metric+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Hoffman, Robert L.; Johnson, Ted W.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-115</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review is given on the crit. role of lipophilicity in drug discovery and optimization of general absorption, distribution, metab. and excretion properties, toxicol. profiles and ultimately pharmacol. response.  Math. equations are presented concerning the impact of lipophilicity on the dose and the calcn. of the lipophilic ligand efficiency (LipE).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKhEHH7Hf1qbVg90H21EOLACvtfcHk0lhG-4kQC4vYgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D&md5=36170decfa1f1e3ef09ecf772322a210</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.208%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-cook%26aufirst%3DK.%2BD.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26atitle%3DLipophilic%2520efficiency%253A%2520the%2520most%2520important%2520efficiency%2520metric%2520in%2520medicinal%2520chemistry%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D113%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit20"><span><div class="note"><p class="first last">Crizotinib has an extensive tumor distribution profiles with an approximate tumor/plasma AUC ratio of 4 at steady-state (in-house data). Also see </p></div><span class="NLM_contrib-group">Yamazaki, S.</span><span> </span><span class="NLM_article-title">Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">â</span> <span class="NLM_lpage">366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=354-366&author=S.+Yamazaki&title=Translational+pharmacokinetic-pharmacodynamic+modeling+from+nonclinical+to+clinical+development%3A+a+case+study+of+anticancer+drug%2C+crizotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26atitle%3DTranslational%2520pharmacokinetic-pharmacodynamic%2520modeling%2520from%2520nonclinical%2520to%2520clinical%2520development%253A%2520a%2520case%2520study%2520of%2520anticancer%2520drug%252C%2520crizotinib%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26spage%3D354%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalaeva, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tupper, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.</span><span> </span><span class="NLM_article-title">ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2490</span><span class="NLM_x">â</span> <span class="NLM_lpage">2497</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0100990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2490-2497&author=F.+Lombardoauthor=M.+Y.+Shalaevaauthor=K.+A.+Tupperauthor=F.+Gao&title=ElogD%28oct%29%3A+a+tool+for+lipophilicity+determination+in+drug+discovery.+2.+Basic+and+neutral+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm0100990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0100990%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DShalaeva%26aufirst%3DM.%2BY.%26aulast%3DTupper%26aufirst%3DK.%2BA.%26aulast%3DGao%26aufirst%3DF.%26atitle%3DElogD%2528oct%2529%253A%2520a%2520tool%2520for%2520lipophilicity%2520determination%2520in%2520drug%2520discovery.%25202.%2520Basic%2520and%2520neutral%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2490%26epage%3D2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">â</span> <span class="NLM_lpage">533</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lhG-4kQC4vYgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">4974</span><span class="NLM_x">â</span> <span class="NLM_lpage">4985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitneyauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. Â© 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lgfXTiXn1DYoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nishio, M.; Hirota, M.; Umezawa, Y.</span>, Eds.  <span class="citation_source-book">The CHâPi Interaction: Evidence, Nature, and Consequences</span>; <span class="NLM_publisher-name">WileyâVCH</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1998</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">215</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=1-215&author=M.+Nishio&author=M.+Hirota&author=Y.+Umezawa&title=The+CH%E2%80%93Pi+Interaction%3A+Evidence%2C+Nature%2C+and+Consequences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNishio%26aufirst%3DM.%26btitle%3DThe%2520CH%25E2%2580%2593Pi%2520Interaction%253A%2520Evidence%252C%2520Nature%252C%2520and%2520Consequences%26pub%3DWiley%25E2%2580%2593VCH%26date%3D1998%26spage%3D1%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nishio, M.</span><span> </span><span class="NLM_article-title">CH/Ï hydrogen bonds in crystals</span> <span class="citation_source-journal">CrystEngComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1039%2Fb313104a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Gnu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=130-158&author=M.+Nishio&title=CH%2F%CF%80+hydrogen+bonds+in+crystals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">CH/Ï hydrogen bonds in crystals</span></div><div class="casAuthors">Nishio, Motohiro</div><div class="citationInfo"><span class="NLM_cas:title">CrystEngComm</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-158</span>CODEN:
                <span class="NLM_cas:coden">CRECF4</span>;
        ISSN:<span class="NLM_cas:issn">1466-8033</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The nature and characteristics of the CH/Ï interaction are discussed by comparison with other weak mol. forces such as the CH/O and OH/Ï interaction.  The CH/Ï interaction is a kind of hydrogen bond operating between a soft acid CH and a soft base Ï-system (double and triple bonds, C6 and C5 arom. rings, heteroaroms., convex surfaces of fullerenes and nanotubes).  The consequences of CH/Ï hydrogen bonds in supramol. chem. are reviewed on grounds of recent crystallog. findings and database analyses.  The topics include intramol. interactions, crystal packing (org. and organometallic compds.), host/guest complexes (cavity-type inclusion compds. of cyclodextrins and synthetic macrocyclic hosts such as calixarenes, catenanes, rotaxanes and pseudorotaxanes), lattice-inclusion type clathrates (including liq. crystals, porphyrin derivs., cyclopentadienyl compds. and C60 fullerenes), enantioselective clathrate formation, catalytic enantioface discriminating reactions and solid-state photoreaction.  The implications of the CH/Ï concept for crystal engineering and drug design are evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp66q0y6L3qvrVg90H21EOLACvtfcHk0lgfXTiXn1DYoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Gnu7g%253D&md5=191ddb4c549623bb6e6b7b6ceb5fd101</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1039%2Fb313104a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb313104a%26sid%3Dliteratum%253Aachs%26aulast%3DNishio%26aufirst%3DM.%26atitle%3DCH%252F%25CF%2580%2520hydrogen%2520bonds%2520in%2520crystals%26jtitle%3DCrystEngComm%26date%3D2004%26volume%3D6%26spage%3D130%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Novel target in non-small cell lung cancer: ROS1 and RET fusions</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">â</span> <span class="NLM_lpage">875</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=865-875&author=J.+F.+Gainorauthor=A.+T.+Shaw&title=Novel+target+in+non-small+cell+lung+cancer%3A+ROS1+and+RET+fusions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DNovel%2520target%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520ROS1%2520and%2520RET%2520fusions%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D865%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chin, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span> </span><span class="NLM_article-title">Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1625</span><span class="NLM_x">â</span> <span class="NLM_lpage">1630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1097%2FJTO.0b013e31826baf83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=23070242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgt7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1625-1630&author=L.+P.+Chinauthor=R.+A.+Sooauthor=R.+Soongauthor=S.+H.+Ou&title=Targeting+ROS1+with+anaplastic+lymphoma+kinase+inhibitors%3A+a+promising+therapeutic+strategy+for+a+newly+defined+molecular+subset+of+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chin, Leow Pay; Soo, Ross A.; Soong, Richie; Ou, Sai-Hong I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1625-1630</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described in a variety of human malignancies including non-small-cell lung cancer (NSCLC), cholangiocarcinoma and glioblastoma multiforme.  Recently, clinicopathol. characteristics of c-ros oncogene 1, receptor tyrosine kinase (ROS1)-rearranged NSCLC patients have been described.  Furthermore, anaplastic lymphoma kinase inhibitor, novel class of drugs targeting this tyrosine kinase receptor is currently under clin. trial in this mol. subset of NSCLC patients.  This review will focus on the current knowledge of ROS1 rearrangements in NSCLC, methods to detect ROS1 rearrangement, and targeting ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgGb8cXIS3bVg90H21EOLACvtfcHk0lgDj_4uwyTnIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgt7%252FO&md5=f6a1d2380911daa1c0ba4749e2f21f55</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31826baf83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31826baf83%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DL.%2BP.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DSoong%26aufirst%3DR.%26aulast%3DOu%26aufirst%3DS.%2BH.%26atitle%3DTargeting%2520ROS1%2520with%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%253A%2520a%2520promising%2520therapeutic%2520strategy%2520for%2520a%2520newly%2520defined%2520molecular%2520subset%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1625%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brown, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekharan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, P. V.</span><span> </span><span class="NLM_article-title">Chiral synthesis via organoboranes. 14. Selective reductions. 41. Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">â</span> <span class="NLM_lpage">1546</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00213a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaL1cXhtFamsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=1988&pages=1539-1546&author=H.+C.+Brownauthor=J.+Chandrasekharanauthor=P.+V.+Ramachandran&title=Chiral+synthesis+via+organoboranes.+14.+Selective+reductions.+41.+Diisopinocampheylchloroborane%2C+an+exceptionally+efficient+chiral+reducing+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral synthesis via organoboranes.  14.  Selective reductions.  41.  Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent</span></div><div class="casAuthors">Brown, Herbert C.; Chandrasekharan, J.; Ramachandran, P. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1539-46</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Diisopinocampheylchloroborane (I), readily prepd. in both enantiomers in high chem. and optical purities (99% ee) via hydroboration, reduces prochiral ketones at convenient rates.  Redn. of simple dialkyl ketones, 2-butanone, 2-octanone, and 3-methyl-2-butanone, yields the corresponding alcs. with 4%, 7%, and 32% optical induction.  Aralkyl ketones are reduced with very high asym. induction.  Thus, acetophenone, propiophenone, butyrophenone, and decanophenone are reduced with 98%, 98%, 98%, and 97% ee, resp.  Branching of the alkyl chain diminishes the induction.  Functional groups in the arom. ring are not affected by the reagent and do not appear to influence significantly the optical yield realized.  Heteroaryl alkyl ketones are also reduced with excellent optical induction.  The reagent reduces Î±-tertiary aliph. ketones under neat condition at room temp. with very high optical induction.  Î±,Î²-Unsatd. ketones are reduced with lesser optical induction.  Certain Î±-keto esters are reduced in 50-70% ee.  The mechanism of the redn. is postulated to be via a six-membered cyclic boat-like transition state.  X-ray crystal structure data for I are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsVAEQNaLjjrVg90H21EOLACvtfcHk0lgDj_4uwyTnIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhtFamsbw%253D&md5=efea4959eb07a0f0ed74860f2840cad9</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fja00213a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00213a030%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DH.%2BC.%26aulast%3DChandrasekharan%26aufirst%3DJ.%26aulast%3DRamachandran%26aufirst%3DP.%2BV.%26atitle%3DChiral%2520synthesis%2520via%2520organoboranes.%252014.%2520Selective%2520reductions.%252041.%2520Diisopinocampheylchloroborane%252C%2520an%2520exceptionally%2520efficient%2520chiral%2520reducing%2520agent%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1988%26volume%3D110%26spage%3D1539%26epage%3D1546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ramachandran, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H. C.</span><span> </span><span class="NLM_article-title">A remarkable inversion in configuration of the product alcohols from the asymmetric reduction of <i>ortho</i>-hydroxyacetophenones with Î²-chlorodiisopinocampheylborane</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">â</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2FS0040-4039%2800%2976780-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaK2cXltVyjurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=2141-2144&author=P.+V.+Ramachandranauthor=B.+Gongauthor=H.+C.+Brown&title=A+remarkable+inversion+in+configuration+of+the+product+alcohols+from+the+asymmetric+reduction+of+ortho-hydroxyacetophenones+with+%CE%B2-chlorodiisopinocampheylborane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">A remarkable inversion in configuration of the product alcohols from the asymmetric reduction of ortho-hydroxyacetophenones with B-chlorodiisopinocampheylborane</span></div><div class="casAuthors">Ramachandran, P. Veeraraghavan; Gong, Baoqing; Brown, Herbert C.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2141-4</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Asym. redn. of o-hydroxyacetophenones I (R = H, 5-, 6-MeO, 5-Me, 5-F, 3,5-Cl2, 4-MeO-6-CO2Me) with B-chlorodiisopinocampheylborane provides product alcs. with the opposite configuration compared to those produced in the redn. of the corresponding o-methoxyacetophenones II (same R).  The ee% from these redns. were generally >80%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcTk2pJd1bvrVg90H21EOLACvtfcHk0lgDj_4uwyTnIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltVyjurk%253D&md5=018eaa6f071f123dd2f72d13e5512964</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2976780-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252976780-3%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DP.%2BV.%26aulast%3DGong%26aufirst%3DB.%26aulast%3DBrown%26aufirst%3DH.%2BC.%26atitle%3DA%2520remarkable%2520inversion%2520in%2520configuration%2520of%2520the%2520product%2520alcohols%2520from%2520the%2520asymmetric%2520reduction%2520of%2520ortho-hydroxyacetophenones%2520with%2520%25CE%25B2-chlorodiisopinocampheylborane%26jtitle%3DTetrahedron%2520Lett.%26date%3D1994%26volume%3D35%26spage%3D2141%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Nieuwenhze, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Catalytic asymmetric dihydroxylation</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">â</span> <span class="NLM_lpage">2547</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00032a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1994&pages=2483-2547&author=H.+C.+Kolbauthor=M.+S.+Van+Nieuwenhzeauthor=K.+B.+Sharpless&title=Catalytic+asymmetric+dihydroxylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Asymmetric Dihydroxylation</span></div><div class="casAuthors">Kolb, Hartmuth C.; VanNieuwenhze, Michael S.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2483-547</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 285 refs. on enantioselective prepn. of chiral 1,2-diols from olefins and synthetic applications of the 1,2-diols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6vlkXRJjKLVg90H21EOLACvtfcHk0lgDj_4uwyTnIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D&md5=71bace539bfee0542d17edcdb889cdd9</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fcr00032a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00032a009%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DVan%2BNieuwenhze%26aufirst%3DM.%2BS.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DCatalytic%2520asymmetric%2520dihydroxylation%26jtitle%3DChem.%2520Rev.%26date%3D1994%26volume%3D94%26spage%3D2483%26epage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, S. L.</span><span> </span><span class="NLM_article-title">Asymmetric dihydroxylation of alkenes</span> <span class="citation_source-journal">Org. React.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1002%2F0471264180.or066.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2ns7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2005&pages=109&author=M.+C.+Noeauthor=M.+A.+Letavicauthor=S.+L.+Snow&title=Asymmetric+dihydroxylation+of+alkenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric dihydroxylation of alkenes</span></div><div class="casAuthors">Noe, Mark C.; Letavic, Michael A.; Snow, Sheri L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Reactions (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-625</span>CODEN:
                <span class="NLM_cas:coden">ORREAW</span>;
        ISSN:<span class="NLM_cas:issn">0078-6179</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review of asym. dihydroxylation reactions of alkenes including mechanism, stereochem., scope and limitations, and exptl. conditions and procedures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkhwxk_oiw37Vg90H21EOLACvtfcHk0lhhJ6DTK-xVYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2ns7rI&md5=005540cdbdcb44603cfc752b6ed20fef</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1002%2F0471264180.or066.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264180.or066.02%26sid%3Dliteratum%253Aachs%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSnow%26aufirst%3DS.%2BL.%26atitle%3DAsymmetric%2520dihydroxylation%2520of%2520alkenes%26jtitle%3DOrg.%2520React.%26date%3D2005%26volume%3D66%26spage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8a','cit8b','cit8c','cit8d','cit8e','cit8f'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c','cit11d'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e','cit13f'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25a','cit25b'],'ref26':['cit26a','cit26b'],'ref27':['cit27a','cit27b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 67 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jennifer Alisa Amrhein, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Hanke</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7991-8009. <a href="https://doi.org/10.1021/acs.jmedchem.1c00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00217%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BOpportunities%252Band%252BChallenges%252Bfor%252BMacrocyclic%252BKinase%252BInhibitors%26aulast%3DAmrhein%26aufirst%3DJennifer%2BAlisa%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04022021%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7991%26epage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zheng Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Philip E. Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2020,</strong> <em>16 </em>
                                    (5)
                                     , 3152-3161. <a href="https://doi.org/10.1021/acs.jctc.9b01134" title="DOI URL">https://doi.org/10.1021/acs.jctc.9b01134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.9b01134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.9b01134%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DRevealing%252BAcquired%252BResistance%252BMechanisms%252Bof%252BKinase-Targeted%252BDrugs%252BUsing%252Ban%252Bon-the-Fly%25252C%252BFunction-Site%252BInteraction%252BFingerprint%252BApproach%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D13112019%26date%3D24042020%26date%3D13042020%26volume%3D16%26issue%3D5%26spage%3D3152%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haobo Pang, Ye Wang, Fabrice Gallou, <span class="NLM_string-name hlFld-ContribAuthor">Bruce H. Lipshutz</span>. </span><span class="cited-content_cbyCitation_article-title">Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (43)
                                     , 17117-17124. <a href="https://doi.org/10.1021/jacs.9b04510" title="DOI URL">https://doi.org/10.1021/jacs.9b04510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b04510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b04510%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DFe-Catalyzed%252BReductive%252BCouplings%252Bof%252BTerminal%252B%252528Hetero%252529Aryl%252BAlkenes%252Band%252BAlkyl%252BHalides%252Bunder%252BAqueous%252BMicellar%252BConditions%26aulast%3DPang%26aufirst%3DHaobo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26042019%26date%3D16102019%26date%3D27092019%26volume%3D141%26issue%3D43%26spage%3D17117%26epage%3D17124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brajesh K. Rai, Vishnu Sresht, Qingyi Yang, Ray Unwalla, Meihua Tu, Alan M. Mathiowetz, <span class="NLM_string-name hlFld-ContribAuthor">Gregory A. Bakken</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive Assessment of Torsional Strain in Crystal Structures of Small Molecules and ProteinâLigand Complexes using ab Initio Calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (10)
                                     , 4195-4208. <a href="https://doi.org/10.1021/acs.jcim.9b00373" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComprehensive%252BAssessment%252Bof%252BTorsional%252BStrain%252Bin%252BCrystal%252BStructures%252Bof%252BSmall%252BMolecules%252Band%252BProtein%2525E2%252580%252593Ligand%252BComplexes%252Busing%252Bab%252BInitio%252BCalculations%26aulast%3DRai%26aufirst%3DBrajesh%2BK.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03052019%26date%3D16102019%26date%3D01102019%26volume%3D59%26issue%3D10%26spage%3D4195%26epage%3D4208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Robert    Dugger </span><span class="hlFld-ContribAuthor "> Bryan    Li    </span><span class="hlFld-ContribAuthor "> Paul    Richardson </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 27-59. <a href="https://doi.org/10.1021/bk-2019-1332.ch002" title="DOI URL">https://doi.org/10.1021/bk-2019-1332.ch002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2019-1332.ch002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2019-1332.ch002%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BLorlatinib%25253A%252BA%252BMacrocyclic%252BInhibitor%252Bof%252BEML4-ALK%252Bfor%252Bthe%252BTreatment%252Bof%252BNSCLC%26aulast%3DDugger%26aufirst%3DRobert%26date%3D2019%26date%3D2019%26spage%3D27%26epage%3D59%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B2%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2019%26date%3D2019%26volume%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masahiro Ito, Toshio Tanaka, Akinori Toita, Noriko Uchiyama, Hironori Kokubo, Nao Morishita, Michael G. Klein, Hua Zou, Morio Murakami, Mitsuyo Kondo, Tomoya Sameshima, Shinsuke Araki, Satoshi Endo, Tomohiro Kawamoto, Gregg B. Morin, Samuel A. Aparicio, Atsushi Nakanishi, Hironobu Maezaki, <span class="NLM_string-name hlFld-ContribAuthor">Yasuhiro Imaeda</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7710-7728. <a href="https://doi.org/10.1021/acs.jmedchem.8b00683" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00683%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-Benzyl-1-%252528trans-4-%252528%2525285-cyanopyridin-2-yl%252529amino%252529cyclohexyl%252529-1-arylurea%252BDerivatives%252Bas%252BNovel%252Band%252BSelective%252BCyclin-Dependent%252BKinase%252B12%252B%252528CDK12%252529%252BInhibitors%26aulast%3DIto%26aufirst%3DMasahiro%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30042018%26date%3D20082018%26date%3D01082018%26volume%3D61%26issue%3D17%26spage%3D7710%26epage%3D7728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, Alexei Brooun, Dan Gehlhaar, <span class="NLM_string-name hlFld-ContribAuthor">Michele McTigue</span>. </span><span class="cited-content_cbyCitation_article-title">Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 878-883. <a href="https://doi.org/10.1021/acsmedchemlett.8b00147" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00147%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReviving%252BB-Factors%25253A%252BRetrospective%252BNormalized%252BB-Factor%252BAnalysis%252Bof%252Bc-ros%252BOncogene%252B1%252BReceptor%252BTyrosine%252BKinase%252Band%252BAnaplastic%252BLymphoma%252BKinase%252BL1196M%252Bwith%252BCrizotinib%252Band%252BLorlatinib%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28032018%26date%3D18062018%26date%3D28082018%26date%3D18062018%26volume%3D9%26issue%3D9%26spage%3D878%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, <span class="NLM_string-name hlFld-ContribAuthor">Martin P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Lipophilic Efficiency as an Important Metric in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6401-6420. <a href="https://doi.org/10.1021/acs.jmedchem.8b00077" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLipophilic%252BEfficiency%252Bas%252Ban%252BImportant%252BMetric%252Bin%252BDrug%252BDesign%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D17042018%26date%3D28032018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Jung Hee  Park</span>, <span class="hlFld-ContribAuthor ">Hoi-Yun  Jung</span>, <span class="hlFld-ContribAuthor ">Kukcheol  Ahn</span>, <span class="hlFld-ContribAuthor ">Soyeon  Choi</span>, <span class="hlFld-ContribAuthor ">Hyun Seop  Tae</span>, <span class="hlFld-ContribAuthor ">Kyung Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Jin Kyung  Rho</span>, <span class="hlFld-ContribAuthor ">Jae Cheol  Lee</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (22)
                                     , 9205-9221. <a href="https://doi.org/10.1021/acs.jmedchem.7b01039" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B4-Phenoxyquinoline%252BBased%252BInhibitors%252Bfor%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bby%252BStructure-Based%252BDesign%26aulast%3DMah%26aufirst%3DShinmee%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17072017%26date%3D09112017%26date%3D22112017%26date%3D01112017%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saemina  Shin</span>, <span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>, and <span class="hlFld-ContribAuthor ">Hwangseo  Park</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (4)
                                     , 802-810. <a href="https://doi.org/10.1021/acs.jcim.6b00026" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BLow%252BMicromolar%252BDual%252BInhibitors%252Bfor%252BWild%252BType%252Band%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bthrough%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DShin%26aufirst%3DSaemina%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20012016%26date%3D04042016%26date%3D25042016%26date%3D25032016%26volume%3D56%26issue%3D4%26spage%3D802%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span>, and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4383-4438. <a href="https://doi.org/10.1021/jm501853m" title="DOI URL">https://doi.org/10.1021/jm501853m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501853m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSurvey%252Bof%252Bthe%252BRole%252Bof%252BNoncovalent%252BSulfur%252BInteractions%252Bin%252BDrug%252BDesign%26aulast%3DBeno%26aufirst%3DBrett%2BR.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D01122014%26date%3D03032015%26date%3D11062015%26volume%3D58%26issue%3D11%26spage%3D4383%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Yanhong  Yang</span>, <span class="hlFld-ContribAuthor ">Zhiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Junfeng  Guo</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Kui  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Ao  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 197-211. <a href="https://doi.org/10.1021/jm5005144" title="DOI URL">https://doi.org/10.1021/jm5005144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5005144%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252B2%25252C4-Diarylaminopyrimidine%252BAnalogues%252B%252528DAAPalogues%252529%252BShowing%252BPotent%252BInhibitory%252BActivities%252Bagainst%252BBoth%252BWild-type%252Band%252BMutant%252BALK%252BKinases%26aulast%3DSong%26aufirst%3DZilan%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D01042014%26date%3D08052014%26date%3D08012015%26date%3D30042014%26volume%3D58%26issue%3D1%26spage%3D197%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Paul F.  Richardson</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Alexei  Brooun</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Burke</span>, <span class="hlFld-ContribAuthor ">Michael R.  Collins</span>, <span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Ya-Li  Deng</span>, <span class="hlFld-ContribAuthor ">Dac  Dinh</span>, <span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Mingying  He</span>, <span class="hlFld-ContribAuthor ">Jacqui  Hoffman</span>, <span class="hlFld-ContribAuthor ">Robert L.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Qinhua  Huang</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Hieu  Lam</span>, <span class="hlFld-ContribAuthor ">Justine L.  Lam</span>, <span class="hlFld-ContribAuthor ">Phuong T.  Le</span>, <span class="hlFld-ContribAuthor ">Laura  Lingardo</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Cynthia L.  Palmer</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Graham L.  Smith</span>, <span class="hlFld-ContribAuthor ">Albert E.  Stewart</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Huichun  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinjiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Helen Y.  Zou</span>, and <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 4720-4744. <a href="https://doi.org/10.1021/jm500261q" title="DOI URL">https://doi.org/10.1021/jm500261q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500261q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%25252810R%252529-7-Amino-12-fluoro-2%25252C10%25252C16-trimethyl-15-oxo-10%25252C15%25252C16%25252C17-tetrahydro-2H-8%25252C4-%252528metheno%252529pyrazolo%25255B4%25252C3-h%25255D%25255B2%25252C5%25252C11%25255D-benzoxadiazacyclotetradecine-3-carbonitrile%252B%252528PF-06463922%252529%25252C%252Ba%252BMacrocyclic%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252Band%252Bc-ros%252BOncogene%252B1%252B%252528ROS1%252529%252Bwith%252BPreclinical%252BBrain%252BExposure%252Band%252BBroad-Spectrum%252BPotency%252Bagainst%252BALK-Resistant%252BMutations%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17022014%26date%3D03062014%26date%3D12062014%26date%3D13052014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span> and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel Anaplastic Lymphoma Kinase Inhibitors Targeting Clinically Acquired Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (4)
                                     , 1167-1169. <a href="https://doi.org/10.1021/jm500178r" title="DOI URL">https://doi.org/10.1021/jm500178r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500178r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500178r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BAnaplastic%252BLymphoma%252BKinase%252BInhibitors%252BTargeting%252BClinically%252BAcquired%252BResistance%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D02022014%26date%3D05022014%26date%3D27022014%26volume%3D57%26issue%3D4%26spage%3D1167%26epage%3D1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>, <span class="hlFld-ContribAuthor ">Shraddha  Parate</span>, <span class="hlFld-ContribAuthor ">Sanghwa  Yoon</span>, <span class="hlFld-ContribAuthor ">Gihwan  Lee</span>, <span class="hlFld-ContribAuthor ">Donghwan  Kim</span>, <span class="hlFld-ContribAuthor ">Keun Woo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of ACK1 inhibitors as anticancer agents by using computer-aided drug designing. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1235 </em>, 130200. <a href="https://doi.org/10.1016/j.molstruc.2021.130200" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DIdentification%252Bof%252BACK1%252Binhibitors%252Bas%252Banticancer%252Bagents%252Bby%252Busing%252Bcomputer-aided%252Bdrug%252Bdesigning%26aulast%3DKumar%26aufirst%3DVikas%26date%3D2021%26volume%3D1235%26spage%3D130200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shyni  V.</span>, <span class="hlFld-ContribAuthor ">Leenaraj  D. R.</span>, <span class="hlFld-ContribAuthor ">Lynnette  Joseph</span>, <span class="hlFld-ContribAuthor ">D.  Sajan</span>. </span><span class="cited-content_cbyCitation_article-title">Investigations of
              DianhydroâD
              âglucitol adsorbed on
              AuNPs
              surface: In silico and in vitro approach based on anticancer activity studies against
              A549
              lung cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Recognition</span><span> <strong>2021,</strong> <em>37 </em><a href="https://doi.org/10.1002/jmr.2899" title="DOI URL">https://doi.org/10.1002/jmr.2899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jmr.2899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjmr.2899%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Recognition%26atitle%3DInvestigations%252Bof%252BDianhydro%2525E2%252580%252590D%252B%2525E2%252580%252590glucitol%252Badsorbed%252Bon%252BAuNPs%252Bsurface%25253A%252BIn%252Bsilico%252Band%252Bin%252Bvitro%252Bapproach%252Bbased%252Bon%252Banticancer%252Bactivity%252Bstudies%252Bagainst%252BA549%252Blung%252Bcancer%252Bcell%252Blines%26aulast%3DV.%26aufirst%3DShyni%26date%3D2021%26date%3D2021%26volume%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomoyuki  Naito</span>, <span class="hlFld-ContribAuthor ">Hideaki  Shiraishi</span>, <span class="hlFld-ContribAuthor ">Yutaka  Fujiwara</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. </span><span class="cited-content_cbyCitation_journal-name">Japanese Journal of Clinical Oncology</span><span> <strong>2021,</strong> <em>51 </em>
                                    (1)
                                     , 37-44. <a href="https://doi.org/10.1093/jjco/hyaa192" title="DOI URL">https://doi.org/10.1093/jjco/hyaa192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jjco/hyaa192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjjco%2Fhyaa192%26sid%3Dliteratum%253Aachs%26jtitle%3DJapanese%2520Journal%2520of%2520Clinical%2520Oncology%26atitle%3DBrigatinib%252Band%252Blorlatinib%25253A%252Btheir%252Beffect%252Bon%252BALK%252Binhibitors%252Bin%252BNSCLC%252Bfocusing%252Bon%252Bresistant%252Bmutations%252Band%252Bcentral%252Bnervous%252Bsystem%252Bmetastases%26aulast%3DNaito%26aufirst%3DTomoyuki%26date%3D2021%26date%3D2020%26volume%3D51%26issue%3D1%26spage%3D37%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Haibo  Sun</span>, <span class="hlFld-ContribAuthor ">Laixue  Pang</span>, <span class="hlFld-ContribAuthor ">Baohua  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2020,</strong> <em>34 </em>
                                    (12)
                                     , 1289-1305. <a href="https://doi.org/10.1007/s10822-020-00355-5" title="DOI URL">https://doi.org/10.1007/s10822-020-00355-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-020-00355-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-020-00355-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DMutation-mediated%252Binfluences%252Bon%252Bbinding%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bto%252Bcrizotinib%252Bdecoded%252Bby%252Bmultiple%252Breplica%252BGaussian%252Baccelerated%252Bmolecular%252Bdynamics%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D12%26spage%3D1289%26epage%3D1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Misako  Nagasaka</span>, <span class="hlFld-ContribAuthor ">Yubin  Ge</span>, <span class="hlFld-ContribAuthor ">Ammar  Sukari</span>, <span class="hlFld-ContribAuthor ">Geetika  Kukreja</span>, <span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>. </span><span class="cited-content_cbyCitation_article-title">A userâs guide to lorlatinib. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2020,</strong> <em>151 </em>, 102969. <a href="https://doi.org/10.1016/j.critrevonc.2020.102969" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2020.102969</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2020.102969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2020.102969%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DA%252Buser%2525E2%252580%252599s%252Bguide%252Bto%252Blorlatinib%26aulast%3DNagasaka%26aufirst%3DMisako%26date%3D2020%26volume%3D151%26spage%3D102969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wayland  Yeung</span>, <span class="hlFld-ContribAuthor ">Zheng  Ruan</span>, <span class="hlFld-ContribAuthor ">Natarajan  Kannan</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging roles of the Î±CâÎ²4 loop in protein kinase structure, function, evolution, and disease. </span><span class="cited-content_cbyCitation_journal-name">IUBMB Life</span><span> <strong>2020,</strong> <em>72 </em>
                                    (6)
                                     , 1189-1202. <a href="https://doi.org/10.1002/iub.2253" title="DOI URL">https://doi.org/10.1002/iub.2253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/iub.2253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fiub.2253%26sid%3Dliteratum%253Aachs%26jtitle%3DIUBMB%2520Life%26atitle%3DEmerging%252Broles%252Bof%252Bthe%252B%2525CE%2525B1C%2525E2%252580%252590%2525CE%2525B24%252Bloop%252Bin%252Bprotein%252Bkinase%252Bstructure%25252C%252Bfunction%25252C%252Bevolution%25252C%252Band%252Bdisease%26aulast%3DYeung%26aufirst%3DWayland%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D6%26spage%3D1189%26epage%3D1202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdulaziz B.  Hamid</span>, <span class="hlFld-ContribAuthor ">Ruben C.  Petreaca</span>. </span><span class="cited-content_cbyCitation_article-title">Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 927. <a href="https://doi.org/10.3390/cancers12040927" title="DOI URL">https://doi.org/10.3390/cancers12040927</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12040927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12040927%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSecondary%252BResistant%252BMutations%252Bto%252BSmall%252BMolecule%252BInhibitors%252Bin%252BCancer%252BCells%26aulast%3DHamid%26aufirst%3DAbdulaziz%2BB.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenteng  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao  Guo</span>, <span class="hlFld-ContribAuthor ">Can  Zhang</span>, <span class="hlFld-ContribAuthor ">Di  Ke</span>, <span class="hlFld-ContribAuthor ">Guolin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongping  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111734. <a href="https://doi.org/10.1016/j.ejmech.2019.111734" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111734</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111734%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-aminopyridines%252Bbearing%252Ba%252Bpyridone%252Bmoiety%252Bas%252Bpotent%252BALK%252Binhibitors%252Bto%252Bovercome%252Bthe%252Bcrizotinib-resistant%252Bmutants%26aulast%3DChen%26aufirst%3DWenteng%26date%3D2019%26volume%3D183%26spage%3D111734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solventâexposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siming  Liu</span>, <span class="hlFld-ContribAuthor ">Ying  Jiang</span>, <span class="hlFld-ContribAuthor ">Ruohong  Yan</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Ju  Hou</span>, <span class="hlFld-ContribAuthor ">Zhengguang  Zhu</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Tian</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 358-375. <a href="https://doi.org/10.1016/j.ejmech.2019.06.043" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.043%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluations%252Bof%252B2-amino-4-%2525281-piperidine%252529%252Bpyridine%252Bderivatives%252Bas%252Bnovel%252Banti%252Bcrizotinib-resistant%252BALK%25252FROS1%252Bdual%252Binhibitors%26aulast%3DLiu%26aufirst%3DSiming%26date%3D2019%26volume%3D179%26spage%3D358%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Wenjie  Li</span>, <span class="hlFld-ContribAuthor ">Yating  Luo</span>, <span class="hlFld-ContribAuthor ">Tingyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyu  Zhao</span>, <span class="hlFld-ContribAuthor ">TianTian  Qi</span>, <span class="hlFld-ContribAuthor ">Fangling  Xu</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Ma</span>, <span class="hlFld-ContribAuthor ">Huan  Ge</span>, <span class="hlFld-ContribAuthor ">Yingfan  Liang</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin  Liang</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1507-1513. <a href="https://doi.org/10.1016/j.bmcl.2019.04.011" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure-activity%252Brelationship%252Bstudy%252Bof%252Baminopyridine%252Bderivatives%252Bas%252Bnovel%252Binhibitors%252Bof%252BJanus%252Bkinase%252B2%26aulast%3DWang%26aufirst%3DWanqi%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1507%26epage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Hua  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Mei  Wu</span>, <span class="hlFld-ContribAuthor ">Sai-Nan  Deng</span>, <span class="hlFld-ContribAuthor ">Rui-Xia  Chai</span>, <span class="hlFld-ContribAuthor ">Muriira Cyrus  Mwenda</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Peng</span>, <span class="hlFld-ContribAuthor ">Dong  Cai</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2,4-disubstituted thiazole amide derivatives as anticancer agent. </span><span class="cited-content_cbyCitation_journal-name">Chemical Papers</span><span> <strong>2019,</strong> <em>73 </em>
                                    (2)
                                     , 355-364. <a href="https://doi.org/10.1007/s11696-018-0587-3" title="DOI URL">https://doi.org/10.1007/s11696-018-0587-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11696-018-0587-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11696-018-0587-3%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Papers%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C4-disubstituted%252Bthiazole%252Bamide%252Bderivatives%252Bas%252Banticancer%252Bagent%26aulast%3DZhang%26aufirst%3DZhi-Hua%26date%3D2019%26date%3D2018%26volume%3D73%26issue%3D2%26spage%3D355%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunju  Nam</span>, <span class="hlFld-ContribAuthor ">Dongkeun  Hwang</span>, <span class="hlFld-ContribAuthor ">Namdoo  Kim</span>, <span class="hlFld-ContribAuthor ">Hong-Seog  Seo</span>, <span class="hlFld-ContribAuthor ">Khalid B.  Selim</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 1
              H
              -pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1426-1438. <a href="https://doi.org/10.1080/14756366.2019.1639694" title="DOI URL">https://doi.org/10.1080/14756366.2019.1639694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1639694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1639694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B1%252BH%252B-pyrazolo%25255B3%25252C4-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BALK-L1196M%252Binhibitors%26aulast%3DNam%26aufirst%3DYunju%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1426%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silky  Bedi</span>, <span class="hlFld-ContribAuthor ">Shah A.  Khan</span>, <span class="hlFld-ContribAuthor ">Majed M.  AbuKhader</span>, <span class="hlFld-ContribAuthor ">Perwez  Alam</span>, <span class="hlFld-ContribAuthor ">Nasir A.  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Asif  Husain</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review on Brigatinib â A wonder drug for targeted cancer therapy in non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Saudi Pharmaceutical Journal</span><span> <strong>2018,</strong> <em>26 </em>
                                    (6)
                                     , 755-763. <a href="https://doi.org/10.1016/j.jsps.2018.04.010" title="DOI URL">https://doi.org/10.1016/j.jsps.2018.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsps.2018.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsps.2018.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Pharmaceutical%2520Journal%26atitle%3DA%252Bcomprehensive%252Breview%252Bon%252BBrigatinib%252B%2525E2%252580%252593%252BA%252Bwonder%252Bdrug%252Bfor%252Btargeted%252Bcancer%252Btherapy%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DBedi%26aufirst%3DSilky%26date%3D2018%26volume%3D26%26issue%3D6%26spage%3D755%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siming  Liu</span>, <span class="hlFld-ContribAuthor ">Haikui  Yang</span>, <span class="hlFld-ContribAuthor ">Ying  Jiang</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruohong  Yan</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (14)
                                     , 1705-1720. <a href="https://doi.org/10.4155/fmc-2018-0033" title="DOI URL">https://doi.org/10.4155/fmc-2018-0033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0033%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DEvolution%252Bstrategy%252Bof%252BROS1%252Bkinase%252Binhibitors%252Bfor%252Buse%252Bin%252Bcancer%252Btherapy%26aulast%3DLiu%26aufirst%3DSiming%26date%3D2018%26volume%3D10%26issue%3D14%26spage%3D1705%26epage%3D1720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  SchlÃ¼tke</span>, <span class="hlFld-ContribAuthor ">Markus  Immer</span>, <span class="hlFld-ContribAuthor ">Lutz  Preu</span>, <span class="hlFld-ContribAuthor ">Frank  Totzke</span>, <span class="hlFld-ContribAuthor ">Christoph  SchÃ¤chtele</span>, <span class="hlFld-ContribAuthor ">Michael H.G.  Kubbutat</span>, <span class="hlFld-ContribAuthor ">Conrad  Kunick</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutics and Biopharmaceutics</span><span> <strong>2018,</strong> <em>126 </em>, 89-94. <a href="https://doi.org/10.1016/j.ejpb.2017.03.011" title="DOI URL">https://doi.org/10.1016/j.ejpb.2017.03.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejpb.2017.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejpb.2017.03.011%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutics%2520and%2520Biopharmaceutics%26atitle%3DScaffold%252Bhopping%252Bidentifies%252B6%25252C8-disubstituted%252Bpurines%252Bas%252Bnovel%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%26aulast%3DSchl%25C3%25BCtke%26aufirst%3DLaura%26date%3D2018%26volume%3D126%26spage%3D89%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bruce W.  Konicek</span>, <span class="hlFld-ContribAuthor ">Andrew R.  Capen</span>, <span class="hlFld-ContribAuthor ">Kelly M.  Credille</span>, <span class="hlFld-ContribAuthor ">Philip J.  Ebert</span>, <span class="hlFld-ContribAuthor ">Beverly L.  Falcon</span>, <span class="hlFld-ContribAuthor ">Gary L.  Heady</span>, <span class="hlFld-ContribAuthor ">Bharvin K.R.  Patel</span>, <span class="hlFld-ContribAuthor ">Victoria L.  Peek</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Stephens</span>, <span class="hlFld-ContribAuthor ">Julie A.  Stewart</span>, <span class="hlFld-ContribAuthor ">Stephanie L.  Stout</span>, <span class="hlFld-ContribAuthor ">David E.  Timm</span>, <span class="hlFld-ContribAuthor ">Suzane L.  Um</span>, <span class="hlFld-ContribAuthor ">Melinda D.  Willard</span>, <span class="hlFld-ContribAuthor ">Isabella H.  Wulur</span>, <span class="hlFld-ContribAuthor ">Yi  Zeng</span>, <span class="hlFld-ContribAuthor ">Yong  Wang</span>, <span class="hlFld-ContribAuthor ">Richard A.  Walgren</span>, <span class="hlFld-ContribAuthor ">Sau-Chi  Betty Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (17)
                                     , 13796-13806. <a href="https://doi.org/10.18632/oncotarget.24488" title="DOI URL">https://doi.org/10.18632/oncotarget.24488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.24488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.24488%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DMerestinib%252B%252528LY2801653%252529%252Binhibits%252Bneurotrophic%252Breceptor%252Bkinase%252B%252528NTRK%252529%252Band%252Bsuppresses%252Bgrowth%252Bof%252BNTRK%252Bfusion%252Bbearing%252Btumors%26aulast%3DKonicek%26aufirst%3DBruce%2BW.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D17%26spage%3D13796%26epage%3D13806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Rahi</span>, <span class="hlFld-ContribAuthor ">Alisha  Dhiman</span>, <span class="hlFld-ContribAuthor ">Damini  Singh</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Lynn</span>, <span class="hlFld-ContribAuthor ">Mohd  Rehan</span>, <span class="hlFld-ContribAuthor ">Rakesh  Bhatnagar</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the interaction between
              Mycobacterium tuberculosis
              enolase and human plasminogen using computational methods and experimental techniques. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Biochemistry</span><span> <strong>2018,</strong> <em>119 </em>
                                    (2)
                                     , 2408-2417. <a href="https://doi.org/10.1002/jcb.26403" title="DOI URL">https://doi.org/10.1002/jcb.26403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcb.26403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcb.26403%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Biochemistry%26atitle%3DExploring%252Bthe%252Binteraction%252Bbetween%252BMycobacterium%252Btuberculosis%252Benolase%252Band%252Bhuman%252Bplasminogen%252Busing%252Bcomputational%252Bmethods%252Band%252Bexperimental%252Btechniques%26aulast%3DRahi%26aufirst%3DAmit%26date%3D2018%26date%3D2017%26volume%3D119%26issue%3D2%26spage%3D2408%26epage%3D2417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abhilash  Jayaraj</span>, <span class="hlFld-ContribAuthor ">Ruchika  Bhat</span>, <span class="hlFld-ContribAuthor ">Amita  Pathak</span>, <span class="hlFld-ContribAuthor ">Manpreet  Singh</span>, <span class="hlFld-ContribAuthor ">B.  Jayaram</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Web-Server for Identification of Common Lead Molecules for Multiple Protein Targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 487-504. <a href="https://doi.org/10.1007/7653_2018_9" title="DOI URL">https://doi.org/10.1007/7653_2018_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7653_2018_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7653_2018_9%26sid%3Dliteratum%253Aachs%26atitle%3DDevelopment%252Bof%252Ba%252BWeb-Server%252Bfor%252BIdentification%252Bof%252BCommon%252BLead%252BMolecules%252Bfor%252BMultiple%252BProtein%252BTargets%26aulast%3DJayaraj%26aufirst%3DAbhilash%26date%3D2018%26date%3D2018%26spage%3D487%26epage%3D504%26pub%3DSpringer%2520New%2520York%26atitle%3DMulti-Target%252BDrug%252BDesign%252BUsing%252BChem-Bioinformatic%252BApproaches%26aulast%3DRoy%26aufirst%3DKunal%26date%3D2019%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Zaman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Sulman  Basit</span>, <span class="hlFld-ContribAuthor ">Abdul  Ghaffar</span>, <span class="hlFld-ContribAuthor ">Muhammad Sohail  Zafar</span>, <span class="hlFld-ContribAuthor ">Aamer  Saeed</span>, <span class="hlFld-ContribAuthor ">Sultan Ayoub  Meo</span>. </span><span class="cited-content_cbyCitation_article-title">Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (30)
                                     , 16470-16493. <a href="https://doi.org/10.1039/C8RA01934G" title="DOI URL">https://doi.org/10.1039/C8RA01934G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA01934G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA01934G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DLatest%252Bperspectives%252Bof%252Borally%252Bbioavailable%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252B%252528DAAPalogues%252529%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Bdiscovery%252Band%252Bclinical%252Bdevelopments%26aulast%3DLatif%26aufirst%3DMuhammad%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D30%26spage%3D16470%26epage%3D16493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dilip  Narayanan</span>, <span class="hlFld-ContribAuthor ">Osman A. B. S. M.  Gani</span>, <span class="hlFld-ContribAuthor ">Franz X. E.  Gruber</span>, <span class="hlFld-ContribAuthor ">Richard A.  Engh</span>. </span><span class="cited-content_cbyCitation_article-title">Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2017,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-017-0229-8" title="DOI URL">https://doi.org/10.1186/s13321-017-0229-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-017-0229-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-017-0229-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DData%252Bdriven%252Bpolypharmacological%252Bdrug%252Bdesign%252Bfor%252Blung%252Bcancer%25253A%252Banalyses%252Bfor%252Btargeting%252BALK%25252C%252BMET%25252C%252Band%252BEGFR%26aulast%3DNarayanan%26aufirst%3DDilip%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Justine L.  Lam</span>, <span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Pharmacokinetic-Pharmacodynamic Evaluation of an Orally Available Novel Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 519-543. <a href="https://doi.org/10.1002/9781119092599.ch18" title="DOI URL">https://doi.org/10.1002/9781119092599.ch18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119092599.ch18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119092599.ch18%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BPharmacokinetic-Pharmacodynamic%252BEvaluation%252Bof%252Ban%252BOrally%252BAvailable%252BNovel%252BMacrocyclic%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Band%252Bc-Ros%252BOncogene%252B1%26aulast%3DYamazaki%26aufirst%3DShinji%26date%3D2017%26date%3D2017%26spage%3D519%26epage%3D543%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPractical%252BMedicinal%252BChemistry%252Bwith%252BMacrocycles%26aulast%3DMarsault%26aufirst%3DEric%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryam  Kay</span>, <span class="hlFld-ContribAuthor ">Fariba  Dehghanian</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2017,</strong> <em>23 </em>
                                    (11)
                                     <a href="https://doi.org/10.1007/s00894-017-3495-5" title="DOI URL">https://doi.org/10.1007/s00894-017-3495-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-017-3495-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-017-3495-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DExploring%252Bthe%252Bcrizotinib%252Bresistance%252Bmechanism%252Bof%252BNSCLC%252Bwith%252Bthe%252BL1196M%252Bmutation%252Busing%252Bmolecular%252Bdynamics%252Bsimulation%26aulast%3DKay%26aufirst%3DMaryam%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sulman  Basit</span>, <span class="hlFld-ContribAuthor ">Zaman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>, <span class="hlFld-ContribAuthor ">Muhammad  Latif</span>. </span><span class="cited-content_cbyCitation_article-title">First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>134 </em>, 348-356. <a href="https://doi.org/10.1016/j.ejmech.2017.04.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFirst%252Bmacrocyclic%252B3%252Brd%252B-generation%252BALK%252Binhibitor%252Bfor%252Btreatment%252Bof%252BALK%25252FROS1%252Bcancer%25253A%252BClinical%252Band%252Bdesigning%252Bstrategy%252Bupdate%252Bof%252Blorlatinib%26aulast%3DBasit%26aufirst%3DSulman%26date%3D2017%26volume%3D134%26spage%3D348%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael T.  Werner</span>, <span class="hlFld-ContribAuthor ">Chen  Zhao</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Mariusz A.  Wasik</span>. </span><span class="cited-content_cbyCitation_article-title">Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2017,</strong> <em>129 </em>
                                    (7)
                                     , 823-831. <a href="https://doi.org/10.1182/blood-2016-05-717793" title="DOI URL">https://doi.org/10.1182/blood-2016-05-717793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2016-05-717793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2016-05-717793%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DNucleophosmin-anaplastic%252Blymphoma%252Bkinase%25253A%252Bthe%252Bultimate%252Boncogene%252Band%252Btherapeutic%252Btarget%26aulast%3DWerner%26aufirst%3DMichael%2BT.%26date%3D2017%26volume%3D129%26issue%3D7%26spage%3D823%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yazan  Haddad</span>, <span class="hlFld-ContribAuthor ">ZbynÄk  Heger</span>, <span class="hlFld-ContribAuthor ">Vojtech  Adam</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Neuroblastoma Cell Surface Proteins: Recommendations for Homology Modeling of hNET, ALK, and TrkB. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Neuroscience</span><span> <strong>2017,</strong> <em>10 </em><a href="https://doi.org/10.3389/fnmol.2017.00007" title="DOI URL">https://doi.org/10.3389/fnmol.2017.00007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnmol.2017.00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnmol.2017.00007%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Neuroscience%26atitle%3DTargeting%252BNeuroblastoma%252BCell%252BSurface%252BProteins%25253A%252BRecommendations%252Bfor%252BHomology%252BModeling%252Bof%252BhNET%25252C%252BALK%25252C%252Band%252BTrkB%26aulast%3DHaddad%26aufirst%3DYazan%26date%3D2017%26date%3D2017%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors of ALK. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 435-467. <a href="https://doi.org/10.1007/7355_2017_18" title="DOI URL">https://doi.org/10.1007/7355_2017_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_18%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecule%252BInhibitors%252Bof%252BALK%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2017%26spage%3D435%26epage%3D467%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Tsui</span>, <span class="hlFld-ContribAuthor ">Q.  Zeng</span>, <span class="hlFld-ContribAuthor ">K.  Chen</span>, <span class="hlFld-ContribAuthor ">X.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting Kinases in the CNS. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 408-446. <a href="https://doi.org/10.1016/B978-0-12-409547-2.13815-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.13815-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.13815-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.13815-6%26sid%3Dliteratum%253Aachs%26atitle%3DInhibiting%252BKinases%252Bin%252Bthe%252BCNS%26aulast%3DTsui%26aufirst%3DH.%26date%3D2017%26spage%3D408%26epage%3D446%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 353-374. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00016-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00016-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00016-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00016-0%26sid%3Dliteratum%253Aachs%26atitle%3DCrizotinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D353%26epage%3D374%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 245-361. <a href="https://doi.org/10.1016/bs.aihch.2016.11.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BSynopsis%252Bof%252Bthe%252BProperties%252Band%252BApplications%252Bof%252BHeteroaromatic%252BRings%252Bin%252BMedicinal%252BChemistry%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D245%26epage%3D361%26pub%3DElsevier%26date%3D2017%26volume%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Chung Hyo  Kang</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Raghavendra  Achary</span>, <span class="hlFld-ContribAuthor ">Ha-Yeon  Lee</span>, <span class="hlFld-ContribAuthor ">Joo-Youn  Lee</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Hee Jung  Jung</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 536-549. <a href="https://doi.org/10.1016/j.ejmech.2016.11.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DReplacing%252Bthe%252Bterminal%252Bpiperidine%252Bin%252Bceritinib%252Bwith%252Baliphatic%252Bamines%252Bconfers%252Bactivities%252Bagainst%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DMathi%26aufirst%3DGangadhar%2BRao%26date%3D2017%26volume%3D126%26spage%3D536%26epage%3D549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Jinan  Wang</span>, <span class="hlFld-ContribAuthor ">Weiliang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2017,</strong> <em>19 </em>
                                    (44)
                                     , 30239-30248. <a href="https://doi.org/10.1039/C7CP05418A" title="DOI URL">https://doi.org/10.1039/C7CP05418A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CP05418A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CP05418A%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DMutation%252BL1196M-induced%252Bconformational%252Bchanges%252Band%252Bthe%252Bdrug%252Bresistant%252Bmechanism%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bstudied%252Bby%252Bfree%252Benergy%252Bperturbation%252Band%252Bumbrella%252Bsampling%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D44%26spage%3D30239%26epage%3D30248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebecca L.  Boddicker</span>, <span class="hlFld-ContribAuthor ">Gina L.  Razidlo</span>, <span class="hlFld-ContribAuthor ">Surendra  Dasari</span>, <span class="hlFld-ContribAuthor ">Yu  Zeng</span>, <span class="hlFld-ContribAuthor ">Guangzhen  Hu</span>, <span class="hlFld-ContribAuthor ">Ryan A.  Knudson</span>, <span class="hlFld-ContribAuthor ">Patricia T.  Greipp</span>, <span class="hlFld-ContribAuthor ">Jaime I.  Davila</span>, <span class="hlFld-ContribAuthor ">Sarah H.  Johnson</span>, <span class="hlFld-ContribAuthor ">Julie C.  Porcher</span>, <span class="hlFld-ContribAuthor ">James B.  Smadbeck</span>, <span class="hlFld-ContribAuthor ">Bruce W.  Eckloff</span>, <span class="hlFld-ContribAuthor ">Daniel D.  Billadeau</span>, <span class="hlFld-ContribAuthor ">Paul J.  Kurtin</span>, <span class="hlFld-ContribAuthor ">Mark A.  McNiven</span>, <span class="hlFld-ContribAuthor ">Brian K.  Link</span>, <span class="hlFld-ContribAuthor ">Stephen M.  Ansell</span>, <span class="hlFld-ContribAuthor ">James R.  Cerhan</span>, <span class="hlFld-ContribAuthor ">Yan W.  Asmann</span>, <span class="hlFld-ContribAuthor ">George  Vasmatzis</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Feldman</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2016,</strong> <em>128 </em>
                                    (9)
                                     , 1234-1245. <a href="https://doi.org/10.1182/blood-2016-03-707141" title="DOI URL">https://doi.org/10.1182/blood-2016-03-707141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2016-03-707141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2016-03-707141%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DIntegrated%252Bmate-pair%252Band%252BRNA%252Bsequencing%252Bidentifies%252Bnovel%25252C%252Btargetable%252Bgene%252Bfusions%252Bin%252Bperipheral%252BT-cell%252Blymphoma%26aulast%3DBoddicker%26aufirst%3DRebecca%2BL.%26date%3D2016%26volume%3D128%26issue%3D9%26spage%3D1234%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.  Guan</span>, <span class="hlFld-ContribAuthor ">E. R.  Tucker</span>, <span class="hlFld-ContribAuthor ">H.  Wan</span>, <span class="hlFld-ContribAuthor ">D.  Chand</span>, <span class="hlFld-ContribAuthor ">L. S.  Danielson</span>, <span class="hlFld-ContribAuthor ">K.  Ruuth</span>, <span class="hlFld-ContribAuthor ">A.  El Wakil</span>, <span class="hlFld-ContribAuthor ">B.  Witek</span>, <span class="hlFld-ContribAuthor ">Y.  Jamin</span>, <span class="hlFld-ContribAuthor ">G.  Umapathy</span>, <span class="hlFld-ContribAuthor ">S. P.  Robinson</span>, <span class="hlFld-ContribAuthor ">T. W.  Johnson</span>, <span class="hlFld-ContribAuthor ">T.  Smeal</span>, <span class="hlFld-ContribAuthor ">T.  Martinsson</span>, <span class="hlFld-ContribAuthor ">L.  Chesler</span>, <span class="hlFld-ContribAuthor ">R. H.  Palmer</span>, <span class="hlFld-ContribAuthor ">B.  Hallberg</span>. </span><span class="cited-content_cbyCitation_article-title">The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. </span><span class="cited-content_cbyCitation_journal-name">Disease Models & Mechanisms</span><span> <strong>2016,</strong> <em>9 </em>
                                    (9)
                                     , 941-952. <a href="https://doi.org/10.1242/dmm.024448" title="DOI URL">https://doi.org/10.1242/dmm.024448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1242/dmm.024448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1242%2Fdmm.024448%26sid%3Dliteratum%253Aachs%26jtitle%3DDisease%2520Models%2520%2526%2520Mechanisms%26atitle%3DThe%252BALK%252Binhibitor%252BPF-06463922%252Bis%252Beffective%252Bas%252Ba%252Bsingle%252Bagent%252Bin%252Bneuroblastoma%252Bdriven%252Bby%252Bexpression%252Bof%252BALK%252Band%252BMYCN%26aulast%3DGuan%26aufirst%3DJ.%26date%3D2016%26volume%3D9%26issue%3D9%26spage%3D941%26epage%3D952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit Dipak  Amin</span>, <span class="hlFld-ContribAuthor ">Lingxiao  Li</span>, <span class="hlFld-ContribAuthor ">Soumya S.  Rajan</span>, <span class="hlFld-ContribAuthor ">Vijay  Gokhale</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Groysman</span>, <span class="hlFld-ContribAuthor ">Praechompoo  Pongtornpipat</span>, <span class="hlFld-ContribAuthor ">Edgar O.  Tapia</span>, <span class="hlFld-ContribAuthor ">Mengdie  Wang</span>, <span class="hlFld-ContribAuthor ">Jonathan H.  Schatz</span>. </span><span class="cited-content_cbyCitation_article-title">TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (17)
                                     , 23715-23729. <a href="https://doi.org/10.18632/oncotarget.8173" title="DOI URL">https://doi.org/10.18632/oncotarget.8173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.8173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.8173%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTKI%252Bsensitivity%252Bpatterns%252Bof%252Bnovel%252Bkinase-domain%252Bmutations%252Bsuggest%252Btherapeutic%252Bopportunities%252Bfor%252Bpatients%252Bwith%252Bresistant%252BALK%25252B%252Btumors%26aulast%3DAmin%26aufirst%3DAmit%2BDipak%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D17%26spage%3D23715%26epage%3D23729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qidong  Tang</span>, <span class="hlFld-ContribAuthor ">Linxiao  Wang</span>, <span class="hlFld-ContribAuthor ">Yayi  Tu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>, <span class="hlFld-ContribAuthor ">Rong  Luo</span>, <span class="hlFld-ContribAuthor ">Qidong  Tu</span>, <span class="hlFld-ContribAuthor ">Ping  Wang</span>, <span class="hlFld-ContribAuthor ">Chunjiang  Wu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (7)
                                     , 1680-1684. <a href="https://doi.org/10.1016/j.bmcl.2016.02.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.02.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.02.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrrolo%25255B2%25252C3-b%25255Dpyridine%252Bderivatives%252Bbearing%252B1%25252C2%25252C3-triazole%252Bmoiety%252Bas%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DTang%26aufirst%3DQidong%26date%3D2016%26volume%3D26%26issue%3D7%26spage%3D1680%26epage%3D1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suneet  Shukla</span>, <span class="hlFld-ContribAuthor ">Atish  Patel</span>, <span class="hlFld-ContribAuthor ">Suresh V.  Ambudkar</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 227-272. <a href="https://doi.org/10.1007/978-3-319-23476-2_10" title="DOI URL">https://doi.org/10.1007/978-3-319-23476-2_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-23476-2_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-23476-2_10%26sid%3Dliteratum%253Aachs%26atitle%3DMechanistic%252Band%252BPharmacological%252BInsights%252Binto%252BModulation%252Bof%252BABC%252BDrug%252BTransporters%252Bby%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DShukla%26aufirst%3DSuneet%26date%3D2016%26date%3D2015%26spage%3D227%26epage%3D272%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DABC%252BTransporters%252B-%252B40%252BYears%252Bon%26aulast%3DGeorge%26aufirst%3DAnthony%2BM.%26date%3D2016%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Simionato</span>, <span class="hlFld-ContribAuthor ">Carmine  Carbone</span>, <span class="hlFld-ContribAuthor ">Giampaolo  Tortora</span>, <span class="hlFld-ContribAuthor ">Davide  Melisi</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance to ALK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 147-163. <a href="https://doi.org/10.1007/978-3-319-46091-8_5" title="DOI URL">https://doi.org/10.1007/978-3-319-46091-8_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-46091-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-46091-8_5%26sid%3Dliteratum%253Aachs%26atitle%3DResistance%252Bto%252BALK%252BInhibitors%26aulast%3DSimionato%26aufirst%3DFrancesca%26date%3D2016%26date%3D2016%26spage%3D147%26epage%3D163%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DResistance%252Bto%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DFocosi%26aufirst%3DDaniele%26date%3D2016%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolong  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Zhou</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Yong  Xi</span>, <span class="hlFld-ContribAuthor ">Junfeng  Guo</span>, <span class="hlFld-ContribAuthor ">Qizheng  Yao</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structureâactivity relationship study. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>105 </em>, 39-56. <a href="https://doi.org/10.1016/j.ejmech.2015.10.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.10.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.10.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Btetracyclic%252Bbenzo%25255Bb%25255Dcarbazolones%252Bas%252Bhighly%252Bpotent%252Band%252Borally%252Bbioavailable%252BALK%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bstructure%2525E2%252580%252594activity%252Brelationship%252Bstudy%26aulast%3DJiang%26aufirst%3DXiaolong%26date%3D2015%26volume%3D105%26spage%3D39%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Osman A.  Gani</span>, <span class="hlFld-ContribAuthor ">Balmukund  Thakkar</span>, <span class="hlFld-ContribAuthor ">Dilip  Narayanan</span>, <span class="hlFld-ContribAuthor ">Kazi A.  Alam</span>, <span class="hlFld-ContribAuthor ">Peter  Kyomuhendo</span>, <span class="hlFld-ContribAuthor ">Ulli  Rothweiler</span>, <span class="hlFld-ContribAuthor ">Veronica  Tello-Franco</span>, <span class="hlFld-ContribAuthor ">Richard A.  Engh</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics</span><span> <strong>2015,</strong> <em>1854 </em>
                                    (10)
                                     , 1605-1616. <a href="https://doi.org/10.1016/j.bbapap.2015.05.004" title="DOI URL">https://doi.org/10.1016/j.bbapap.2015.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbapap.2015.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbapap.2015.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Proteins%2520and%2520Proteomics%26atitle%3DAssessing%252Bprotein%252Bkinase%252Btarget%252Bsimilarity%25253A%252BComparing%252Bsequence%25252C%252Bstructure%25252C%252Band%252Bcheminformatics%252Bapproaches%26aulast%3DGani%26aufirst%3DOsman%2BA.%26date%3D2015%26volume%3D1854%26issue%3D10%26spage%3D1605%26epage%3D1616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Konstantinos M.  Kasiotis</span>, <span class="hlFld-ContribAuthor ">Evangelia N.  Tzanetou</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Stagos</span>, <span class="hlFld-ContribAuthor ">Nikolas  Fokialakis</span>, <span class="hlFld-ContribAuthor ">Eleni  Koutsotheodorou</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Kouretas</span>, <span class="hlFld-ContribAuthor ">Serkos A.  Haroutounian</span>. </span><span class="cited-content_cbyCitation_article-title">Novel conformationally constrained pyrazole derivatives as potential anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift fÃ¼r Naturforschung B</span><span> <strong>2015,</strong> <em>70 </em>
                                    (9)
                                     , 677-690. <a href="https://doi.org/10.1515/znb-2015-0053" title="DOI URL">https://doi.org/10.1515/znb-2015-0053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/znb-2015-0053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fznb-2015-0053%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Naturforschung%2520B%26atitle%3DNovel%252Bconformationally%252Bconstrained%252Bpyrazole%252Bderivatives%252Bas%252Bpotential%252Banti-cancer%252Bagents%26aulast%3DKasiotis%26aufirst%3DKonstantinos%2BM.%26date%3D2015%26date%3D2015%26volume%3D70%26issue%3D9%26spage%3D677%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">HelenÂ Y.  Zou</span>, <span class="hlFld-ContribAuthor ">Luc  Friboulet</span>, <span class="hlFld-ContribAuthor ">DavidÂ P.  Kodack</span>, <span class="hlFld-ContribAuthor ">LarsÂ D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Li</span>, <span class="hlFld-ContribAuthor ">Melissa  West</span>, <span class="hlFld-ContribAuthor ">RuthÂ W.  Tang</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Konstantinos  Tsaparikos</span>, <span class="hlFld-ContribAuthor ">Jinwei  Wang</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>, <span class="hlFld-ContribAuthor ">DacÂ M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Hieu  Lam</span>, <span class="hlFld-ContribAuthor ">JustineÂ L.  Lam</span>, <span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Wenyue  Hu</span>, <span class="hlFld-ContribAuthor ">Bhushankumar  Patel</span>, <span class="hlFld-ContribAuthor ">Divya  Bezwada</span>, <span class="hlFld-ContribAuthor ">RosaÂ L.  Frias</span>, <span class="hlFld-ContribAuthor ">Eugene  Lifshits</span>, <span class="hlFld-ContribAuthor ">Sidra  Mahmood</span>, <span class="hlFld-ContribAuthor ">JustinÂ F.  Gainor</span>, <span class="hlFld-ContribAuthor ">Timothy  Affolter</span>, <span class="hlFld-ContribAuthor ">PatrickÂ B.  Lappin</span>, <span class="hlFld-ContribAuthor ">Hovhannes  Gukasyan</span>, <span class="hlFld-ContribAuthor ">Nathan  Lee</span>, <span class="hlFld-ContribAuthor ">Shibing  Deng</span>, <span class="hlFld-ContribAuthor ">RakeshÂ K.  Jain</span>, <span class="hlFld-ContribAuthor ">TedÂ W.  Johnson</span>, <span class="hlFld-ContribAuthor ">AliceÂ T.  Shaw</span>, <span class="hlFld-ContribAuthor ">ValeriaÂ R.  Fantin</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2015,</strong> <em>28 </em>
                                    (1)
                                     , 70-81. <a href="https://doi.org/10.1016/j.ccell.2015.05.010" title="DOI URL">https://doi.org/10.1016/j.ccell.2015.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DPF-06463922%25252C%252Ban%252BALK%25252FROS1%252BInhibitor%25252C%252BOvercomes%252BResistance%252Bto%252BFirst%252Band%252BSecond%252BGeneration%252BALK%252BInhibitors%252Bin%252BPreclinical%252BModels%26aulast%3DZou%26aufirst%3DHelen%25C2%25A0Y.%26date%3D2015%26volume%3D28%26issue%3D1%26spage%3D70%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helen Y.  Zou</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Li</span>, <span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Melissa  West</span>, <span class="hlFld-ContribAuthor ">Vicky  Appleman</span>, <span class="hlFld-ContribAuthor ">Katy A.  Wong</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Ya-Li  Deng</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Alexei  Brooun</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Scott R. P.  McDonnell</span>, <span class="hlFld-ContribAuthor ">Ping  Jiang</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Falk</span>, <span class="hlFld-ContribAuthor ">Patrick B.  Lappin</span>, <span class="hlFld-ContribAuthor ">Timothy  Affolter</span>, <span class="hlFld-ContribAuthor ">Tim  Nichols</span>, <span class="hlFld-ContribAuthor ">Wenyue  Hu</span>, <span class="hlFld-ContribAuthor ">Justine  Lam</span>, <span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Al  Charest</span>, <span class="hlFld-ContribAuthor ">Valeria R.  Fantin</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2015,</strong> <em>112 </em>
                                    (11)
                                     , 3493-3498. <a href="https://doi.org/10.1073/pnas.1420785112" title="DOI URL">https://doi.org/10.1073/pnas.1420785112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DPF-06463922%252Bis%252Ba%252Bpotent%252Band%252Bselective%252Bnext-generation%252BROS1%25252FALK%252Binhibitor%252Bcapable%252Bof%252Bblocking%252Bcrizotinib-resistant%252BROS1%252Bmutations%26aulast%3DZou%26aufirst%3DHelen%2BY.%26date%3D2015%26date%3D2015%26volume%3D112%26issue%3D11%26spage%3D3493%26epage%3D3498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anish  Kumar</span>, <span class="hlFld-ContribAuthor ">V.  Shanthi</span>, <span class="hlFld-ContribAuthor ">K.  Ramanathan</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2015,</strong> <em>34 </em>
                                    (2-3)
                                     , 105-114. <a href="https://doi.org/10.1002/minf.201400070" title="DOI URL">https://doi.org/10.1002/minf.201400070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201400070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201400070%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DComputational%252BInvestigation%252Band%252BExperimental%252BValidation%252Bof%252BCrizotinib%252BResistance%252BConferred%252Bby%252BC1156Y%252BMutant%252BAnaplastic%252BLymphoma%252BKinase%26aulast%3DKumar%26aufirst%3DAnish%26date%3D2015%26date%3D2015%26volume%3D34%26issue%3D2-3%26spage%3D105%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth H.  Palmer</span>, <span class="hlFld-ContribAuthor ">Bengt  Hallberg</span>. </span><span class="cited-content_cbyCitation_article-title">The ALK Receptor Family. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 1-51. <a href="https://doi.org/10.1007/978-3-319-11888-8_1" title="DOI URL">https://doi.org/10.1007/978-3-319-11888-8_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-11888-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-11888-8_1%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BALK%252BReceptor%252BFamily%26aulast%3DPalmer%26aufirst%3DRuth%2BH.%26date%3D2015%26spage%3D1%26epage%3D51%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DReceptor%252BTyrosine%252BKinases%25253A%252BFamily%252Band%252BSubfamilies%26aulast%3DWheeler%26aufirst%3DDeric%2BL.%26date%3D2015%26volume%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Camille G.  Wermuth</span>, <span class="hlFld-ContribAuthor ">Serge  Grisoni</span>, <span class="hlFld-ContribAuthor ">Bruno  Villoutreix</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Rocher</span>. </span><span class="cited-content_cbyCitation_article-title">Application Strategies for the Primary StructureâActivity Relationship Exploration. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 301-318. <a href="https://doi.org/10.1016/B978-0-12-417205-0.00012-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-417205-0.00012-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-417205-0.00012-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-417205-0.00012-2%26sid%3Dliteratum%253Aachs%26atitle%3DApplication%252BStrategies%252Bfor%252Bthe%252BPrimary%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BExploration%26aulast%3DWermuth%26aufirst%3DCamille%2BG.%26date%3D2015%26spage%3D301%26epage%3D318%26pub%3DElsevier%26atitle%3DThe%252BPractice%252Bof%252BMedicinal%252BChemistry%26date%3D2015%26volume%3Dvol.%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toby A.  Eyre</span>, <span class="hlFld-ContribAuthor ">Dalia  Khan</span>, <span class="hlFld-ContribAuthor ">Georgina W.  Hall</span>, <span class="hlFld-ContribAuthor ">Graham P.  Collins</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Haematology</span><span> <strong>2014,</strong> <em>93 </em>
                                    (6)
                                     , 455-468. <a href="https://doi.org/10.1111/ejh.12360" title="DOI URL">https://doi.org/10.1111/ejh.12360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ejh.12360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fejh.12360%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Haematology%26atitle%3DAnaplastic%252Blymphoma%252Bkinase-positive%252Banaplastic%252Blarge%252Bcell%252Blymphoma%25253A%252Bcurrent%252Band%252Bfuture%252Bperspectives%252Bin%252Badult%252Band%252Bpaediatric%252Bdisease%26aulast%3DEyre%26aufirst%3DToby%2BA.%26date%3D2014%26date%3D2014%26volume%3D93%26issue%3D6%26spage%3D455%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aswin  Somasundaram</span>, <span class="hlFld-ContribAuthor ">Mark A  Socinski</span>, <span class="hlFld-ContribAuthor ">Timothy F  Burns</span>. </span><span class="cited-content_cbyCitation_article-title">Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2014,</strong> <em>15 </em>
                                    (18)
                                     , 2693-2708. <a href="https://doi.org/10.1517/14656566.2014.971013" title="DOI URL">https://doi.org/10.1517/14656566.2014.971013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14656566.2014.971013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14656566.2014.971013%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DPersonalized%252Btreatment%252Bof%252BEGFR%252Bmutant%252Band%252BALK-positive%252Bpatients%252Bin%252BNSCLC%26aulast%3DSomasundaram%26aufirst%3DAswin%26date%3D2014%26date%3D2014%26volume%3D15%26issue%3D18%26spage%3D2693%26epage%3D2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alice T.  Shaw</span>, <span class="hlFld-ContribAuthor ">Sai-Hong I.  Ou</span>, <span class="hlFld-ContribAuthor ">Yung-Jue  Bang</span>, <span class="hlFld-ContribAuthor ">D. Ross  Camidge</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Solomon</span>, <span class="hlFld-ContribAuthor ">Ravi  Salgia</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Riely</span>, <span class="hlFld-ContribAuthor ">Marileila  Varella-Garcia</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Daniel B.  Costa</span>, <span class="hlFld-ContribAuthor ">Robert C.  Doebele</span>, <span class="hlFld-ContribAuthor ">Long Phi  Le</span>, <span class="hlFld-ContribAuthor ">Zongli  Zheng</span>, <span class="hlFld-ContribAuthor ">Weiwei  Tan</span>, <span class="hlFld-ContribAuthor ">Patricia  Stephenson</span>, <span class="hlFld-ContribAuthor ">S. Martin  Shreeve</span>, <span class="hlFld-ContribAuthor ">Lesley M.  Tye</span>, <span class="hlFld-ContribAuthor ">James G.  Christensen</span>, <span class="hlFld-ContribAuthor ">Keith D.  Wilner</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Clark</span>, <span class="hlFld-ContribAuthor ">A. John  Iafrate</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib in
              ROS1
              -Rearranged NonâSmall-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">New England Journal of Medicine</span><span> <strong>2014,</strong> <em>371 </em>
                                    (21)
                                     , 1963-1971. <a href="https://doi.org/10.1056/NEJMoa1406766" title="DOI URL">https://doi.org/10.1056/NEJMoa1406766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1056/NEJMoa1406766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1056%2FNEJMoa1406766%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520England%2520Journal%2520of%2520Medicine%26atitle%3DCrizotinib%252Bin%252BROS1%252B-Rearranged%252BNon%2525E2%252580%252593Small-Cell%252BLung%252BCancer%26aulast%3DShaw%26aufirst%3DAlice%2BT.%26date%3D2014%26volume%3D371%26issue%3D21%26spage%3D1963%26epage%3D1971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected clinical ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of crizotinib bound to the ALK kinase domain, showing the positions of clinically identified crizotinib-resistant mutations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Co-crystal structure of crizotinib with ALK wt (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>) overlaid with L1196M mutant (cyan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yfx">2yfx</a>) and the G1269 residue from L1196M apo structure (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yhv">2yhv</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystal structures of crizotinib/ALK wt (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>) and <b>6d</b>/ALK wt (cyan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb">4ccb</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Co-crystal structure of <b>7h</b> and ALK wt protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu">4ccu</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Relative energy profile for the torsion angle between the aminopyridine core and the R<sup>3</sup> aryl ring for <b>6d</b> and <b>7a</b>â<b>7i</b> as calculated by the density functional theory (DFT) B3LYP/6-31g** method in Jaguar.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Co-crystal structure of <b>8e</b> and ALK L1196M protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0">4cd0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Doseâresponse curve of <b>8e</b> in H3122<sup>L1196M</sup> xenografts in athymic mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Twice-daily dose PK of <b>8e</b> from last day of TGI experiment (day 29) in H3122-L1196M xenografts in athymic mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of <b>6a</b>â<b>c</b> from Alcohol <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.1 equiv of Ph<sub>3</sub>P, 1.1 equiv of 5-bromo-3-hydroxy-2-nitropyridine, 1.1 equiv of DIAD, toluene, 0 Â°C, 18 h. (b) 5 equiv of Fe, dioxane/AcOH (4:1), 40 Â°C reflux, 0.5 h. (c) 2 equiv of pyrazole boronate ester, 0.1 equiv of Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 equiv of NaHCO<sub>3</sub>, dioxane/water (2.5/1), 110 Â°C, 1.5 h.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>6d</b>, <b>7a</b>â<b>i</b>, and <b>8a</b>-<b>e</b> from Ketone <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.5 equiv of triazole, 1.0 equiv of Cs<sub>2</sub>CO<sub>3</sub>, NMP, 140 Â°C, 3 h, 35%. (b) 1.25 equiv of (â)-DIP-Cl, THF, â35 Â°C for 3 h and then rt for 18 h; 2.7 equiv of diethanolamine, TBME, rt reflux, 2 h, 99%, 96% ee. (c) 1.2 equiv of MsCl, 1.5 equiv of Et<sub>3</sub>N, TBME, â10 Â°C to rt, 17 h. (d) 1.2 equiv of 2-amino-5-bromo-3-hydroxypyridine, 1.2 equiv of Cs<sub>2</sub>CO<sub>3</sub>, acetone, 60 Â°C, 16 h, 56% over two steps. (e) 1.7 equiv of bis(pinacalato)diboron, Pd(dppf)Cl<sub>2</sub> (5 mol %), 3.5 equiv of KOAc, DMSO, 80 Â°C, 3 h, 77%. (f) 1.5 equiv of ArBr, 0.05 equiv of Pd(dppf)Cl<sub>2</sub>, 3.0 equiv of K<sub>2</sub>CO<sub>3</sub>, DME/water (5:1), 120 Â°C microwave, 1 h; or 1.5 equiv of ArBr, 0.05 equiv of Pd(dppf)Cl<sub>2</sub>, 2.5 equiv of CsF, MeOH, 120 Â°C microwave, 1 h; or 1.3 equiv of ArBr, 0.05 equiv of Pd-132, 3 equiv of CsF, MeOH, 50 Â°C, 1 h. (g) 5 equiv of methylimidazole, 1.5 equiv of CuI, 3 equiv of Cs<sub>2</sub>CO<sub>3</sub>, NMP, 150 Â°C, microwave, 5 h, 2%.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/medium/jm-2013-01805h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthesis of Thiazole Halides as Precursors for Suzuki Coupling Reactions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401805h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.0 equiv of ketone, 1.0 equiv of <i>n</i>-BuLi, THF, â78 Â°C, 0.5 h. (b) 1.0 equiv of NBS, DMF 0 Â°C, overnight. (c) 1.1 equiv of H<sub>2</sub>SO<sub>4</sub>, AcOH, 80â85 Â°C, 20 h. (d) AD-mix-Î± or -Î², THF/<i>t</i>-BuOH/H<sub>2</sub>O (1:1:1), 25 Â°C, 60 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04013" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04013" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. P.</span><span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkinâs lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2175</span><span class="NLM_x">â</span> <span class="NLM_lpage">2188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bilsland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeldon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mead, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Znamenskiy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heavens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiting, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz-Sanjuan, I.</span><span> </span><span class="NLM_article-title">Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">â</span> <span class="NLM_lpage">700</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=685-700&author=J.+G.+Bilslandauthor=A.+Wheeldonauthor=A.+Meadauthor=P.+Znamenskiyauthor=S.+Almondauthor=K.+A.+Watersauthor=M.+Thakurauthor=V.+Beaumontauthor=T.+P.+Bonnertauthor=R.+Heavensauthor=P.+Whitingauthor=G.+McAllisterauthor=I.+Munoz-Sanjuan&title=Behavioral+and+neurochemical+alterations+in+mice+deficient+in+anaplastic+lymphoma+kinase+suggest+therapeutic+potential+for+psychiatric+indications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBilsland%26aufirst%3DJ.%2BG.%26aulast%3DWheeldon%26aufirst%3DA.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DZnamenskiy%26aufirst%3DP.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DThakur%26aufirst%3DM.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DBonnert%26aufirst%3DT.%2BP.%26aulast%3DHeavens%26aufirst%3DR.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DBehavioral%2520and%2520neurochemical%2520alterations%2520in%2520mice%2520deficient%2520in%2520anaplastic%2520lymphoma%2520kinase%2520suggest%2520therapeutic%2520potential%2520for%2520psychiatric%2520indications%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D685%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chiarle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">â</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0liSRete_cp2lA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rentrop, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">â</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+lymphoma+kinase%3A+role+in+cancer+pathogenesis+and+small-molecule+inhibitor+development+for+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lj-GqK8LcJ5zA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520cancer%2520pathogenesis%2520and%2520small-molecule%2520inhibitor%2520development%2520for%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Iwahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cupples, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratzkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span> </span><span class="NLM_article-title">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">â</span> <span class="NLM_lpage">449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=439-449&author=T.+Iwaharaauthor=J.+Fujimotoauthor=D.+Wenauthor=R.+Cupplesauthor=N.+Bucayauthor=T.+Arakawaauthor=S.+Moriauthor=B.+Ratzkinauthor=T.+Yamamoto&title=Molecular+characterization+of+ALK%2C+a+receptor+tyrosine+kinase+expressed+specifically+in+the+nervous+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIwahara%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DBucay%26aufirst%3DN.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DRatzkin%26aufirst%3DB.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DMolecular%2520characterization%2520of%2520ALK%252C%2520a%2520receptor%2520tyrosine%2520kinase%2520expressed%2520specifically%2520in%2520the%2520nervous%2520system%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D439%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkinâs lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">â</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">ALK-positive large B-cell lymphoma: report of two cases and review of the literature</span> <span class="citation_source-journal">J. Cancer Sci. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.4172%2F1948-5956.1000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Oqu7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=228-232&author=H.+Yuauthor=X.+Liuauthor=H.+Liauthor=D.+Shiauthor=C.+Wang&title=ALK-positive+large+B-cell+lymphoma%3A+report+of+two+cases+and+review+of+the+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-postive large B-cell lymphoma: report of two cases and review of the literature</span></div><div class="casAuthors">Yu, Hong; Liu, Xiao-Jian; Li, Hui; Shi, Da-Ren; Wang, Chao-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Science & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">228-232</span>CODEN:
                <span class="NLM_cas:coden">JCSTGU</span>;
        ISSN:<span class="NLM_cas:issn">1948-5956</span>.
    
            (<span class="NLM_cas:orgname">OMICS Publishing Group</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase pos. large B-cell lymphoma (ALK+LBCL) is a rare variant of large B-cell lymphoma, but it rarely expresses B-lineage antigens (e.g CD20, CD79a) while showing an abnormal immunophenotype, such as pos. for ALK, EMA, CD38, CD138.  Only 55 cases of ALK+LBCL have been reported so far in the published literature.  We present two addnl. cases of ALK+LBCL, which were sent to our department for consultation from other hospitals.  One was initially diagnosed as metastatic poorly differentiated carcinoma and the other was not able to be diagnosed.  The two cases were finally diagnosed as "ALK+LBCL" at our department of pathol.  The chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) was given, resp.  Case 1 was given radiation therapy after chemotherapy, and case 2 wasn't.  Case 1, followed up for 16 mo, was free of disease.  Case 2 died at 8 mo after the diagnosis.  Due to the abnormal immunophenotype and rareness, the diagnosis of ALK+LBCL is often difficult, even being misdiagnosed as carcinoma or plasma cell neoplasm.  However, the treatment for these diseases is quite different from each another.  Avoiding misdiagnosis of ALK+LBCL is of great clinic importance.  In this report, we describe the clin., morphol., immunohistiochem. and cytogenetic features of the two ALK+LBCL cases, reviewed 55 published cases, and compared the features with those of literature-reported cases.  We came to the conclusions: 1. ALK+LBCL could affect non-adult and adult with a bimodal age distribution, with an av. age of 12.5 years in the non-adult, and 43.5 years in the adult.  2. ALK+LBCL is a potential diagnostic pitfall for pathologists.  Its diagnosis clues are that neoplastic cells are immunoblastic or/and plasmacytoid with prominent central nucleoli, pos. for ALK, EMA and some markers of late (plasma cell-like) B-cell differentiation, like CD138, VS38 and Igs, neg. for B-cell markers like CD20 and CD79a.  3. The investigation of involved genetic abnormality (CLTC-ALK fusion, or NPM-ALK rearrangement) contributes to confirm ALK+LBCL.  ALK+LBCL has highly aggressive biobehavior and poor response to std. therapies.  More patient case collection and prospective studies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv7AvZfJEk5rVg90H21EOLACvtfcHk0lg1Btb7iWum-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Oqu7fP&md5=d95d55af9f260685279f1d9152bc9d3a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4172%2F1948-5956.1000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F1948-5956.1000094%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DALK-positive%2520large%2520B-cell%2520lymphoma%253A%2520report%2520of%2520two%2520cases%2520and%2520review%2520of%2520the%2520literature%26jtitle%3DJ.%2520Cancer%2520Sci.%2520Ther.%26date%3D2011%26volume%3D3%26spage%3D228%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">â</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lg1Btb7iWum-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4âALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4%E2%80%93ALK+fusion+gene+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4%25E2%2580%2593ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2349</span><span class="NLM_x">â</span> <span class="NLM_lpage">2355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1111%2Fj.1349-7006.2008.00972.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=19032370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=2349-2355&author=H.+Mano&title=Non-solid+oncogenes+in+solid+tumors%3A+EML4-ALK+fusion+genes+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span></div><div class="casAuthors">Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2349-2355</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that recurrent chromosome translocations play a major role in the mol. pathogenesis of hematol. malignancies but not of solid tumors.  However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.  Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-assocd. protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.  A recurrent chromosome translocation, inv(2)(p21p23), in NSCLC generates fused mRNA encoding the amino-terminal half of EML4 ligated to the intracellular region of the receptor-type protein tyrosine kinase ALK.  EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.  Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute -5% of NSCLC cases, at least in the Asian ethnic group.  In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are pos. for the fusion gene, and discuss whether suppression of ALK enzymic activity could be an effective treatment strategy against this intractable disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbxSS7U51wKbVg90H21EOLACvtfcHk0ljzGEZMhQ6guw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D&md5=84386550daedbd29b3a34b11a4774684</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00972.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00972.x%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DNon-solid%2520oncogenes%2520in%2520solid%2520tumors%253A%2520EML4-ALK%2520fusion%2520genes%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D2349%26epage%3D2355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Targeting anaplastic lymphoma kinase in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">â</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+anaplastic+lymphoma+kinase+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0ljzGEZMhQ6guw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Caren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinsson, I.</span><span> </span><span class="NLM_article-title">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">416</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Carenauthor=F.+Abelauthor=P.+Kognerauthor=I.+Martinsson&title=High+incidence+of+DNA+mutations+and+gene+amplifications+of+the+ALK+gene+in+advanced+sporadic+neuroblastoma+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaren%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DI.%26atitle%3DHigh%2520incidence%2520of%2520DNA%2520mutations%2520and%2520gene%2520amplifications%2520of%2520the%2520ALK%2520gene%2520in%2520advanced%2520sporadic%2520neuroblastoma%2520tumors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">MossÃ©, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">â</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">â</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0livoeUfuGwVJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">â</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=Li.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DLi.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanael, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provides a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">â</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+Gregorauthor=T.+R.+Webbauthor=S.+Nathanaelauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=W.+Stephanauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provides+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DNathanael%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DStephan%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provides%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Azarova, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span> </span><span class="NLM_article-title">Emerging importance of ALK in neuroblastoma</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8f&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2Fj.semcancer.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8f&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21945349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8f&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=267-275&author=A.+M.+Azarovaauthor=G.+Gautamauthor=R.+E.+George&title=Emerging+importance+of+ALK+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8fR"><div class="casContent"><span class="casTitleNuber">8f</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging importance of ALK in neuroblastoma</span></div><div class="casAuthors">Azarova, Anna M.; Gautam, Gargi; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated.  As a group, the activating point mutations in full-length ALK, found in approx. 8% of all neuroblastoma tumors, are distributed evenly across different clin. stages.  However, the most frequent somatic mutation, F1174L, is assocd. with amplification of the MYCN oncogene.  This combination of features appears to confer a worse prognosis than MYCN amplification alone, suggesting a cooperative effect on neuroblastoma formation by these two proteins.  Indeed, F1174L has shown more potent transforming activity in vivo than the second most common activating mutation, R1275Q, and is responsible for innate and acquired resistance to crizotinib, a clin. relevant ALK inhibitor that will soon be com. available.  These advances cast ALK as a bona fide oncoprotein in neuroblastoma and emphasize the need to understand ALK-mediated signaling in this tumor.  This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clin. effective targeted treatments based on ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqmFzh9Q3frVg90H21EOLACvtfcHk0lgUCA_KKtGeLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN&md5=e07445aecd9829c465f1f4023124521f</span></div><a href="/servlet/linkout?suffix=cit8f&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DGautam%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DEmerging%2520importance%2520of%2520ALK%2520in%2520neuroblastoma%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D267%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">ALK gene amplified in most inflammatory breast cancers</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1093%2Fjnci%2Fdjr553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=22215853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=87-88&author=R.+S.+Tuma&title=ALK+gene+amplified+in+most+inflammatory+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Gene Amplified in Most Inflammatory Breast Cancers</span></div><div class="casAuthors">Tuma, Rabiya S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from non-inflammatory breast cancer in presentation and response to therapy. Despite those differences, researchers have uncovered few mol. characteristics that distinguish IBC from non-inflammatory breast cancer, and IBC treatment generally relies on std. breast cancer regimens.  Recently, it has been reported that ALK gene amplification is a common feature of IBC tumors and that small-mol. ALK inhibitors are effective in mouse xenograft models.  Current developments on this recent report are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9yX6fegRi7Vg90H21EOLACvtfcHk0lgUCA_KKtGeLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D&md5=46e7633055aadc3aacfc6bac9b4cb591</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr553%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DALK%2520gene%2520amplified%2520in%2520most%2520inflammatory%2520breast%2520cancers%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D87%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beausoleil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">â</span> <span class="NLM_lpage">3323</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=X.+Z.+Tanauthor=C.+Crosbyauthor=H.+Haackauthor=J.-M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.-M.+Zhouauthor=T.-L.+Guauthor=Y.-F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DX.%2BZ.%26aulast%3DCrosby%26aufirst%3DC.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.-M.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DY.-F.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">â</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=B.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-MET%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lhNeAuniHeg7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DB.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-MET%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">â</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+Altonauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-MET%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, â¼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-Î³, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lhwl0W4XYb5hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-MET%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymalâepithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">â</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Case History: Xalkori<sup>TM</sup> (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=421-432&author=J.+J.+Cuiauthor=M.+McTigueauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Case+History%3A+XalkoriTM+%28crizotinib%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal+epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DCase%2520History%253A%2520XalkoriTM%2520%2528crizotinib%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%2520epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520for%2520cancer%2520treatment%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2013%26volume%3D48%26spage%3D421%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">â</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2FS1470-2045%2811%2970232-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21933749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1004-1012&author=A.+T.+Shawauthor=B.+Y.+Yeapauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=J.+Gainorauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=D.+B.+Costaauthor=S.-H.+I.+Ouauthor=M.+Butaneyauthor=R.+Salgiaauthor=R.+G.+Makiauthor=M.+Varella-Garciaauthor=R.+C.+Doebeleauthor=Y.-J.+Bangauthor=K.+Kuligauthor=P.+Selaruauthor=Y.+Tangauthor=K.+D.+Wilnerauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=A.+J.+Iafrateauthor=D.+R.+Camidge&title=Effect+of+crizotinib+on+overall+survival+in+patients+with+advanced+non-small-cell+lung+cancer+harbouring+ALK+gene+rearrangement%3A+a+retrospective+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</span></div><div class="casAuthors">Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1004-1012</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">ALK gene rearrangement defines a new mol. subtype of non-small-cell lung cancer (NSCLC).  In a recent phase 1 clin. trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumor activity in patients with advanced, ALK-pos. NSCLC.  To assess whether crizotinib affects overall survival in these patients, we did a retrospective study comparing survival outcomes in crizotinib-treated patients in the trial and crizotinib-naive controls screened during the same time period.  We examd. overall survival in patients with advanced, ALK-pos. NSCLC who enrolled in the phase 1 clin. trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010.  For comparators, we identified 36 ALK-pos. patients from trial sites who were not given crizotinib (ALK-pos. controls), 67 patients without ALK rearrangement but pos. for EGFR mutation, and 253 wild-type patients lacking either ALK rearrangement or EGFR mutation.  To assess differences in overall survival, we assessed subsets of clin. comparable ALK-pos. and ALK-neg. patients.  Among 82 ALK-pos. patients who were given crizotinib, median overall survival from initiation of crizotinib has not been reached (95% CI 17 mo to not reached); 1-yr overall survival was 74% (95% CI 63-82), and 2-yr overall survival was 54% (40-66).  Overall survival did not differ based on age, sex, smoking history, or ethnic origin.  Survival in 30 ALK-pos. patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-pos. controls given any second-line therapy (median overall survival not reached [95% CI 14 mo to not reached] vs 6 mo [4-17], 1-yr overall survival 70% [95% CI 50-83] vs 44% [23-64], and 2-yr overall survival 55% [33-72] vs 12% [2-30]; hazard ratio 0.36, 95% CI 0.17-0.75; p = 0.004).  Survival in 56 crizotinib-treated, ALK-pos. patients was similar to that in 63 ALK-neg., EGFR-pos. patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 mo to not reached] vs 24 mo [15-34], 1-yr overall survival 71% [95% CI 58-81] vs 74% [61-83], and 2-yr overall survival 57% [40-71] vs 52% [38-65]; p = 0.786), whereas survival in 36 crizotinib-naive, ALK-pos. controls was similar to that in 253 wild-type controls (median overall survival 20 mo [95% CI 13-26] vs 15 mo [13-17]; p = 0.244).  In patients with advanced, ALK-pos. NSCLC, crizotinib therapy is assocd. with improved survival compared with that of crizotinib-naive controls.  ALK rearrangement is not a favorable prognostic factor in advanced NSCLC.  Funding: Pfizer Inc, V Foundation for Cancer Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMS7fRYJSyrrVg90H21EOLACvtfcHk0lhwl0W4XYb5hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KmtrzL&md5=5482da97726293764c9fe42419d187cb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970232-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970232-7%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DGainor%26aufirst%3DJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKulig%26aufirst%3DK.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DEffect%2520of%2520crizotinib%2520on%2520overall%2520survival%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harbouring%2520ALK%2520gene%2520rearrangement%253A%2520a%2520retrospective%2520analysis%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D1004%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">â</span> <span class="NLM_lpage">1739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lgzSJvvXwIzFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">6051</span><span class="NLM_x">â</span> <span class="NLM_lpage">6060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=A+novel+ALK+secondary+mutation+and+EGFR+signaling+cause+resistance+to+ALK+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520ALK%2520secondary%2520mutation%2520and%2520EGFR%2520signaling%2520cause%2520resistance%2520to%2520ALK%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6051%26epage%3D6060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miret, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">â</span> <span class="NLM_lpage">1005</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1111%2Fj.1747-0285.2011.01239.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=22034911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=999-1005&author=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=X.+Zhuauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=L.+Moranauthor=Q.+K.+Mohemmadauthor=R.+Anjumauthor=Y.+Wangauthor=N.+I.+Narasimhanauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=J.+J.+Miretauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Crizotinib-resistant+mutants+of+EML4-ALK+identified+through+an+accelerated+mutagenesis+screen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</span></div><div class="casAuthors">Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1005</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers.  Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clin. activity in patients with non-small-cell lung cancer and inflammatory myofibroblastic tumors harboring ALK translocations.  Inhibitors of driver kinases often elicit kinase domain mutations that confer resistance, and such mutations have been successfully predicted using in vitro mutagenesis screens.  Here, this approach was used to discover an extensive set of ALK mutations that can confer resistance to crizotinib.  Mutations at 16 residues were identified, structurally clustered into five regions around the kinase active site, which conferred varying degrees of resistance.  The screen successfully predicted the L1196M, C1156Y, and F1174L mutations, recently identified in crizotinib-resistant patients.  In sep. studies, we demonstrated that crizotinib has relatively modest potency in ALK-pos. non-small-cell lung cancer cell lines.  A more potent ALK inhibitor, TAE684, maintained substantial activity against mutations that conferred resistance to crizotinib.  Our study identifies multiple novel mutations in ALK that may confer clin. resistance to crizotinib, suggests that crizotinib's narrow selectivity window may underlie its susceptibility to such resistance and demonstrates that a more potent ALK inhibitor may be effective at overcoming resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU21SkJFhWI7Vg90H21EOLACvtfcHk0lgzSJvvXwIzFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLbI&md5=7f1f1d4ad48d1801cd3f9c44f7ef4615</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2011.01239.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2011.01239.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMiret%26aufirst%3DJ.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DCrizotinib-resistant%2520mutants%2520of%2520EML4-ALK%2520identified%2520through%2520an%2520accelerated%2520mutagenesis%2520screen%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D78%26spage%3D999%26epage%3D1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutateladze, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to crizotinib in patients with ALK gene rearranged nonâsmall cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1472</span><span class="NLM_x">â</span> <span class="NLM_lpage">1482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+resistance+to+crizotinib+in+patients+with+ALK+gene+rearranged+non%E2%80%93small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0lhWlL_ZBevhbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520crizotinib%2520in%2520patients%2520with%2520ALK%2520gene%2520rearranged%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancer</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_elocation-id">120ra17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2FB978-0-12-396492-2.00019-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=281-293&author=K.+Kinoshitaauthor=N.+Oikawaauthor=T.+Tsukuda&title=Anaplastic+lymphoma+kinase+inhibitors+for+the+treatment+of+ALK-positive+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13fR"><div class="casContent"><span class="casTitleNuber">13f</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers</span></div><div class="casAuthors">Kinoshita, Kazutomo; Oikawa, Nobuhiro; Tsukuda, Takuo</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-293</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review on the development of anaplastic lymphoma kinase (ALK) inhibitors which is the most highly competitive drug targets in oncol. research.  A no. of research groups have identified promising drugs, where Pfizer succeeded in launching a potent ALK inhibitor, crizotinib, for treatment of EML4-ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX549XOu0aZrVg90H21EOLACvtfcHk0lhWlL_ZBevhbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7vE&md5=2fb9597a39e7dd478a4ef41be4df7be6</span></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00019-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00019-9%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520ALK-positive%2520cancers%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D281%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+potent%2C+selective%2C+and+efficacious+inhibitor+of+NPM-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Marsilje, T. H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structureâactivity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">â</span> <span class="NLM_lpage">5690</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kuromitsu, S.; Mori, M.; Shimada, I.; Kondoh, Y.; Shindoh, N.; Soga, T.; Furutani, T.; Konagai, S.; Sakagami, H.; Nakata, M.; Ueno, Y.; Saito, R.; Sasamata, M.; Kudou, M.</span> Anti-tumor activity of ASP3026, a novel and selective ALK inhibitor of anaplastic lymphoma kinase (ALK). Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 2821.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kuromitsu%2C+S.%3B+Mori%2C+M.%3B+Shimada%2C+I.%3B+Kondoh%2C+Y.%3B+Shindoh%2C+N.%3B+Soga%2C+T.%3B+Furutani%2C+T.%3B+Konagai%2C+S.%3B+Sakagami%2C+H.%3B+Nakata%2C+M.%3B+Ueno%2C+Y.%3B+Saito%2C+R.%3B+Sasamata%2C+M.%3B+Kudou%2C+M.+Anti-tumor+activity+of+ASP3026%2C+a+novel+and+selective+ALK+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29.+Presented+at+the+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Orlando%2C+FL%2C+2011%3B+Abstract+2821."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKuromitsu%26aufirst%3DS.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">â</span> <span class="NLM_lpage">690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6286</span><span class="NLM_x">â</span> <span class="NLM_lpage">6294</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0ljpctuIckyhNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eb, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">River, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">â</span> <span class="NLM_lpage">7540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebauthor=V.+M.+Riverauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=A.+Jeffreyauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEb%26aufirst%3DH.%26aulast%3DRiver%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DJeffrey%26aufirst%3DA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">â</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+ligand+lipophilicity+efficiency+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520efficiency%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Freeman-cook, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span> </span><span class="NLM_article-title">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">â</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.4155%2Ffmc.12.208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=23360135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=113-115&author=K.+D.+Freeman-cookauthor=R.+L.+Hoffmanauthor=T.+W.+Johnson&title=Lipophilic+efficiency%3A+the+most+important+efficiency+metric+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Hoffman, Robert L.; Johnson, Ted W.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-115</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review is given on the crit. role of lipophilicity in drug discovery and optimization of general absorption, distribution, metab. and excretion properties, toxicol. profiles and ultimately pharmacol. response.  Math. equations are presented concerning the impact of lipophilicity on the dose and the calcn. of the lipophilic ligand efficiency (LipE).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKhEHH7Hf1qbVg90H21EOLACvtfcHk0lgA81x0BDSTMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D&md5=36170decfa1f1e3ef09ecf772322a210</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.208%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-cook%26aufirst%3DK.%2BD.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26atitle%3DLipophilic%2520efficiency%253A%2520the%2520most%2520important%2520efficiency%2520metric%2520in%2520medicinal%2520chemistry%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D113%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><div class="note"><p class="first last">Crizotinib has an extensive tumor distribution profiles with an approximate tumor/plasma AUC ratio of 4 at steady-state (in-house data). Also see </p></div><span class="NLM_contrib-group">Yamazaki, S.</span><span> </span><span class="NLM_article-title">Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">â</span> <span class="NLM_lpage">366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=354-366&author=S.+Yamazaki&title=Translational+pharmacokinetic-pharmacodynamic+modeling+from+nonclinical+to+clinical+development%3A+a+case+study+of+anticancer+drug%2C+crizotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26atitle%3DTranslational%2520pharmacokinetic-pharmacodynamic%2520modeling%2520from%2520nonclinical%2520to%2520clinical%2520development%253A%2520a%2520case%2520study%2520of%2520anticancer%2520drug%252C%2520crizotinib%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26spage%3D354%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalaeva, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tupper, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.</span><span> </span><span class="NLM_article-title">ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2490</span><span class="NLM_x">â</span> <span class="NLM_lpage">2497</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0100990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2490-2497&author=F.+Lombardoauthor=M.+Y.+Shalaevaauthor=K.+A.+Tupperauthor=F.+Gao&title=ElogD%28oct%29%3A+a+tool+for+lipophilicity+determination+in+drug+discovery.+2.+Basic+and+neutral+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm0100990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0100990%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DShalaeva%26aufirst%3DM.%2BY.%26aulast%3DTupper%26aufirst%3DK.%2BA.%26aulast%3DGao%26aufirst%3DF.%26atitle%3DElogD%2528oct%2529%253A%2520a%2520tool%2520for%2520lipophilicity%2520determination%2520in%2520drug%2520discovery.%25202.%2520Basic%2520and%2520neutral%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2490%26epage%3D2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">â</span> <span class="NLM_lpage">533</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lgA81x0BDSTMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">4974</span><span class="NLM_x">â</span> <span class="NLM_lpage">4985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitneyauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. Â© 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lh45DPhJ741gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nishio, M.; Hirota, M.; Umezawa, Y.</span>, Eds.  <span class="citation_source-book">The CHâPi Interaction: Evidence, Nature, and Consequences</span>; <span class="NLM_publisher-name">WileyâVCH</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1998</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">215</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=1-215&author=M.+Nishio&author=M.+Hirota&author=Y.+Umezawa&title=The+CH%E2%80%93Pi+Interaction%3A+Evidence%2C+Nature%2C+and+Consequences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNishio%26aufirst%3DM.%26btitle%3DThe%2520CH%25E2%2580%2593Pi%2520Interaction%253A%2520Evidence%252C%2520Nature%252C%2520and%2520Consequences%26pub%3DWiley%25E2%2580%2593VCH%26date%3D1998%26spage%3D1%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nishio, M.</span><span> </span><span class="NLM_article-title">CH/Ï hydrogen bonds in crystals</span> <span class="citation_source-journal">CrystEngComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1039%2Fb313104a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Gnu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=130-158&author=M.+Nishio&title=CH%2F%CF%80+hydrogen+bonds+in+crystals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">CH/Ï hydrogen bonds in crystals</span></div><div class="casAuthors">Nishio, Motohiro</div><div class="citationInfo"><span class="NLM_cas:title">CrystEngComm</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-158</span>CODEN:
                <span class="NLM_cas:coden">CRECF4</span>;
        ISSN:<span class="NLM_cas:issn">1466-8033</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The nature and characteristics of the CH/Ï interaction are discussed by comparison with other weak mol. forces such as the CH/O and OH/Ï interaction.  The CH/Ï interaction is a kind of hydrogen bond operating between a soft acid CH and a soft base Ï-system (double and triple bonds, C6 and C5 arom. rings, heteroaroms., convex surfaces of fullerenes and nanotubes).  The consequences of CH/Ï hydrogen bonds in supramol. chem. are reviewed on grounds of recent crystallog. findings and database analyses.  The topics include intramol. interactions, crystal packing (org. and organometallic compds.), host/guest complexes (cavity-type inclusion compds. of cyclodextrins and synthetic macrocyclic hosts such as calixarenes, catenanes, rotaxanes and pseudorotaxanes), lattice-inclusion type clathrates (including liq. crystals, porphyrin derivs., cyclopentadienyl compds. and C60 fullerenes), enantioselective clathrate formation, catalytic enantioface discriminating reactions and solid-state photoreaction.  The implications of the CH/Ï concept for crystal engineering and drug design are evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp66q0y6L3qvrVg90H21EOLACvtfcHk0lh45DPhJ741gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Gnu7g%253D&md5=191ddb4c549623bb6e6b7b6ceb5fd101</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1039%2Fb313104a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb313104a%26sid%3Dliteratum%253Aachs%26aulast%3DNishio%26aufirst%3DM.%26atitle%3DCH%252F%25CF%2580%2520hydrogen%2520bonds%2520in%2520crystals%26jtitle%3DCrystEngComm%26date%3D2004%26volume%3D6%26spage%3D130%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Novel target in non-small cell lung cancer: ROS1 and RET fusions</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">â</span> <span class="NLM_lpage">875</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=865-875&author=J.+F.+Gainorauthor=A.+T.+Shaw&title=Novel+target+in+non-small+cell+lung+cancer%3A+ROS1+and+RET+fusions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DNovel%2520target%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520ROS1%2520and%2520RET%2520fusions%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D865%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chin, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span> </span><span class="NLM_article-title">Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1625</span><span class="NLM_x">â</span> <span class="NLM_lpage">1630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1097%2FJTO.0b013e31826baf83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Fjm401805h&amp;key=23070242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgt7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1625-1630&author=L.+P.+Chinauthor=R.+A.+Sooauthor=R.+Soongauthor=S.+H.+Ou&title=Targeting+ROS1+with+anaplastic+lymphoma+kinase+inhibitors%3A+a+promising+therapeutic+strategy+for+a+newly+defined+molecular+subset+of+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chin, Leow Pay; Soo, Ross A.; Soong, Richie; Ou, Sai-Hong I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1625-1630</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described in a variety of human malignancies including non-small-cell lung cancer (NSCLC), cholangiocarcinoma and glioblastoma multiforme.  Recently, clinicopathol. characteristics of c-ros oncogene 1, receptor tyrosine kinase (ROS1)-rearranged NSCLC patients have been described.  Furthermore, anaplastic lymphoma kinase inhibitor, novel class of drugs targeting this tyrosine kinase receptor is currently under clin. trial in this mol. subset of NSCLC patients.  This review will focus on the current knowledge of ROS1 rearrangements in NSCLC, methods to detect ROS1 rearrangement, and targeting ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgGb8cXIS3bVg90H21EOLACvtfcHk0lgz5qb2K7NYUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgt7%252FO&md5=f6a1d2380911daa1c0ba4749e2f21f55</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31826baf83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31826baf83%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DL.%2BP.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DSoong%26aufirst%3DR.%26aulast%3DOu%26aufirst%3DS.%2BH.%26atitle%3DTargeting%2520ROS1%2520with%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%253A%2520a%2520promising%2520therapeutic%2520strategy%2520for%2520a%2520newly%2520defined%2520molecular%2520subset%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1625%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brown, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekharan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, P. V.</span><span> </span><span class="NLM_article-title">Chiral synthesis via organoboranes. 14. Selective reductions. 41. Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">â</span> <span class="NLM_lpage">1546</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00213a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaL1cXhtFamsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=1988&pages=1539-1546&author=H.+C.+Brownauthor=J.+Chandrasekharanauthor=P.+V.+Ramachandran&title=Chiral+synthesis+via+organoboranes.+14.+Selective+reductions.+41.+Diisopinocampheylchloroborane%2C+an+exceptionally+efficient+chiral+reducing+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral synthesis via organoboranes.  14.  Selective reductions.  41.  Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent</span></div><div class="casAuthors">Brown, Herbert C.; Chandrasekharan, J.; Ramachandran, P. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1539-46</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Diisopinocampheylchloroborane (I), readily prepd. in both enantiomers in high chem. and optical purities (99% ee) via hydroboration, reduces prochiral ketones at convenient rates.  Redn. of simple dialkyl ketones, 2-butanone, 2-octanone, and 3-methyl-2-butanone, yields the corresponding alcs. with 4%, 7%, and 32% optical induction.  Aralkyl ketones are reduced with very high asym. induction.  Thus, acetophenone, propiophenone, butyrophenone, and decanophenone are reduced with 98%, 98%, 98%, and 97% ee, resp.  Branching of the alkyl chain diminishes the induction.  Functional groups in the arom. ring are not affected by the reagent and do not appear to influence significantly the optical yield realized.  Heteroaryl alkyl ketones are also reduced with excellent optical induction.  The reagent reduces Î±-tertiary aliph. ketones under neat condition at room temp. with very high optical induction.  Î±,Î²-Unsatd. ketones are reduced with lesser optical induction.  Certain Î±-keto esters are reduced in 50-70% ee.  The mechanism of the redn. is postulated to be via a six-membered cyclic boat-like transition state.  X-ray crystal structure data for I are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsVAEQNaLjjrVg90H21EOLACvtfcHk0lgz5qb2K7NYUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhtFamsbw%253D&md5=efea4959eb07a0f0ed74860f2840cad9</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fja00213a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00213a030%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DH.%2BC.%26aulast%3DChandrasekharan%26aufirst%3DJ.%26aulast%3DRamachandran%26aufirst%3DP.%2BV.%26atitle%3DChiral%2520synthesis%2520via%2520organoboranes.%252014.%2520Selective%2520reductions.%252041.%2520Diisopinocampheylchloroborane%252C%2520an%2520exceptionally%2520efficient%2520chiral%2520reducing%2520agent%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1988%26volume%3D110%26spage%3D1539%26epage%3D1546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ramachandran, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H. C.</span><span> </span><span class="NLM_article-title">A remarkable inversion in configuration of the product alcohols from the asymmetric reduction of <i>ortho</i>-hydroxyacetophenones with Î²-chlorodiisopinocampheylborane</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">â</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1016%2FS0040-4039%2800%2976780-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaK2cXltVyjurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=2141-2144&author=P.+V.+Ramachandranauthor=B.+Gongauthor=H.+C.+Brown&title=A+remarkable+inversion+in+configuration+of+the+product+alcohols+from+the+asymmetric+reduction+of+ortho-hydroxyacetophenones+with+%CE%B2-chlorodiisopinocampheylborane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">A remarkable inversion in configuration of the product alcohols from the asymmetric reduction of ortho-hydroxyacetophenones with B-chlorodiisopinocampheylborane</span></div><div class="casAuthors">Ramachandran, P. Veeraraghavan; Gong, Baoqing; Brown, Herbert C.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2141-4</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Asym. redn. of o-hydroxyacetophenones I (R = H, 5-, 6-MeO, 5-Me, 5-F, 3,5-Cl2, 4-MeO-6-CO2Me) with B-chlorodiisopinocampheylborane provides product alcs. with the opposite configuration compared to those produced in the redn. of the corresponding o-methoxyacetophenones II (same R).  The ee% from these redns. were generally >80%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcTk2pJd1bvrVg90H21EOLACvtfcHk0lgz5qb2K7NYUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltVyjurk%253D&md5=018eaa6f071f123dd2f72d13e5512964</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2976780-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252976780-3%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DP.%2BV.%26aulast%3DGong%26aufirst%3DB.%26aulast%3DBrown%26aufirst%3DH.%2BC.%26atitle%3DA%2520remarkable%2520inversion%2520in%2520configuration%2520of%2520the%2520product%2520alcohols%2520from%2520the%2520asymmetric%2520reduction%2520of%2520ortho-hydroxyacetophenones%2520with%2520%25CE%25B2-chlorodiisopinocampheylborane%26jtitle%3DTetrahedron%2520Lett.%26date%3D1994%26volume%3D35%26spage%3D2141%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Nieuwenhze, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Catalytic asymmetric dihydroxylation</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">â</span> <span class="NLM_lpage">2547</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00032a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1994&pages=2483-2547&author=H.+C.+Kolbauthor=M.+S.+Van+Nieuwenhzeauthor=K.+B.+Sharpless&title=Catalytic+asymmetric+dihydroxylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Asymmetric Dihydroxylation</span></div><div class="casAuthors">Kolb, Hartmuth C.; VanNieuwenhze, Michael S.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2483-547</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 285 refs. on enantioselective prepn. of chiral 1,2-diols from olefins and synthetic applications of the 1,2-diols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6vlkXRJjKLVg90H21EOLACvtfcHk0lgz5qb2K7NYUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D&md5=71bace539bfee0542d17edcdb889cdd9</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fcr00032a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00032a009%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DVan%2BNieuwenhze%26aufirst%3DM.%2BS.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DCatalytic%2520asymmetric%2520dihydroxylation%26jtitle%3DChem.%2520Rev.%26date%3D1994%26volume%3D94%26spage%3D2483%26epage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, S. L.</span><span> </span><span class="NLM_article-title">Asymmetric dihydroxylation of alkenes</span> <span class="citation_source-journal">Org. React.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm401805h&amp;key=10.1002%2F0471264180.or066.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm401805h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2ns7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2005&pages=109&author=M.+C.+Noeauthor=M.+A.+Letavicauthor=S.+L.+Snow&title=Asymmetric+dihydroxylation+of+alkenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric dihydroxylation of alkenes</span></div><div class="casAuthors">Noe, Mark C.; Letavic, Michael A.; Snow, Sheri L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Reactions (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-625</span>CODEN:
                <span class="NLM_cas:coden">ORREAW</span>;
        ISSN:<span class="NLM_cas:issn">0078-6179</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review of asym. dihydroxylation reactions of alkenes including mechanism, stereochem., scope and limitations, and exptl. conditions and procedures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkhwxk_oiw37Vg90H21EOLACvtfcHk0lg3KpOR208kOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2ns7rI&md5=005540cdbdcb44603cfc752b6ed20fef</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1002%2F0471264180.or066.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264180.or066.02%26sid%3Dliteratum%253Aachs%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSnow%26aufirst%3DS.%2BL.%26atitle%3DAsymmetric%2520dihydroxylation%2520of%2520alkenes%26jtitle%3DOrg.%2520React.%26date%3D2005%26volume%3D66%26spage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2','PDB','2xp2'); return false;">PDB: 2xp2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj','PDB','2wgj'); return false;">PDB: 2wgj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yfx" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yfx','PDB','2yfx'); return false;">PDB: 2yfx</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yhv" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yhv','PDB','2yhv'); return false;">PDB: 2yhv</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb','PDB','4ccb'); return false;">PDB: 4ccb</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu','PDB','4ccu'); return false;">PDB: 4ccu</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0','PDB','4cd0'); return false;">PDB: 4cd0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anl" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anl','PDB','4anl'); return false;">PDB: 4anl</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anq" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anq','PDB','4anq'); return false;">PDB: 4anq</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a href="/doi/suppl/10.1021/jm401805h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70535"></div></div></div></div></div><hr /></hr><p class="last">One table listing additional experimental details of biochemical kinase selectivity for <b>8e</b>, and SMILES molecular formula strings and compound data information in a csv file. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401805h/suppl_file/jm401805h_si_001.pdf">jm401805h_si_001.pdf (146.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401805h/suppl_file/jm401805h_si_002.csv">jm401805h_si_002.csv (1.8 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">ALK kinase domain crystal structures deposited to the Protein Data Bank (wwPDB) are wtâcrizotinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>), L1196M (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yhv">2yhv</a>), L1196Mâcrizotinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2yfx">2yfx</a>), G1269A (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anl">4anl</a>), G1269Aâcrizotinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4anq">4anq</a>), wtâ<b>6d</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccb">4ccb</a>), wtâ<b>7h</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ccu">4ccu</a>), and L1196Mâ<b>8e</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4cd0">4cd0</a>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401805h&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm401805h" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401805h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995ad0b9a23d7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
